<PAGE> 1
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
<TABLE>
<S> <C>
(Mark One)
[X] Annual Report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 For the fiscal year ended
September 30, 2000
or
[ ] Transition Report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 For the transition period
from________ to________
Commission file number 1-11091
</TABLE>
SYBRON INTERNATIONAL CORPORATION
(TO BE RENAMED APOGENT TECHNOLOGIES INC.)
(Exact name of registrant as specified in charter)
<TABLE>
<S> <C>
WISCONSIN 22-2849508
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
48 CONGRESS STREET 03801
PORTSMOUTH, NEW HAMPSHIRE (Zip Code)
(Address of principal executive offices)
</TABLE>
Registrant's telephone number, including area code: (603) 433-6131
Securities registered pursuant to Section 12(b) of the Act:
<TABLE>
<CAPTION>
NAME OF EACH EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
------------------- ---------------------
<S> <C>
Common Stock, par value $0.01 per share New York Stock Exchange
Preferred Stock Purchase Rights (associated New York Stock Exchange
with the Common Stock)
</TABLE>
Securities registered Pursuant to Section 12(g) of the Act: NONE
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES [X] NO [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [X]
The aggregate market value of the Common Stock held by non-affiliates of
the registrant, based upon the closing sale price of the registrant's Common
Stock on December 12, 2000 as reported on the New York Stock Exchange, was
approximately $2,003,219,985. Shares of Common Stock held by each executive
officer and director and by each person known to beneficially own more than 5%
of the outstanding Common Stock have been excluded in that such persons may be
deemed to be affiliates. This determination of affiliate status is not
necessarily a conclusive determination for other purposes.
At December 12, 2000, there were 105,326,165 shares of the registrant's
Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Certain portions of the registrant's Proxy Statement for its Annual Meeting
of Shareholders to be held on January 30, 2001 have been incorporated by
reference into Part III of this Form 10-K.
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
<PAGE> 2
SYBRON INTERNATIONAL CORPORATION
TABLE OF CONTENTS
TO
2000 ANNUAL REPORT ON FORM 10-K
<TABLE>
<CAPTION>
ITEM PAGE
---- ----
<S> <C> <C> <C>
PART I
1 Business.................................................... 1
2 Properties.................................................. 14
3 Legal Proceedings........................................... 15
4 Submission of Matters to a Vote of Security Holders......... 16
Executive Officers of the Registrant........................ 16
PART II
5 Market for Registrant's Common Equity and Related
Stockholder Matters....................................... 18
6 Selected Financial Data..................................... 19
7 Management's Discussion and Analysis of Financial Condition
and Results of Operations................................. 20
7A Quantitative and Qualitative Disclosures About Market
Risk...................................................... 38
8 Financial Statements and Supplementary Data................. 41
9 Changes in and Disagreements with Accountants on Accounting
and Financial Disclosure.................................. 80
PART III
10 Directors and Executive Officers of the Registrant.......... 80
11 Executive Compensation...................................... 80
12 Security Ownership of Certain Beneficial Owners and
Management................................................ 80
13 Certain Relationships and Related Transactions.............. 80
PART IV
14 Exhibits, Financial Statement Schedules and Reports on Form
8-K....................................................... 80
Signatures.................................................. 82
</TABLE>
<PAGE> 3
PART I
ITEM 1. BUSINESS
GENERAL
Sybron International Corporation doing business as Apogent Technologies
("Apogent" or the "Company") is a Wisconsin corporation, incorporated in 1993 to
be the successor by merger in January 1994 to Sybron Corporation, a Delaware
corporation. The merger was accomplished to change the Company's corporate
domicile from Delaware to Wisconsin. On December 11, 2000, the Company spun off
its dental business by way of a pro rata distribution to its shareholders of all
the outstanding common stock and related preferred stock purchase rights (the
"Distribution" or "Spin-Off") of Sybron Dental Specialties, Inc. ("SDS"). As a
result of the Distribution, SDS became an independent public company operating
what was the Company's dental business which included the Professional Dental,
Orthodontics and Infection Control business segments. Included in the dental
business are certain allocations of corporate expenses directly attributable to
those businesses. The Company, which began doing business as Apogent
Technologies in connection with the Distribution, continues to operate its
Labware and Life Sciences, Clinical and Industrial, Diagnostics and Microbiology
and Laboratory Equipment businesses, as described herein. The Company plans to
seek shareholder approval to change its name to Apogent Technologies Inc. at its
2001 annual meeting.
TERMS; YEAR REFERENCES; STOCK SPLITS; DIVESTITURE
When we use the terms "Company," "Apogent," "we" or "our" in this Annual
Report, we are referring to Sybron International Corporation d/b/a Apogent
Technologies and its subsidiaries and their respective predecessors, without the
dental business. Our fiscal year ends on September 30. All references to a
particular year mean the fiscal year ended September 30 of that year, unless we
indicate otherwise. As a result of the Distribution, SDS is accounted for as a
discontinued operation. In addition, on March 31, 1999, the Company sold Nalge
Process Technologies Group, Inc. ("NPT") (the "NPT Sale"). NPT has also been
accounted for as a discontinued operation. All data, unless otherwise indicated,
has been restated to reflect the Distribution and the NPT Sale.
TRANSACTIONS AND AGREEMENTS BETWEEN THE COMPANY AND SDS
In order to effect the Distribution, the Company and SDS have entered into
a number of interrelated agreements. These agreements describe the
reorganization of the Company in preparation for the Distribution and define the
ongoing relationship between the parties after the Distribution. Because these
agreements were negotiated while SDS was a wholly owned subsidiary, they are not
the result of negotiations between independent parties, although the Company and
SDS have set pricing terms for interim services believed to be comparable to
what would have been achieved through arm's-length negotiations. Following the
Distribution, additional or modified agreements, arrangements and transactions
may be entered into and such agreements and transactions will be determined
through arm's-length negotiations.
CONTRIBUTION AGREEMENT
Pursuant to the Contribution Agreement, Plan and Agreement of
Reorganization and Distribution, immediately prior to the Distribution, all of
the capital stock of Sybron Dental Management, Inc. ("SDM") (formerly known as
Sybron Dental Specialties, Inc.), which owned, directly or indirectly, the stock
or other equity interests in the subsidiaries which hold substantially all of
the assets and liabilities of the dental business, was transferred by the
Company to SDS along with certain other assets relating to the dental business.
Under this agreement, prior to such transfer, the Company paid SDM the amount
necessary to settle all intercompany loans and advances made to the Company by
SDM, and SDM paid the Company a dividend equal to that payment plus the
difference between $375 million and the actual allocation of the Company bank
debt to SDS as of the date of the Distribution.
1
<PAGE> 4
ASSIGNMENT AND ASSUMPTION AGREEMENT
Pursuant to the General Assignment, Assumption and Agreement Regarding
Litigation, Claims and Other Liabilities, in general SDS and its U.S.
subsidiaries indemnify the Company and its subsidiaries and affiliates against
liabilities, litigation and claims actually or allegedly arising out of the
dental business, including discontinued operations within those business
segments. Similarly, the Company and its U.S. subsidiaries indemnify SDS and its
subsidiaries and affiliates against liabilities, litigation and claims actually
or allegedly arising out of the Company's laboratory and life science business,
including discontinued operations within those business segments, and other
items not transferred to SDS. In circumstances in which any liability of the
Company and SDS is joint, the parties will share responsibility for such
liability on a mutually agreed basis consistent with the allocation of the
business segments.
TRADE NAME ASSIGNMENT AND TRANSITIONAL TRADE NAME USE AND LICENSE AGREEMENT
Pursuant to the Trade Name Assignment and Transitional Trade Name Use and
License Agreement, the unregistered trade name "Sybron" has been transferred to
SDS, subject to a royalty free, nontransferable, nonexclusive license for the
Company to continue to use the name for a period of one year after the
Distribution. This is intended to give the Company the necessary time to change
its name to Apogent Technologies Inc. and to cease using the name "Sybron" in
its and its subsidiaries' businesses.
INSURANCE MATTERS AGREEMENT
An Insurance Matters Agreement governs the rights and obligations of the
Company and SDS with respect to various pre-existing contracts insuring the
Company and covering risks associated with, or arising out of, the dental
business. The types of policies covered by the Insurance Matters Agreement
include, without limitation, automobile liability and comprehensive, and general
liability. The Insurance Matters Agreement also establishes certain procedures
for dealing with pending litigation, new litigation and the resolution of
disputes between the parties concerning that agreement.
EMPLOYEE BENEFITS AGREEMENT
Various Company employee benefit plans have been modified to reflect the
fact that they no longer cover employees of the dental businesses, and SDS has
created new employee benefit plans on behalf of the dental business employees.
The Employee Benefits Agreement sets forth the agreements of SDS and the Company
regarding this transition.
TAX INDEMNIFICATION AGREEMENT
The Tax Sharing and Indemnification Agreement (the "Tax Indemnification
Agreement") governs the allocation of certain tax responsibilities between the
Company and its subsidiaries on the one hand and SDS and its subsidiaries on the
other hand after the Distribution. The Tax Indemnification Agreement defines
each company's rights and obligations with respect to deficiencies and refunds
of federal, state and other taxes relating to the business operations for tax
years (or portions thereof) ending on or prior to the Distribution and with
respect to certain tax attributes of the companies after the Distribution. The
Tax Indemnification Agreement also specifies the parties' respective obligations
in connection with any audit or investigation concerning any federal, state or
other taxes or in the event the Distribution is subsequently determined not to
qualify as tax-free for U.S. federal income tax purposes.
INTERIM ADMINISTRATIVE SERVICES AGREEMENT
The Company and SDS entered into an Interim Administrative Services
Agreement as of the date of the Distribution. This agreement governs the
administrative and financial services that the Company will continue to provide
to SDS on an interim basis and those which SDS will provide to the Company. In
general, the Company will provide specified accounting, tax management, legal
and cash management services to SDS, and SDS will provide certain insurance and
risk management services to the Company, for a period of up to six months after
the Distribution. Each party will compensate the other parties at negotiated
amounts which,
2
<PAGE> 5
the Company believes, are comparable to rates the Company could have achieved
through arm's-length negotiations.
CONFIDENTIALITY AND NONDISCLOSURE AGREEMENT
As of the date of the Distribution, SDS and the Company entered into a
Confidentiality and Nondisclosure Agreement whereby, subject to certain
exceptions, each party has agreed to treat as confidential and not disclose
certain proprietary and other confidential information belonging to the other
company.
BUSINESSES AND PRODUCTS
The subsidiaries of Apogent are leading manufacturers of value-added
products for the labware and life sciences, clinical and industrial, diagnostics
and microbiology, and laboratory equipment industries. The Company provides
products under four business segments -- Labware and Life Sciences, Clinical and
Industrial, Diagnostics and Microbiology, and Laboratory Equipment. The primary
subsidiaries in each of our business segments are as follows:
<TABLE>
<CAPTION>
LABWARE AND LIFE SCIENCES CLINICAL AND INDUSTRIAL
<S> <C>
Matrix Technologies Corporation Erie Scientific Company
Nalge Nunc International Corporation Chase Scientific Glass, Inc.
National Scientific Company The Naugatuck Glass Company
Nunc A/S Richard-Allan Scientific Company
Molecular BioProducts, Inc. Samco Scientific Corporation
Robbins Scientific Corporation Microm International GmbH
Genevac Limited Gerhard Menzel Glasbearbeitungswerk
GmbH & Co. K.G.
</TABLE>
<TABLE>
<CAPTION>
DIAGNOSTICS AND MICROBIOLOGY LABORATORY EQUIPMENT
<S> <C>
Applied Biotech, Inc. Barnstead Thermolyne Corporation
Microgenics Corporation Lab-Line Instruments, Inc.
Alexon-Trend, Inc. Electrothermal Engineering, Ltd.
Remel Inc.
</TABLE>
GROWTH STRATEGY
Our goals are to consistently grow our worldwide sales and earnings. Key
elements of our strategy to achieve these goals are:
COMPETITIVE FOCUS. We focus on product development and manufacturing and
marketing efforts to increase our range of specialty and value-added products
and to increase the range of end-users for our products.
ACQUISITIONS. We have an active acquisition program. Since 1993, when we
adopted this element of our strategy, we have made more than 70 acquisitions in
the United States and abroad, including 10 completed in 2000 and one in 2001
through December 12, 2000. See Note 15 to our consolidated financial statements
in Item 8 of this Annual Report. Our operating subsidiaries' have been able to
use their existing distribution channels to market many of the acquired product
lines and in some cases have acquired additional distribution channels through
which the subsidiaries existing products can be sold. We have achieved other
synergies, such as the elimination of duplicative administrative functions or
the combining of manufacturing operations, with some of these acquisitions.
NEW PRODUCT INTRODUCTIONS. Our operating subsidiaries consistently strive
to develop and introduce new products which contribute to net sales. We believe
that new product introductions are important to the ability of our operating
subsidiaries to maintain their competitive positions.
3
<PAGE> 6
INTERNATIONAL GROWTH. We devote significant resources to international
manufacturing, sales and marketing efforts in order to capitalize on foreign
sales opportunities. As a result of our efforts, sales outside the United States
have grown from $135.7 million in the year ended September 30, 1998 to $220.4
million in 2000. In 1998, 1999 and 2000, sales outside the United States
represented approximately 24%, 24% and 26%, of our net sales, respectively. See
Item 7, "Management's Discussion and Analysis of Financial Condition and Results
of Operations."
The execution of the various elements of our strategy resulted in a
significant expansion of our business in 2000. Overall sales growth in 2000 was
$148.5 million, or 21%.
FORWARD-LOOKING STATEMENTS
The description of our businesses included in this Item 1, "Management's
Discussion and Analysis of Financial Condition and Results of Operations" in
Item 7, and other portions of this report contain statements that could be
deemed to be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Those statements concern, among other
things, our intent, belief or current expectations with respect to our operating
and growth strategies, our capital expenditures, financing or other matters,
regulatory matters pertaining to us specifically and the industry in general,
industry trends, competition, risks attendant to foreign operations, reliance on
key distributors and large OEM customers, litigation, environmental matters, and
other factors affecting our financial condition or results of operations. Such
forward-looking statements involve certain risks and uncertainties, many of
which are beyond our control, that could cause actual results to differ
materially from those contemplated in the forward-looking statements. Factors
which could cause or contribute to such differences include, but are not limited
to, those discussed in connection with such statements as well as those
described in the section entitled "Cautionary Factors" in Item 7 of this Annual
Report.
CERTAIN FINANCIAL INFORMATION
The following table sets forth our net sales by business segment for the
years indicated.
<TABLE>
<CAPTION>
YEARS ENDED SEPTEMBER 30,
------------------------------
1998 1999 2000
-------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Labware and Life Sciences............................ $228,775 $268,788 $347,437
Clinical and Industrial.............................. 135,438 176,059 208,686
Diagnostics and Microbiology......................... 114,683 171,647 210,147
Laboratory Equipment................................. 78,866 98,543 97,305
-------- -------- --------
Total Net Sales...................................... $557,762 $715,037 $863,575
======== ======== ========
</TABLE>
We have included other financial information about our business segments
and foreign operations in Note 16 to our consolidated financial statements
included in this Annual Report, and such information is incorporated herein by
reference.
SEGMENT INFORMATION
HISTORY
In May 1998, we realigned our laboratory subsidiaries under a single
management team which is headquartered in Portsmouth, New Hampshire. We did this
in order to take advantage of sales, marketing, administrative and manufacturing
synergies among companies which have related product lines, customers and
methods of distribution. This team is responsible for managing subsidiaries in
our four business segments: a) Labware and Life Sciences, b) Clinical and
Industrial, c) Diagnostics and Microbiology and d) Laboratory Equipment.
Products in these segments bear brand names such as NALGENE(R), NUNC(TM),
BARNSTEAD(R),
4
<PAGE> 7
THERMOLYNE(R), REMEL(R), SUPERFROST(R) and COLORFROST(R), which are well
recognized in the laboratory and life sciences industry.
BUSINESS SEGMENTS
LABWARE AND LIFE SCIENCES. Products in our Labware and Life Sciences
business segment include approximately 4,900 items, including reusable plastic
products (bottles, carboys, graduated ware, beakers and flasks) and disposable
plastic products (microfiltration and cryogenic storage products). Other Labware
products include products for critical packaging applications (bottles for
packaging diagnostic and other reagents, media, pharmaceuticals and specialty
chemicals), safety products (hazard labeled containers and biohazard disposal
products), environmental containers, and autosampler vials and seals used in
chromatography analysis. Life Sciences products include applications of cell
culture, filtration, molecular biology, cryopreservation, immunology,
electrophoresis, liquid handling, genomics and high throughput screening for
pharmaceutical drug discovery.
Labware products are primarily manufactured at Nalge Nunc International
Corporation ("NNI"). NNI's NALGENE(R) brand laboratory products are typically
sold at prices ranging from $5 to $1,000 to general, industrial, and research
laboratories. In general, these products are designed to offer the scientist or
laboratory technician a safer, less expensive and more durable alternative to
labware products made of glass or other materials. NNI also manufactures a line
of popular consumer products such as bicycle bottles and recreation containers
for camping and hiking.
We have expanded the breadth of our product offerings in labware products
through our acquisition program. In 1993, NNI added its line of environmental
containers with the purchase of I-CHEM Research Inc., and in 1997 it added,
through a merger with National Scientific Company, autosampler vials and seals
and accessories used in chromatography analysis. We broadened our participation
in life sciences product markets in 1995 through the purchase of Owl Scientific,
Inc., a manufacturer of electrophoresis equipment used in molecular biology. In
1997, we strengthened the electrophoresis product line by purchasing Integrated
Separation Systems, and then combined Owl and Integrated Separation Systems to
form Owl Separation Systems, Inc. In July 1995, we acquired the Nunc group of
companies, manufacturers of plastic labware used in research applications such
as cell culture, molecular biology, cryopreservation and immunology. In 1997,
NNI formed a joint venture with the owner of the Japanese distributor of Nunc's
products by acquiring 75% of the stock of Nippon InterMed K.K. In 1998, we
acquired Lida Manufacturing Corporation, a manufacturer of syringe filters for
chromatography sample preparation, biological research, genetic research, and
general laboratory filtration, and in 1999, we acquired Invitro Scientific
Products, Inc., a producer of roller bottles and packaging containers used in
biological production facilities to manufacture vaccines, pharmaceuticals, and
other reagents; the ultra filtration product line of Intersep Filtration
Products, a subsidiary of Pacofin Ltd.; Scientific Resources, Inc., a producer
and distributor of chromatography supplies; Molecular BioProducts, Inc., a
manufacturer of disposable liquid handling products used in molecular biology
and life sciences; and Matrix Technologies Corporation, a manufacturer of liquid
handling products used by laboratories in the research, medical and clinical
markets. In 2000, we acquired Robbins Scientific Corporation, a manufacturer of
biomedical products used in genomics, molecular biology, chemical synthesis and
tissue typing; Sun International, a supplier of consumables for high pressure
liquid chromatography, gas chromatography and high throughput screening
applications; Genevac Limited (and Genevac, Inc., an affiliated corporation), a
manufacturer of specialty evaporators used in chemical, agrochemical and
biotechnology laboratories for drug discovery and other chemistry related
applications; and the Versi-Dry(R) product line from National Packaging Services
Corporation, which products are used to absorb and contain chemicals and other
spills in laboratory settings.
Molecular BioProducts, Matrix and Robbins manufacture liquid handling
products such as specialty pipette tips, microdispensers, automated dispensing
machines, and plastic plates and tubes which are used in high throughput
screening, a broadly defined process in which high volumes of compounds are
screened against a wide range of therapeutic agents. The complementary products
of these acquired companies, along with certain products of Nunc, give us the
ability to address a wide range of high throughput screening needs,
5
<PAGE> 8
from the high volume needs of drug researchers to the lower volume, very precise
applications used in areas such as genome research. A line of Genevac's
specialty evaporators also are designed to meet the high volume needs of
customers involved in drug discovery.
The Labware and Life Sciences business segment accounted for approximately
41%, 38% and 40%, of our consolidated net sales in 1998, 1999 and 2000,
respectively.
CLINICAL AND INDUSTRIAL. Products in our Clinical and Industrial business
segment include microscope slides, cover glass, glass tubes and vials, stains
and reagents and histology and immunochemistry instrumentation for clinical
testing, thin glass for watch crystals, cosmetic mirrors, precision and coated
glass used in various optic applications, and precision thin film optical
coating equipment.
Our earliest products in this business segment were plain microscope slides
and cover glass, manufactured by Erie Scientific Company. Erie expanded this
product line through the addition of value-added slides with special printing
and coatings to help lab technicians be more efficient and for specialty
applications. Value-added products include SUPERFROST(R) and COLORFROST(R) brand
printed slides, which provide an indelible marking surface and are disposable;
SUPERFROST(R) Plus brand adhesion slides, disposable slides which are
electrically charged in a way which causes cells to adhere to them; and
disposable and reusable diagnostic slides which are custom designed and printed
to customer specifications for use in diagnostic test kits. We added stains and
fixatives for use in histology laboratories to this business segment when we
acquired Richard-Allan Scientific Company in 1995 and Stephens Scientific, Inc.
in 1996. In 1995, we added consumable histology products, such as tissue
cassettes used for biopsies, through the acquisition of the Secure Medical
Products product line. In 1996, we acquired The Naugatuck Glass Company, a
manufacturer of thin glass mirrors used in the cosmetic industry, and precision
and coated glass used in optics applications. We expanded our opportunities in
the optical coating business by acquiring, in fiscal 2001, Vacuum Process
Technologies, Inc., which designs and manufactures precision thin film optical
coating equipment. A significant disposable laboratory glassware business was
added to this business segment in 1998 with the acquisition of Chase Instruments
Corp., the acquisition of SciCan Scientific and Scherf Prazision GmbH later in
the same year. Also in 1998, we acquired Cel-Line Associates, Inc., a
manufacturer of printed microscope slides and Marks Polarized Corporation, a
manufacturer of laminated filters, polarizers and optical products. In 1999, we
acquired Corning Samco Corporation, a manufacturer of transfer pipettes and
specimen containers; the HistoScreen(TM) and HistoGel(TM) histology processing
tissue cassette product lines of Perk Scientific; Stahmer, Weston & Co., Inc., a
manufacturer of specimen containers and hand care products for health care
workers; and System Sales Associates, Inc., a supplier of urine transport tubes,
serum transport vials, specimen containers, pipette tips and sample cups. We
also added Novelty Glass and Mirror Co., Inc., a supplier of cut-to-order
mirrors to the garment, notion, novelty and dental supply industries, to
Naugatuck Glass. In 2000, we acquired Microm Laborgerate GmbH, a leading
developer, manufacturer and distributor of histology equipment, and Lab Vision
Corporation, a manufacturer and distributor of automated staining instruments
and antibodies used by immunohistochemistry laboratories. The Microm and Lab
Vision product lines represent valuable complements to Richard-Allan's portfolio
of consumables, making Richard-Allan a full line supplier of essential products
used by anatomical pathology laboratories.
The Clinical and Industrial business segment accounted for approximately
24% of our consolidated net sales in each of 1998, 1999 and 2000.
DIAGNOSTICS AND MICROBIOLOGY. Products in our Diagnostics and Microbiology
business segment are used for drug testing, therapeutic drug monitoring,
infectious disease detection, pregnancy testing, glucose tolerance testing,
blood bank saline testing, clinical diagnostic liquid standards and research
application temperature measurement. Products include diagnostic test kits,
culture media, diagnostic reagents, and other products used in detecting causes
of various infections or diseases.
Our participation in these areas evolved through a series of diagnostic
company acquisitions, beginning in 1995 with the purchase of Ever Ready
Thermometer Co., Inc. Ever Ready is a manufacturer of high quality precision
thermometers, hydrometers and temperature calibration equipment. Later in 1995
we acquired New England Reagent Laboratory, Inc. ("NERL"), a manufacturer of
liquid standards and reagents used with clinical diagnostics and testing
equipment. CASCO Standards, Inc., a manufacturer of liquid standards as well
6
<PAGE> 9
as calibration verification and quality control materials used with clinical
diagnostic and testing equipment, was acquired in 1996. NERL was later combined
with CASCO to form CASCO-NERL Diagnostics Corporation. In 1997 we added
drug-screening products with the acquisition of Drug Screening Systems, Inc. and
began to expand into microbiology through the purchase of Trend Scientific, Inc.
and Alexon Biomedical, Inc. These companies have been combined to form
Alexon-Trend, Inc., a manufacturer of test kits used to detect a variety of
parasitic, bacterial and viral causes of infections. We became a significant
manufacturer of microbiology products, including plated and tubed media, with
the 1997 acquisition of Remel Limited Partnership. We added to the Remel
business by acquiring Carr-Scarborough Microbiologicals, Inc. in the same year,
and Clinical Standards Labs, Inc., DiMed Corporation and MicroBio Products, Inc.
in 1998. Also in 1998, we acquired the diagnostic products of Seradyn, Inc., a
manufacturer of infectious disease diagnostic reagents and test kits, as well as
uniform latex particles used in the production of diagnostic reagents.
Additional diagnostic companies added in 1998 include Diagnostic Reagents, Inc.,
a manufacturer of immunoassay reagents used principally for drugs of abuse
testing; Criterion Sciences, a manufacturer of a glucose tolerance beverage,
hematology stains, reagents and other solutions used in laboratory analysis and
testing; Custom Laboratories, Inc., a manufacturer of a glucose tolerance test
beverage; and Applied BioTech, Inc., a manufacturer of test kits for rapid
detection of pregnancy, drugs of abuse and infectious diseases. In 1999, Ever
Ready acquired certain operating assets of Rascher & Betzold, Inc., a
manufacturer of high precision-grade hydrometers, thermometers and scientific
glassware; Remel acquired MicroTest, Inc., a manufacturer of transport media for
various infectious organisms; and Alexon-Trend acquired the bioreagent and ELISA
immunochemistry product lines of Genzyme Diagnostics. In 1999 Diagnostic
Reagents, Inc. acquired Microgenics Corporation, a manufacturer of diagnostic
reagents used in drugs of abuse screening, therapeutic drug monitoring, thyroid
function testing and anemia testing. DRI and Microgenics have since been
combined, creating a leading provider of reagents for drug monitoring, drugs of
abuse screening and thyroid function testing, with multiple homogeneous
immunoassay technologies. In 2000, we acquired Consolidated Technologies Inc., a
manufacturer of intermediate biological products, calibration and controls used
in immunology, clinical chemistry, toxicology, infectious disease and nucleic
acid testing. We also acquired the Abbott Laboratories Murex bacteriology latex
agglutination product line and the Axis-Shield thyroid and coagulation product
lines.
The Diagnostic and Microbiology business segment accounted for
approximately 21%, 24% and 25% of our consolidated net sales in 1998, 1999 and
2000, respectively.
LABORATORY EQUIPMENT. Products in our Laboratory Equipment business
segment include heating, stirring and temperature control apparatus such as hot
plates, stirrers, shakers, heating tapes, muffle furnaces, incubators,
dri-baths, bench top sterilizers and cryogenic storage apparatus, which are
fundamental to basic procedures performed in the laboratory; systems for
producing ultra pure water; bottle top dispensers, positive displacement
micropipettors, and small mixers used in biomolecular research; constant
temperature equipment including refrigerators/freezers, ovens, water baths,
environmental chambers; and furnaces and fluorometers, spectrophotometers, and
strip chart recorders.
Laboratory Equipment is manufactured by Barnstead Thermolyne Corporation
and its subsidiaries. BARNSTEAD(R) brand products are used to produce ultra pure
water, the most common laboratory reagent. Because the water purity requirements
of end-users differ, Barnstead Thermolyne offers distillation, deionization,
reverse osmosis, ultraviolet oxidation, and absorption or filtration
technologies for purifying water. THERMOLYNE(R) brand products include heating,
stirring and temperature control apparatus that are fundamental to basic
procedures performed in the laboratory. Both BARNSTEAD(R) and THERMOLYNE(R)
brand products are typically priced between $100 and $5,000.
Barnstead Thermolyne has added to its product line from time to time
through acquisitions. In 1994, we added bottle top dispensers, positive
displacement micropipettors, and small mixers used in biomolecular research
through the acquisition of Labindustries, Inc. In 1995, we added PMC(R) brand
programmable hotplate/stirrers, TURNER(R)brand fluorometers and
spectrophotometers, and LINEAR(R) brand strip chart recorders through the
acquisition of Biomolecular, Inc. In 1997, we acquired the HARVEY(R) bench top
sterilizer business. In 1998, we acquired Electrothermal Engineering, Ltd., a
manufacturer of heating mantles and controls, and Lab-Line Instruments, Inc.,
which manufactures constant temperature equipment including
7
<PAGE> 10
shakers, refrigerators/freezers, ovens, water baths, environmental chambers, and
furnaces. In 1999, we acquired Laboratory Devices, Inc., a manufacturer of
melting point apparatus and constant temperature laboratory equipment, and Stem
Corporation Ltd., a manufacturer of heating, cooling, stirring and shaking
equipment for combinatorial laboratory applications. Stem's operations have been
combined with those of Electrothermal.
The Laboratory Equipment business segment accounted for approximately 14%,
14% and 11% of our consolidated net sales in 1998, 1999 and 2000, respectively.
NEW PRODUCTS
Apart from the addition of new products through its acquisition program,
product development efforts at the Company's subsidiaries are focused on
expanding product offerings in the laboratory markets currently served. Product
offerings are designed to develop and improve products for new and existing
technologies which will allow laboratories, lab technicians and researchers to
more efficiently perform tests and experiments and reduce the cost of their
procedures, and provide faster diagnostic tests with improved accuracy. Examples
of new products include: a) in Labware and Life Sciences, two new pieces of
equipment and a number of new types of high density microwell plates for use in
high throughput screening, genomics and combinatorial chemistry applications,
and the Nalgene B3 Media Bag system, a flexible container solution marketed for
sterile fluid containment and processing in the pharmaceutical, biotechnology,
and diagnostic applications; b) in the Clinical and Industrial segment,
specialty slides for the new pap smear technology, silinated microassay slides
for drug discovery, and specialty coverglass and glass plates for DNA
hybridization and testing; c) in the Diagnostics and Microbiology segment, rapid
test kits for infections such as strep throat, and a Cyclosporine Plus assay
used for monitoring the concentration of immunosuppression drugs for organ
transplant patients; and d) in the Laboratory Equipment segment, a new "NANOpure
DIamond" water purification system, which is an upgrade from its current water
purification system.
PRODUCT DISTRIBUTION
We estimate that the worldwide laboratory and life sciences market includes
more than 150,000 industrial, academic, clinical, governmental and biotechnology
laboratories. Our products reach those laboratories in several ways. Products
from our Labware and Life Sciences business segment are sold primarily through
distributors, although some of our businesses in this business segment, such as
Matrix and Robbins, have direct sales forces and sell directly to end-users.
Products in the Clinical and Industrial and Laboratory Equipment business
segments are also sold primarily through distributors. Exceptions in these
business segments include Richard-Allan and Microm, who primarily sell directly
to end-users. Most of the products from our Diagnostics and Microbiology
business segment are sold directly to end-users or to original equipment
manufacturers, with fewer products sold through distributors. For example, the
microbiology products of Remel are primarily sold directly to end-users through
Remel's national distribution system, while the drugs of abuse testing products
of Microgenics are primarily sold to manufacturers of automated testing
equipment and to a limited extent through distribution. Most of our subsidiaries
maintain their own sales forces, whether they sell directly to end-users,
through distribution, or otherwise. The combined sales forces of our
subsidiaries include approximately 214 domestic and 73 international sales
people.
As indicated, a large portion of our Labware and Life Sciences, Clinical
and Industrial, and Laboratory Equipment products are sold through distributors,
including approximately 20 domestic and 25 international distributors. Three
(primarily domestic) distributors, Fisher Scientific ("Fisher"), VWR Scientific
("VWR"), and Allegiance Healthcare Corporation ("Allegiance"), accounted in the
aggregate for approximately 43%, 41% and 35% of our Labware and Life Sciences
segment sales in 1998, 1999 and 2000, respectively, approximately 41%, 44% and
44% of our Clinical and Industrial segment sales in 1998, 1999 and 2000,
respectively, and approximately 35%, 39%, and 42% of our Laboratory Equipment
segment sales in 1998, 1999 and 2000, respectively. Laboratory supply
distributors offer a wide variety of supplies, apparatus and instruments for the
laboratory, primarily through catalogs and, increasingly, through their
e-commerce web sites. End-users rely heavily on these catalogs and web sites in
identifying suitable products and making
8
<PAGE> 11
purchase decisions, and the prominence of and the number of product items listed
for a particular vendor are critical marketing variables. We believe the number
of our products offered by the major distributors is among the highest of any of
our competitors. Also, the major distributors often have contracts with large
end-users or purchasing organizations to supply such users or organizations with
a broad array of laboratory products and supplies. Our ability to manufacture
and supply a broad range of products can help distributors be more efficient in
these situations and is, we believe, an advantage to us. Sales to original
equipment manufacturers accounted for approximately 37% of our Diagnostics and
Microbiology business segment in 2000.
INTERNATIONAL
In addition to an extensive distributor network, our subsidiaries maintain
sales offices and manufacturing plants in international locations. Foreign sales
offices are located in the United Kingdom, Japan, Germany, Spain, Hong Kong,
Australia and Switzerland. International manufacturing facilities include Nunc
A/S, a manufacturer of life sciences products, located in Denmark; Gerhard
Menzel Glasbearbeitungswerk GmbH & Co. K.G., a manufacturer of microscope
slides, located in Germany; Erie Electroverre S.A., a manufacturer of thin white
glass, located in Switzerland; Erie Scientific Kft, a manufacturer of microscope
slides, located in Hungary; Erie-Watala Glass Co. Ltd., a joint venture, which
produces cut glass for the watch crystal industry, located in Hong Kong; Scherf
Prazision Europa GmbH, a manufacturer of disposable laboratory glassware
products, located in Meiningen, Germany; Electrothermal Engineering Ltd., a
manufacturer of heating mantels, controls and heating, cooling, stirring and
shaking equipment, located in the U.K; Microm International GmbH, a manufacturer
of histology equipment, located in Walldorf, Germany; Genevac Limited, a
manufacturer of combinatorial chemistry evaporators located in the U.K.; and
other manufacturing operations located in the U.K., Mexico and Puerto Rico.
Domestic and international sales of the Company's products by business
segment are as follows:
<TABLE>
<CAPTION>
YEARS ENDED SEPTEMBER 30,
------------------------------
1998 1999 2000
-------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Labware and Life Sciences:
Domestic........................................... $146,950 $176,618 $232,665
International...................................... 81,825 92,170 114,772
-------- -------- --------
Total................................................ $228,775 $268,788 $347,437
======== ======== ========
Clinical and Industrial:
Domestic........................................... $106,898 $141,524 165,234
International...................................... 28,540 34,535 43,452
-------- -------- --------
Total................................................ $135,438 $176,059 $208,686
======== ======== ========
Diagnostics and Microbiology:
Domestic........................................... $104,745 $147,929 $171,318
International...................................... 9,938 23,718 38,829
-------- -------- --------
Total................................................ $114,683 $171,647 $210,147
======== ======== ========
Laboratory Equipment:
Domestic........................................... $ 63,462 $ 77,775 $ 73,971
International...................................... 15,404 20,768 23,334
-------- -------- --------
Total................................................ $ 78,866 $ 98,543 $ 97,305
======== ======== ========
</TABLE>
MARKETS; COMPETITION
Our products serve a large number of markets worldwide, each of which has
its own inherent growth rates. For 2000, our consolidated internal demand growth
tracked closely with our historical rates, which typically have ranged from 4%
to 6%, with both higher and lower levels reported. The Clinical and Industrial
9
<PAGE> 12
business segment experienced higher than average growth in demand in its core
microscope slide, coverglass, histology, and cytology products. Domestic growth
was higher than average while international sales of products from our Clinical
and Industrial business segment were generally less than the prior year. The
Diagnostics and Microbiology business segment returned average growth for the
year. The diagnostic product lines for infectious disease, drugs of abuse,
therapeutic drug monitoring, and pregnancy testing reported high growth rates
while the manual microbiology lines, utilized in clinical settings, were about
even with the prior year. The majority of the growth in this segment was
domestic. Growth in sales of the Laboratory Equipment business segment was
slightly down this year due to the continued softness in foreign markets,
laboratory consolidation, and tough competition. The Labware and Life Sciences
business segment reported strong growth, particularly in the areas of
chromatography, electrophoresis, packaging, labware, molecular biology, and high
throughput screening for drug discovery applications by pharmaceuticals.
Growth in each of these business segments requires the continuous
development of new products which enable laboratories, lab technicians and
researchers to do more tests and procedures more efficiently and which enable
professionals and consumers to obtain diagnoses faster and with improved
accuracy. We believe that one of our principal competitive advantages is our
ability to respond to this dynamic marketplace with new products. Other
competitive advantages include the breadth and depth of our product lines,
significant brand recognition, the economies associated with vertical
integration in certain product lines, long-term relationships with key industry
distributors and, in several lines of business, expertise in plastic molding
technology and glass making.
There are significant competitors with significant resources in each of our
business segments. Our principal competitors in the Labware and Life Sciences
business segment include Corning Incorporated, Meridian Diagnostics, Millipore
Corporation, Becton Dickinson, and Greiner Holding AG. Principal competitors in
the Clinical and Industrial business segment include Shandon (a subsidiary of
Thermo Electron Corporation), Knittel Glaser, Kimble Glass, Surgipath Medical
Industries, Inc., Sigma-Aldrich Company, Copan Diagnostics Company and Elkay
Products, Inc. Principal competitors in the Diagnostics and Microbiology
business segment include Becton Dickinson, Meridian Diagnostics, Dade Behring,
Roche Diagnostics, Quidel Corporation, Biokit S.A., Dyno Particles AS and
Princeton Biomeditech Corporation. Principal competitors in the Laboratory
Equipment business segment include Corning Incorporated, Millipore Corporation,
New Brunswick Scientific Company, Inc., Forma Scientific, Inc. and Lindberg/Blue
M (owned by SPX Corporation.).
INTERNET STRATEGY
We have developed and implemented a multi-pronged internet strategy, which
gives our products high visibility to our customers.
In the Clinical and Industrial business segment, we list our distributed
products on the Allegiance asap.e.com business information system. All of our
distributed products carried by VWR are available through its e-commerce site.
Our products are also listed by our largest distributor, Fisher Scientific, on
its web site, fishersci.com. In addition to the natural extensions in its
distribution network, we have our own e.commerce site for the Nalgene retail
(outdoor) product line, nalgene-outdoor.com.
As opposed to using non-distributor websites (e.g. sciquest.com and
neoforma.com), we have chosen, primarily, to work with our experienced
distribution partners in adding the internet as another avenue for customers
worldwide to utilize when ordering our products. This solution has little added
costs for us, was implemented quickly, and allows our products high visibility
on the web.
COMPETITION
As we have described above, numerous competitors participate in our
business segments, a number of whom have substantially greater financial and
other resources than ours. There can be no assurance that we will not encounter
increased competition in the future.
10
<PAGE> 13
BACKLOG
Our total backlog of orders at September 30, 1998, 1999 and 2000, was
approximately $36.7 million, $31.1 million and $38.5 million, respectively. We
expect all September 30, 2000 backlog orders to be filled in fiscal 2001.
Our backlog by business segment is as follows:
<TABLE>
<CAPTION>
YEARS ENDED SEPTEMBER 30,
---------------------------
1998 1999 2000
------- ------- -------
(IN THOUSANDS)
<S> <C> <C> <C>
Labware and Life Sciences............................... $13,559 $15,907 $20,685
Clinical and Industrial................................. 12,617 9,685 8,485
Diagnostics and Microbiology............................ 2,056 1,342 3,254
Laboratory Equipment.................................... 8,503 4,184 6,097
------- ------- -------
Total................................................... $36,735 $31,118 $38,521
======= ======= =======
</TABLE>
RESEARCH AND DEVELOPMENT
We have a number of research and development programs in our various
business segments, which we consider to be of importance in maintaining our
market positions. We spent approximately $8.7 million, $12.6 million and $18.3
million on research and development in 1998, 1999 and 2000, respectively.
Our research and development expenditures by business segment are as
follows:
<TABLE>
<CAPTION>
YEARS ENDED SEPTEMBER 30,
--------------------------
1998 1999 2000
------ ------- -------
(IN THOUSANDS)
<S> <C> <C> <C>
Labware and Life Sciences................................ $4,140 $ 4,265 $ 6,964
Clinical and Industrial.................................. 505 498 1,703
Diagnostics and Microbiology............................. 2,125 5,485 6,531
Laboratory Equipment..................................... 1,968 2,314 3,104
------ ------- -------
Total.................................................... $8,738 $12,562 $18,302
====== ======= =======
</TABLE>
EMPLOYEES
Our companies employed approximately 6,000 people at September 30, 2000,
approximately 415 of whom in the U.S. are covered by collective bargaining
agreements. We believe our employee relations are generally good. In the United
States, Barnstead Thermolyne's 225 hourly employees are members of the
International Brotherhood of Electrical Workers; NNI's 150 hourly employees at
its Naperville, Illinois facility are members of the International Brotherhood
of Teamsters; Ever Ready Thermometer Co. Inc.'s 20 hourly employees at its West
Paterson, New Jersey facility are members of the United Furniture Workers Union;
and Naugatuck's 20 hourly employees at its Flushing, New York facility are
members of the United Food and Commercial Workers International Union. The labor
contracts at, Barnstead Thermolyne, NNI, Ever Ready and Naugatuck will expire
on, March 31, 2003, December 20, 2002, December 31, 2002 and December 31, 2000,
respectively. Many of our non-management employees in Europe are subject to
national labor contracts which are negotiated from time to time at the national
level between the national labor union and an employees' council. Once national
contracts are set, further negotiation may take place at the local level. Such
negotiations may affect local operations. Our Danish subsidiary, Nunc A/S, was
closed during the third quarter of 1998 for nine days as the result of the first
national strike in Denmark since 1985. After the national strike was settled,
Nunc A/S non-management employees struck for two days over local issues. All
issues were resolved with a new contract with a term ending in March 2000. That
contract has been extended to March 2002.
11
<PAGE> 14
PATENTS, TRADEMARKS AND LICENSES
Our subsidiaries' products are sold under a variety of trademarks and trade
names. They own or license all of the trademarks and trade names we believe to
be material to the operation of their businesses, including the NALGE(R) and
NALGENE(R) trademarks, the NUNC(TM) and NUNCLON(R) trademarks, Erie's
SUPERFROST(R) and COLORFROST(R) trademarks, the THERMOLYNE(R) and BARNSTEAD(R)
trademarks, and the REMEL(R) and RICHARD-ALLAN(TM) trademarks, each of which we
believe to have widespread name brand recognition in its respective field and
all of which we intend to continue to protect. Our subsidiaries also own various
patents, employ various patented processes, and from time to time acquire
licenses from owners of patents to apply patented processes to their operations.
Except for the trademarks referred to above, we do not believe any single
patent, trademark or license is material to the operations of our business as a
whole.
REGULATION
MEDICAL DEVICES
Certain of our products are medical devices which are subject to regulation
by the United States Food and Drug Administration (the "FDA") and by the
counterpart agencies of the foreign countries where our products are sold. Some
of the regulatory requirements of these foreign countries are more stringent
than those applicable in the United States. Pursuant to the Federal Food, Drug,
and Cosmetic Act (the "FDCA"), the FDA regulates virtually all phases of the
manufacture, sale, and distribution of medical devices, including their
introduction into interstate commerce and their advertising, labeling,
packaging, marketing, distribution and recordkeeping. Pursuant to the FDCA and
FDA regulations, 24 facilities of our operating subsidiaries are registered with
the FDA as medical device manufacturing establishments.
Medical devices are classified into either Class I, II or III. Pursuant to
section 510(K) of the FDCA, the manufacturer or distributor of a Class I or II
device that is initially introduced commercially on or after May 28, 1976 must
notify the FDA of its intent to commercially introduce the device through the
submission of a premarket notification (a "510(K) Notice"). Before commercial
distribution can begin, the FDA must review the 510(K) Notice and clear the
device for commercial distribution. The FDA normally has 90 days to review the
510(K) Notice and grant or deny clearance to market on the basis that it is or
is not substantially equivalent to a device marketed before May 28, 1976.
Alternatively, the FDA may postpone a final decision and require the submission
of additional information, which may include clinical data. If additional
information is required, review and clearance of a 510(K) Notice may be
significantly delayed. In order to clear a Class I or II device for marketing,
the FDA must determine, from the information contained in the 510(K) Notice and
any additional information that is submitted, that the device is substantially
equivalent to one or more Class I or II devices that are legally marketed in the
United States. Most Class I and some Class II devices are exempt from the 510(K)
premarket notification requirement and manufacturers of such products may
proceed to market without any submission to the FDA. If a device is not
considered "substantially equivalent," it is regulated as a Class III medical
device. In general, a Class III medical device must be expressly approved by the
FDA for commercial distribution pursuant to the submission of a premarket
approval application ("PMA"). A PMA must contain, among other information,
substantial information about the manufacture of the device and data from
adequate and well-controlled clinical trials that demonstrate that the device is
both safe and effective. The PMA approval process is substantially more complex
and lengthy than the 510(K) premarket notification process.
A medical device, whether exempt from premarket notification, cleared for
marketing under the 510(K) pathway, or cleared pursuant to a PMA approval, is
subject to ongoing regulatory oversight by the FDA to ensure compliance with
regulatory requirements, including, but not limited to, product labeling
requirements and limitations, including those related to promotion and marketing
efforts, current good manufacturing practice and quality system requirements,
record keeping, and medical device (adverse reaction) reporting.
Most of our diagnostic, life sciences, clinical and microbiology products
are regulated as Class I or Class II medical devices.
12
<PAGE> 15
ENVIRONMENTAL, HEALTH AND SAFETY MATTERS
Our operations entail a number of environmentally sensitive production
processes. Compliance with environmental laws and regulations along with
regulations, relating to workplace safety, is a significant factor in our
businesses. Our domestic facilities are subject to federal, state and local laws
and regulations concerning, among other things, solid and hazardous waste
disposal, air emissions and waste water discharge, and our foreign facilities
are subject to local laws and regulations regarding the environment. Our
operations are also subject to regulation relating to workplace safety, both in
the United States and abroad. Violations of any of these laws or regulations or
the release of toxic or hazardous materials used in our operations into the
environment could expose us to significant liability. Similarly, third party
lawsuits relating to environmental and workplace safety issues could result in
substantial liability.
RAW MATERIALS
We purchase a wide range of raw materials and supplies from a number of
suppliers, and other than our supply of white glass, we do not rely on sole
sources to any material extent. All of our white glass comes from a single
source, our Electroverre, SA facility in Switzerland. In the event that
Electroverre could not continue to supply the necessary white glass, we would
have to seek alternative sources which could have a material effect on our
Clinical and Industrial business segment. We do not foresee any significant
difficulty in obtaining necessary materials or supplies.
RISKS ATTENDANT TO FOREIGN OPERATIONS
We conduct our businesses in numerous foreign countries and as a result are
subject to risks of fluctuations in exchange rates of various foreign currencies
and other risks associated with foreign trade. For the years 1998, 1999 and 2000
our net sales outside the United States accounted for approximately 24%, 24% and
26%, respectively, of consolidated net sales. See Item 7, "Management's
Discussion and Analysis of Financial Condition and Results of
Operations -- General" for further information concerning the possible effects
of foreign currency fluctuations and currency hedges intended to mitigate their
impact.
RISKS RELATED TO KEY DISTRIBUTORS AND OEM CUSTOMERS
A substantial portion of our sales are made through major independent
distributors. As set forth above, in the Labware and Life Sciences, Clinical and
Industrial and Laboratory Equipment business segments, those major distributors
are Fisher, VWR and Allegiance. From time to time, the Company's net sales
performance has been affected by short-term volatility in demand from
distributors. The Company has also experienced volatility in demand when
distributors merge or consolidate, when distributors do not manage their
inventories to end-user demand and when distributors otherwise experience
softness in sales. For example, the Company felt the effects of inventory
re-balancing by distributors in the third quarter of 1998 and the third and
fourth quarters of 2000.
The loss of any one of our major laboratory distributors (currently Fisher,
VWR and Allegiance) could have a material adverse effect on our business. Only a
few of our subsidiaries have written contractual relationships with these
distributors. However, our subsidiaries have long-standing relationships with
them or their predecessors.
Apogent's subsidiaries private label for and sell products to a number of
original equipment manufacturers ("OEM's"). These OEM relationships are most
prevalent in our Diagnostic and Microbiology segment, although subsidiaries in
our other segments also enter into OEM and private label relationships as
opportunities arise. Volatility in demand can arise if the OEM's fail to manage
inventories to end-user demand, discontinue product lines or switch business to
other manufacturers.
Sales to distributors and OEM customers are sometimes unpredictable and
wide variances sometimes occur quarter to quarter.
13
<PAGE> 16
ITEM 2. PROPERTIES
We operate manufacturing facilities in the United States and certain
foreign countries. The following table sets forth information regarding our
principal properties by business segment. Properties with less than 20,000
square feet of building space have been omitted from this table.
<TABLE>
<CAPTION>
SUBSIDIARY/LOCATION OF FACILITY BUILDING SPACE AND USE OWNED OR LEASED
------------------------------- ---------------------- ---------------
<S> <C> <C>
Labware and Life Sciences
Penfield, New York 300,000 sq. ft./manufacturing, warehouse and leased
office
New Castle, Delaware 26,000 sq. ft./manufacturing, warehouse and leased
office
Wiesbaden, Germany 21,000 sq. ft./warehouse and office leased
Naperville, Illinois 103,000 sq. ft./manufacturing, warehouse and owned
office
Roskilde, Denmark 151,000 sq. ft./manufacturing, warehouse and owned
office
Ichikana, Japan 38,000 sq. ft./warehouse leased
Hudson, New Hampshire 44,000 sq. ft./manufacturing, warehouse and leased
office
Otay, California 29,000 sq. ft./warehouse leased
Duluth, Georgia 38,000 sq. ft./office and warehouse leased
Tijuana, Mexico 25,000 sq. ft./manufacturing, warehouse and leased
office
San Diego, California 44,000 sq. ft./manufacturing and office leased
Hereford, England 24,000 sq. ft./warehouse and office leased
Portsmouth, New Hampshire 27,000 sq. ft./manufacturing, warehouse and leased
office
Sunnyvale, California 70,000 sq. ft./manufacturing and office leased
Clinical and Industrial
Rockwood, Tennessee 250,000 sq. ft./manufacturing and office owned
Portsmouth, New Hampshire 126,000 sq. ft./manufacturing, warehouse and leased
office
Braunschweig, Germany 40,000 sq. ft./manufacturing, warehouse and owned
office
Romont, Switzerland 200,000 sq. ft./manufacturing, warehouse and owned
office
Aguadilla, Puerto Rico 23,000 sq. ft./manufacturing, warehouse and leased
office
Naugatuck, Connecticut 80,000 sq. ft./manufacturing, warehouse and owned
office
Budapest, Hungary 28,000 sq. ft./manufacturing, warehouse and owned
office
San Fernando, California 77,000 sq. ft./manufacturing, warehouse and owned
office
Meiningen, Germany 22,000 sq. ft./manufacturing, warehouse and owned
office
Holtsville, New York 30,000 sq. ft./manufacturing, warehouse and owned
office
Baltimore, Maryland 21,000 sq. ft./manufacturing and office leased
Wayne, New Jersey 32,000 sq. ft./manufacturing, warehouse and leased
office
Kalamazoo, Michigan 116,000 sq. ft./manufacturing, warehouse and leased
office
Walldorf, Germany 24,000 sq. ft./manufacturing leased
Diagnostics and Microbiology
Indianapolis, Indiana 42,000 sq. ft./manufacturing, warehouse and R leased
& D
Lenexa, Kansas 116,000 sq. ft./manufacturing and office owned
Lenexa, Kansas 30,000 sq. ft./warehouse leased
Lake Charles, Louisiana 24,000 sq. ft./manufacturing and office owned
Ramsey, Minnesota 25,000 sq. ft./manufacturing, warehouse and leased
office
Portland, Maine 33,000 sq. ft./manufacturing, warehouse and leased
office
San Diego, California 76,000 sq. ft./manufacturing, warehouse, leased
office and labs
Fremont, California 109,000 sq. ft./manufacturing, warehouse and leased
office
Austin, Texas 26,000 sq. ft/manufacturing, warehouse and leased
office
East Providence, Rhode Island 64,000 sq. ft./manufacturing, warehouse and leased
office
West Paterson, New Jersey 20,000 sq. ft./manufacturing leased
</TABLE>
14
<PAGE> 17
<TABLE>
<CAPTION>
SUBSIDIARY/LOCATION OF FACILITY BUILDING SPACE AND USE OWNED OR LEASED
------------------------------- ---------------------- ---------------
<S> <C> <C>
Laboratory Equipment
Dubuque, Iowa 180,000 sq. ft./manufacturing and office leased
Melrose Park, Illinois 117,000 sq. ft./manufacturing and office owned
Southend-on-Sea, England 29,000 sq. ft./manufacturing, warehouse and leased
office
</TABLE>
We consider our plants and equipment to be well maintained and suitable for
their purposes. We have, from time to time, expanded and will continue to expand
our facilities as the need arises. We expect to fund such expansions through
internally generated funds or borrowings under our credit facilities described
in Note 7 to our consolidated financial statements contained in Item 8 of this
Annual Report. See Item 7, "Management's Discussion and Analysis of Financial
Condition and Results of Operations -- Liquidity and Capital Resources."
ITEM 3. LEGAL PROCEEDINGS
A subsidiary of the Company has been identified as a potentially
responsible party ("PRP") at the Aqua-Tech site in South Carolina (the
"Aqua-Tech Site") with respect to a previously owned facility. An action has
been conducted at the Aqua-Tech Site for the removal of surface contaminants
under the supervision of the Environmental Protection Agency ("EPA") under the
Comprehensive Environmental Response, Compensation and Liability Act of 1980, as
amended ("CERCLA"). The Company's total contribution to such effort, which has
been paid, was approximately $46,000. The site has been placed by the EPA on the
federal National Priority List under CERCLA, which is a prerequisite to any
federally-mandated requirement for long-term remedial work at the site under
CERCLA, such as would be involved in soil and groundwater remediation. The
Company is participating with a PRP group composed of approximately 100 parties
in an agreement with the EPA to undertake a remedial investigation and
feasibility study which will be used by the EPA to determine what remedy, if
any, should be required at the site. A draft remedial investigation was
submitted to the EPA in August 1999, and a draft baseline risk assessment was
submitted in October 1999. After review of the draft remedial investigation, the
EPA requested and obtained additional sampling work from the PRP group. The
final remedial investigation was submitted in 2000, and the feasibility study is
expected to be completed in 2001. Because the study, which involves extensive
testing required to characterize the existence, extent and nature of any
contamination to determine potential remedies, has not yet been completed, an
estimate of the Company's potential liability cannot be made. However, although
CERCLA does provide for joint and several liability, because the Company's share
of waste allegedly sent to the site is reportedly not more than 1% of the total
waste sent, the Company believes any ultimate liability will not have a material
adverse effect on the Company's results of operations or financial condition.
Applied Biotech, Inc. ("ABI"), a subsidiary in our Diagnostics and
Microbiology business segment, manufactures and supplies immunoassay pregnancy
tests to Warner Lambert Co. (now part of Pfizer Inc.). Warner Lambert sells the
tests to retailers who sell them over-the-counter to consumers. ABI supplies the
product to Warner Lambert pursuant to a supply agreement which Warner Lambert
claims requires ABI to defend and indemnify Warner Lambert with respect to any
liability arising out of claims that the product infringes any patents held by
third parties. On January 8, 1999, Conopco, Inc. d/b/a Unipath Diagnostics
Company filed a lawsuit against Warner Lambert in the U.S. District Court for
the District of New Jersey. Conopco claims in the suit that the Warner Lambert
pregnancy test supplied by ABI infringes certain patents owned by Conopco. ABI
agreed to defend the lawsuit on behalf of Warner Lambert. In November 2000, the
U.S. District Court granted a motion for summary judgment in favor of Warner
Lambert and ABI, ruling that ABI's product does not infringe on the Conopco
patents. The Company therefore believes the resolution of this lawsuit will not
have a material adverse effect on the results of operations or financial
condition of the Company. Additionally, another third party has contacted Warner
Lambert regarding patents it holds which may apply to the Warner Lambert
pregnancy test. Thus, Warner Lambert or ABI may in the future be subject to
additional lawsuits by third parties for patent infringement with respect to
these products. ABI believes it has meritorious defenses to these patents and
will vigorously defend any such lawsuits against it, if brought.
15
<PAGE> 18
The Company or its subsidiaries are at any one time parties to a number of
lawsuits or subject to claims arising out of their respective operations, or the
operation of businesses divested in the 1980's for which certain subsidiaries
may continue to have legal or contractual liability, including product
liability, patent and trademark or other intellectual property infringement,
contractual liability, workplace safety and environmental claims and cases, some
of which involve claims for substantial damages. The Company and its
subsidiaries are vigorously defending lawsuits and other claims against them.
Based upon the insurance available under our insurance program and the potential
for liability with respect to claims which are uninsured, the Company believes
that any liabilities which might reasonably result from any of the pending cases
and claims would not have a material adverse effect on the results of operations
or financial condition of the Company. There can be no assurance as to this,
however, or that litigation having such a material adverse effect will not arise
in the future. See Note 14 to our consolidated financial statements contained in
Item 8 of this Annual Report and Item 7, "Management's Discussion and Analysis
of Financial Condition and Results of Operations -- Cautionary Factors."
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
EXECUTIVE OFFICERS OF THE REGISTRANT
The Company made a number of important organizational changes in connection
with the Spin-Off of SDS as discussed in Item 1, "Business -- General," above.
Effective with the Spin-Off on December 11, 2000, Kenneth F. Yontz, the
Company's Chairman of the Board, President and Chief Executive Officer stepped
down as President and Chief Executive Officer. He was succeeded in those roles
by Frank H. Jellinek, Jr. At that time, Dennis Brown and R. Jeffrey Harris
stepped down as Vice President -- Finance, Chief Financial Officer and
Treasurer, and Vice President -- General Counsel and Secretary, respectively.
Jeffrey C. Leathe became Executive Vice President -- Finance, Chief Financial
Officer and Treasurer and Michael K. Bresson became Executive Vice
President -- General Counsel and Secretary. Additional executive officers also
took office effective with the Spin-Off. A complete list of the names, ages,
positions and offices of our current executive officers, effective with the
Spin-Off on December 11, 2000, follows. All executive officers hold office at
the pleasure of the Board of Directors.
<TABLE>
<CAPTION>
NAME AGE POSITIONS
---- --- ---------
<S> <C> <C>
Kenneth F. Yontz.......................... 56 Chairman of the Board
Frank H. Jellinek, Jr. ................... 55 President and Chief Executive Officer
Jeffrey C. Leathe......................... 44 Executive Vice President -- Finance, Chief
Financial Officer and Treasurer
Michael K. Bresson........................ 42 Executive Vice President -- General
Counsel and Secretary
Verner Andersen........................... 44 Group President, Labware and Life Sciences
Mark F. Stuppy............................ 46 Executive Vice President -- Sales and
Marketing, Clinical Products
Stephen K. Wiatt.......................... 55 Executive Vice President -- Worldwide
Glass Operations
Peter Scheu............................... 35 Group President, Clinical Diagnostics
Yuh-geng Tsay............................. 52 Group President, Immunoassay Diagnostics
</TABLE>
The following sets forth the principal occupations of the executive
officers, for the periods specified, as well as directorships of public
companies.
Mr. Yontz. President and Chief Executive Officer of the Company from
October 1987 until December 2000; Chairman of the Board since December 1987;
President and Chief Executive Officer of Sybron's predecessor from February 1986
until September 1992; Director of Sybron's predecessor from February 1986 to
March 1988; previously Group Vice President and Executive Vice President of the
Allen-Bradley
16
<PAGE> 19
Company. Director of Playtex Products, Inc. and Viasystems Group, Inc.; Chairman
of the Board of Sybron Dental Specialties, Inc.
Mr. Jellinek. Director, President and Chief Executive Officer of Apogent
since December 11, 2000; joined Erie Scientific Company in 1967 and served as
President of Erie from 1975 to 1998; became Director, President and Chief
Executive Officer of Sybron Laboratory Products Corporation ("SLP") on May 1,
1998; has from time to time held general management responsibilities for various
businesses of Sybron's predecessor.
Mr. Leathe. Joined Erie Scientific Company in 1990; has been Executive
Vice President -- Chief Financial Officer, and Treasurer of SLP since May 1,
1998; was Vice President, Chief Financial Officer, and Treasurer of Erie
Scientific from August, 1992 to May 1, 1998; became Executive Vice
President -- Chief Financial Officer and Treasurer of Apogent on December 11,
2000.
Mr. Bresson. Joined SLP in April 1998 as SLP Group Counsel; was a partner
with the law firm of Quarles & Brady LLP from October 1990 until April 1998 and
an associate at Quarles & Brady from June 1983 until September 1990; became
Executive Vice President -- General Counsel and Secretary of Apogent on December
11, 2000.
Mr. Andersen. Became Vice President/General Manager of North American
Operations of Nalge Nunc International Corporation ("NNI") in 1995; became
President of NNI in August 1998; became SLP Group President, Labware and Life
Sciences in November 1999; became Group President, Labware and Life Sciences, of
Apogent on December 11, 2000.
Mr. Stuppy. Joined Erie Scientific Company in 1976; became Vice President
of Marketing at Erie in 1986; became Executive Vice President, Sales & Marketing
of SLP in August 1998, and Executive Vice President -- Sales and Marketing,
Clinical Products, of Apogent on December 11, 2000.
Mr. Wiatt. Joined Erie Scientific Company in 1976; became Vice President
of Manufacturing at Erie in 1978; became Executive Vice President, Worldwide
Glass Operations of SLP in August 1998 and Executive Vice President -- Worldwide
Glass Operations, of Apogent on December 11, 2000.
Mr. Scheu. Joined Richard-Allan Scientific Company in 1995 as Executive
Vice President and became President of Richard-Allan in October 1997; from 1989
to 1995, held various management positions in sales and marketing for Baxter
International Corporation; became Group President, Clinical and Diagnostics, of
Apogent on December 11, 2000.
Dr. Tsay. Was President of Diagnostic Reagents, Inc. ("DRI") at the time
the Company acquired the business in January 1998, and had served in that
position since 1991; became President of Microgenics Corporation when the
Company acquired it and merged it into DRI in June 1999; became Group President,
Immunoassay Diagnostics, of Apogent on December 11, 2000.
17
<PAGE> 20
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Since our inception, we have not paid any cash dividends on our Common
Stock. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations -- Liquidity and Capital Resources" in Item 7 of this
Annual Report, and Note 7 to our consolidated financial statements contained in
Item 8 of this Annual Report for a description of certain restrictions on our
ability to pay cash dividends. Subject to such limitations, any future cash
dividends will be at the discretion of our Board of Directors and will depend
upon, among other factors, our earnings, financial condition and other
requirements. We have no current intention to pay cash dividends on our Common
Stock.
Based upon record ownership as of December 12, 2000, the number of holders
of our Common Stock is 413.
Our Common Stock trades on the NYSE under the symbol "AOT" ("SYB" prior to
the Spin-Off). The market information set forth below for our two most recent
fiscal years is based on NYSE sales prices and has not been adjusted to reflect
the Distribution of SDS in which one share of SDS Common Stock (and the
associated preferred stock purchase right) was distributed for each three shares
of the Company's Common Stock held of record as of November 30, 2000. Our Common
Stock began to trade regular way post-Distribution on December 12, 2000.
<TABLE>
<CAPTION>
1999 HIGH LOW
---- ------- -------
<S> <C> <C>
First Quarter............................................... $27.062 $17.938
Second Quarter.............................................. 28.938 22.750
Third Quarter............................................... 28.313 23.438
Fourth Quarter.............................................. 30.813 25.000
</TABLE>
<TABLE>
<CAPTION>
2000 HIGH LOW
---- ------- -------
<S> <C> <C>
First Quarter............................................... $27.813 $20.668
Second Quarter.............................................. 29.313 21.375
Third Quarter............................................... 33.063 16.375
Fourth Quarter.............................................. 25.875 19.063
</TABLE>
18
<PAGE> 21
ITEM 6. SELECTED FINANCIAL DATA
The following table sets forth selected consolidated financial information
for the five years in the period ended September 30, 2000. As a result of the
Distribution, the consolidated data presented herein reflects the
reclassification of the Company's former SDS subsidiary and its affiliates to
discontinued operations. This selected financial information should be read in
conjunction with our consolidated financial statements and the notes thereto
contained in Item 8 of this Annual Report.
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
-------------------------------------------------------------
1996 1997 1998 1999 2000
-------- -------- ---------- ---------- ----------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<S> <C> <C> <C> <C> <C>
Statement of Income Data(a):
Net sales......................... $361,184 $439,940 $ 557,762 $ 715,037 $ 863,575
Income from continuing
operations...................... 31,603 47,045 52,122 77,411 86,724
Discontinued operations........... 31,291(c) 41,493(c) 23,921(d) 47,965(c) 41,597(c)
Income before extraordinary
items........................... 62,894 88,538 76,043 125,376 128,321
Extraordinary items............... -- (404)(b) -- 17,171(e) --
Net income........................ 62,894 88,134 76,043 142,547 128,321
Earnings per share:
Basic earnings per common share
from continuing operations...... .32(f) .47 .51(f) .75 .83(f)
Discontinued operations........... .31 .41 .23 .46 .40
Extraordinary items............... -- -- -- .17 --
Basic earnings per common share... .63(f) .88 .74(f) 1.38 1.23(f)
Diluted earnings per common share
from continuing operations...... .31(f) .45 .49(f) .73 .81(f)
Discontinued operations........... .31 .40 .23 .45 .39
Extraordinary items............... -- -- -- .16 --
Diluted earnings per common
share........................... .62(f) .85 .72(f) 1.34 1.20(f)
</TABLE>
<TABLE>
<CAPTION>
AS OF SEPTEMBER 30,
-------------------------------------------------------------
1996 1997 1998 1999 2000
-------- -------- ---------- ---------- ----------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
Balance Sheet Data:
Net assets of discontinued
operations................... $175,403 $104,800 $ 129,508 $ 155,595 $ 152,970
Total assets.................... 843,579 975,084 1,227,852 1,539,975 1,792,364
Loans and advances from SDS..... 84,137 55,176 29,088 56,777 77,762
Long-term debt.................. 317,384 416,740 541,914 642,268 703,853
Shareholders' equity............ 291,616 378,649 475,244 625,344 749,516
</TABLE>
---------------
(a) Includes results of acquired companies since their effective dates of
acquisition with the exception of the merger of National Scientific Company
("National") with a wholly owned subsidiary of the Company formed for that
purpose, whose results are included from October 1, 1996, the beginning of
the fiscal year in which the merger occurred. (Results of National prior to
October 1, 1996 qualified as an immaterial pooling of interests in relation
to the operations taken as a whole.) See Note 15 to our consolidated
financial statements contained in Item 8 of this Annual Report.
(b) Amount resulted from the refinancing of our debt. See Note 7 to our
consolidated financial statements contained in Item 8 of this Annual
Report.
(c) Amounts resulted from the operations of NPT of $2,840, $4,698 and $121 in
1996, 1997 and 1999, respectively which was sold on March 31, 1999 and the
operations of SDS and its affiliates of $28,451, $36,795, $47,844 and
$41,597 in 1996, 1997, 1999 and 2000, respectively, which became an
unaffiliated company on December 11, 2000 as a result of the Spin-Off. See
Note 15 to our consolidated financial statements contained in Item 8 of
this Annual Report.
19
<PAGE> 22
(d) Amount includes an expense of $7,750 from the settlement of environmental
litigation relating to a facility which was sold in 1983 as part of a
discontinued operation, income of $3,848 from the operations of NPT, sold
on March 31, 1999 and $27,823 from the operations of SDS and its
affiliates, spun off on December 11, 2000. See Notes 15 and 16 to our
consolidated financial statements contained in Item 8 of this Annual
Report.
(e) Amount represents gain on the March 31, 1999 sale of NPT.
(f) Includes a reduction for restructuring charges of $.01, $.05 and $.07 per
basic and diluted common share in 1996, 1998 and 2000, respectively. See
Item 7, "Management's Discussion and Analysis of Financial Condition and
Results of Operations" below, and Note 11 to our consolidated financial
statements contained in Item 8 of this Annual Report.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
On December 11, 2000, Sybron International Corporation doing business as
Apogent Technologies ("Apogent" or the "Company") completed the spin-off of its
dental business as a separate publicly traded company. The spin-off was effected
by way of a pro rata distribution of all the outstanding common stock and
related preferred stock purchase rights of Sybron Dental Specialties, Inc.
("SDS") to the Company's shareholders (the "Distribution" or "Spin-Off"). SDS is
now an independent public company operating what was the Company's dental
business. Apogent continues to operate the laboratory and life science business.
Immediately prior to the Distribution, Sybron Dental Management, Inc.
("SDM"), then a subsidiary of the Company, paid a cash dividend (the "Dividend")
to the Company which was used to settle all intercompany loans and advances and
to reflect an allocation of bank debt to SDS. Immediately after payment of the
dividend, SDM became a subsidiary of SDS. The allocation of bank debt to SDS was
$375 million.
As a result of the Spin-Off, all historical financial data relating to the
operations of SDS and its affiliates has been reclassified to discontinued
operations.
The following discussion should be read in conjunction with our
consolidated financial statements and the accompanying notes contained in Item 8
of this Annual Report.
SPECIAL CHARGES
Our results for 2000 include charges of approximately $11.3 million ($7.5
million after tax) with respect to the restructuring of various parts of our
business. These charges relate primarily to restructured staffing (approximately
$5.5 million), operating location rationalization (approximately $2.7 million),
product rationalization (approximately $2.1 million), and a tax expense from the
restructuring of our U.K. operations (approximately $1.0 million). Of these
charges approximately $7.4 million will be cash expenditures. Through September
30, 2000, approximately $1.1 million has been paid. These charges are referred
to as the "2000 Special Charges." The actions related to the 2000 Special
Charges are expected to eliminate annual costs of approximately $6.6 million.
Savings were projected to result from: i) reduced salaries and related expenses
as a result of consolidating our CASCO operations with our Microgenics
operation, a reduction of workforce at NNI's Naperville facility, and the
elimination of corporate personnel in Milwaukee (approximately $5.6 million);
ii) the consolidation of several facilities, including those of CASCO, NNI
Biotech and Naperville (approximately $0.8 million); and iii) the elimination of
product lines that are either duplicative or no longer meet management's
profitability expectations (approximately $0.2 million). We do not anticipate,
and have not experienced to date, significant offsets to savings in either
increased expenses or reduced revenues.
Our results for 1999 include a charge of approximately $0.3 million ($0.2
million after tax) relating to adjustments made to the 1998 restructuring
reserve, consisting of additional severance. This charge is referred to herein
as the "1999 Special Charge." All historical financial data relating to SDS and
its affiliates and Nalge Process Technologies Group, Inc. ("NPT"), which was
sold in 1999, have been reclassified to discontinued operations.
20
<PAGE> 23
Our results for 1998 contain charges with respect to the restructuring of
our laboratory group. These charges are collectively referred to herein as the
"1998 Special Charges," and together with the 1999 Special Charge and the 2000
Special Charges, are referred to as the "Special Charges."
The 1998 Special Charges totaled $8.5 million ($5.4 million after tax) and
consisted of items relating to the realignment of our laboratory subsidiaries
under Sybron Laboratory Products Corporation ("SLP"). This restructuring charge
consisted primarily of severance expenditures associated with the consolidation
of certain functions, the restructuring of sales and marketing activities, and
costs associated with exiting certain product lines. In 1999, an additional $0.3
million was added to this reserve as an adjustment to original severance
estimates. We expect no additional adjustments to this reserve. Approximately
$3.9 million of these charges are cash expenditures of which $1.0 million was
paid in 1998, $2.0 was paid in 1999 and $0.7 million was paid in 2000. Of the
remaining $0.2 million, we expect to pay the remaining balance in 2001.
These actions eliminated annual costs of approximately $5.3 million. The
savings at SLP were revised from the original estimate of $6.1 million to
eliminate savings associated with the discontinued operations of NPT. Savings at
SLP were projected to result from: i) reduced salaries and related expenses
associated with the elimination of duplicative sales, marketing and
administrative personnel at Nalge Nunc International (approximately $2.5
million); ii) reduced salaries and related expenses from consolidating sales,
marketing and administrative personnel at Remel Inc. and Alexon Trend
(approximately $1.2 million); iii) reduced salaries and related expenses
associated with eliminating duplicative sales personnel due to product line
consolidation at Owl Separation Systems, Inc. (approximately $0.7 million); iv)
reduced salaries and related expenses associated with eliminating duplicative
sales, information systems and marketing personnel at Barnstead Thermolyne
Corporation (approximately $0.5 million); and v) reduced salaries and related
expenses associated with eliminating duplicative sales and administrative
functions at other SLP locations (approximately $0.4 million).
The Company has achieved actual savings in line with these expectations. We
do not anticipate, and have not experienced to date, significant offsets to
savings in either increased expenses or reduced revenues.
Restructuring activity related to the 1998 Special Charges since June 30,
1998 and its components are as follows:
<TABLE>
<CAPTION>
LEASE INVENTORY FIXED
SEVERANCE PAYMENTS WRITE-OFF ASSETS GOODWILL
(A) (B) (C) (C) (D) TOTAL
--------- -------- --------- ------ -------- ------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
1998 Restructuring Charge............. $3,400 $200 $1,800 $1,000 $2,100 $8,500
1998 Cash payments.................... 900 100 -- -- -- 1,000
1998 Non-cash charges................. -- -- 1,800 1,000 2,100 4,900
------ ---- ------ ------ ------ ------
September 30, 1998 balance............ $2,500 $100 $ -- $ -- $ -- $2,600
1999 Cash payments.................... 1,900 100 -- -- -- 2,000
Adjustments(a)........................ 300 -- -- -- -- 300
------ ---- ------ ------ ------ ------
September 30, 1999 balance............ $ 900 $ -- $ -- $ -- $ -- $ 900
2000 Cash payments.................... 700 700
------ ---- ------ ------ ------ ------
September 30, 2000 balance............ $ 200 $ $ $ $ $ 200
====== ==== ====== ====== ====== ======
</TABLE>
---------------
(a) Amount represents severance and termination costs for approximately 65
terminated employees (primarily sales and marketing personnel). As of
September 30, 2000, all 65 employees have been terminated as a result of
the restructuring plan. Payments will continue to certain employees
previously terminated under this restructuring plan. An adjustment of
approximately $0.3 million was made in the third quarter of fiscal 1999 to
adjust the accrual primarily representing under accruals for anticipated
costs associated with severance associated with employees who were
previously notified of termination. No additional employees will be
terminated under this restructuring plan.
(b) Amount represents lease payments and shutdown costs on exited facilities.
21
<PAGE> 24
(c) Amount represents write-offs of inventory and fixed assets associated with
discontinued product lines.
(d) Amount represents goodwill associated with exited product lines.
Restructuring activity related to the 2000 Special Charges and its
components are as follows:
<TABLE>
<CAPTION>
FIXED LEASE SHUT-DOWN
SEVERANCE INVENTORY ASSETS COMMITMENTS COSTS TAX
(A) (B) (B) (C) (C) (D) OTHER TOTAL
--------- --------- ------ ----------- --------- ------ ----- -------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
2000 Restructuring charge...... $5,500 $2,100 $1,000 $500 $300 $1,000 $900 $11,300
2000 Cash payments............. 1,100 -- -- -- -- -- -- 1,100
2000 Non-cash charges.......... -- 2,100 1,000 -- -- -- 800 3,900
------ ------ ------ ---- ---- ------ ---- -------
September 30, 2000 balance..... $4,400 $ -- $ -- $500 $300 $1,000 $100 $ 6,300
====== ====== ====== ==== ==== ====== ==== =======
</TABLE>
---------------
(a) Amount represents severance and termination costs for 151 terminated
employees (primarily sales, marketing and corporate personnel). As of
September 30, 2000, 48 employees have been terminated as a result of the
restructuring plan.
(b) Amount represents write-offs of inventory and fixed assets associated with
discontinued product lines.
(c) Amount represents lease payments and shut down costs on exited facilities.
(d) Amount represents income tax expense associated with the restructuring of
our U.K. facilities.
The Company expects to make cash payments of approximately $1.7 million,
$0.8 million, $2.2 million and $0.4 million in each of the four quarters of
fiscal 2001 and $1.2 million in fiscal 2002 and beyond.
We do not anticipate significant offsets to savings in either increased
expenses or reduced revenues.
SALES GROWTH
Both our net sales and operating income grew in 2000 from the previous
year. Net sales in 2000 increased by 20.8% over 1999. Operating income in 2000
increased by 14.1% over 1999, influenced by the Special Charges discussed above.
Excluding the Special Charges, operating income increased by 20.0% over 1999.
Sales growth for the year ended September 30, 2000 was strong both
domestically and internationally. Domestic and international sales increased by
18.3% and 28.7%, respectively, over the prior year. International sales were
negatively impacted by the strengthening of the U.S. dollar. If currency effects
were removed from sales, the international increase over 1999 would have been
32.1%.
22
<PAGE> 25
2000 ACQUISITIONS
As discussed in Item 1, "Business -- General," we have maintained an active
program of developing and marketing both new products and product line
extensions. We believe that new product introductions are important to the
ability of our operating subsidiaries to maintain their competitive positions.
We have also pursued numerous acquisition opportunities, completing more than 70
acquisitions since 1993, 10 of which we completed in 2000. Acquisitions
completed in 2000 were as follows:
<TABLE>
<CAPTION>
APPROXIMATE
ANNUAL SALES PRIOR ACQUISITION
COMPANY TO ACQUISITION DATE DESCRIPTION
------- ------------------ ----------- -----------
<S> <C> <C> <C>
Labware and Life Sciences
------------------------------------------------------------------------------------------------------------
Robbins Scientific Corporation......... $19.6 million 10/99 Manufacturer of biomedical
products used in certain types
of high throughput screening,
molecular biology, chemical
synthesis and tissue typing.
Versi Dry(R) product line of National
Packaging Services Corporation....... $ 2.5 million 2/00 Absorbent pads used in research
and industrial laboratories
designed to absorb and contain
chemicals and other spillage
occurring in the laboratory.
Sun International...................... $ 5.8 million 2/00 Supplier of consumables for
high-pressure liquid
chromatography, gas
chromatography and high
throughput screening
applications.
Genevac Limited........................ $10.6 million 5/00 Manufacturer of specialty
evaporators used in chemical,
agrochemical and biotechnology
laboratories for drug discovery
and other chemistry-related
applications.
Genevac Inc. .......................... $ 1.6 million 5/00 Distributor of specialty
evaporators used in chemical,
agrochemical and biotechnology
laboratories for drug discovery
and other chemistry-related
applications.
Clinical and Industrial
------------------------------------------------------------------------------------------------------------
Microm Laborgerate GmbH................ $20.7 million 10/99 Manufacturer of microtomes and
other histology instrumentation.
Lab Vision Corporation................. $ 7.5 million 8/00 Manufacturer of automated
staining instruments and
antibodies used in
immunohistochemistry
laboratories.
Diagnostics and Microbiology
------------------------------------------------------------------------------------------------------------
Consolidated Technologies Inc. ........ $ 7.8 million 3/00 Manufacturer of intermediate
biological products,
calibration, and controls used
in immunology, clinical
chemistry, toxicology,
infectious disease and nucleic
acid testing.
</TABLE>
23
<PAGE> 26
<TABLE>
<CAPTION>
APPROXIMATE
ANNUAL SALES PRIOR ACQUISITION
COMPANY TO ACQUISITION DATE DESCRIPTION
------- ------------------ ----------- -----------
<S> <C> <C> <C>
Murex bacteriology latex agglutination
product line of Abbott Laboratories.. $20.5 million 8/00 Manufacturer of latex
agglutination bacteriology
products including antisera,
agglutination reagents, latex
reagents and stained
suspensions.
The thyroid and coagulation products of
Axis Shield.......................... $ 4.5 million 9/00 Distributor of thyroid and
coagulation diagnostic products.
</TABLE>
These acquisitions are consistent with our strategy of acquiring product
lines that complement our existing products or technologies. We intend to
continue to seek out acquisition candidates consistent with our strategy.
However, there can be no assurance of the number or size of future acquisitions.
INTERNATIONAL OPERATIONS
Portions of our sales, income and cash flows are derived internationally.
The financial position and the results of operations from substantially all of
our international operations, other than most U.S. export sales, are measured
using the local currency of the countries in which such operations are conducted
and are then translated into U.S. dollars. While the reported income of foreign
subsidiaries will be affected by a weakening or strengthening of the U.S. dollar
in relation to a particular local currency, the effects of foreign currency
fluctuations are partially mitigated by the fact that manufacturing costs and
other expenses of foreign subsidiaries are generally incurred in the same
currencies in which sales are generated. Such effects of foreign currency
fluctuations are also mitigated by the fact that such subsidiaries' operations
are conducted in numerous foreign countries and, therefore, in numerous foreign
currencies. In addition, our U.S. export sales may be affected by foreign
currency fluctuations relative to the value of the U.S. dollar as foreign
customers may adjust their level of purchases upward or downward according to
the weakness or strength of their respective currencies versus the U.S. dollar.
From time to time we may employ currency hedges to mitigate the effect of
foreign currency fluctuations. If currency hedges are not employed, we may be
exposed to earnings volatility as a result of foreign currency fluctuations. In
November 1999, we employed a series of foreign currency options with a U.S.
dollar notional amount of approximately $9.4 million at a cost of approximately
$0.3 million. These options were designed to protect the Company from potential
detrimental effects of currency movements associated with the U.S. dollar versus
the Danish Krone in the second, third and fourth quarters of fiscal 2000 as
compared to the second, third and fourth quarters of 1999. No foreign currency
hedges are in place for fiscal 2001.
The following table sets forth our domestic sales and sales outside the
United States in 1998, 1999 and 2000. See also Note 16 to our consolidated
financial statements contained in Item 8 of this Annual Report.
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
------------------------------
1998 1999 2000
-------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Domestic net sales................................... $422,055 $543,846 $643,188
International net sales.............................. 135,707 171,191 220,387
-------- -------- --------
Total net sales...................................... $557,762 $715,037 $863,575
======== ======== ========
</TABLE>
LEGAL PROCEEDINGS
Our subsidiaries are at any one time subject to a number of lawsuits or
subject to claims arising out of their respective operations. For information
regarding legal proceedings that may influence our performance, see Item 3,
"Legal Proceedings."
24
<PAGE> 27
RESULTS OF OPERATIONS
YEAR ENDED SEPTEMBER 30, 2000
COMPARED TO THE YEAR ENDED SEPTEMBER 30, 1999
NET SALES.
<TABLE>
<CAPTION>
DOLLAR PERCENT
NET SALES: (IN THOUSANDS) 1999 2000 CHANGE CHANGE
------------------------- -------- -------- -------- -------
<S> <C> <C> <C> <C>
Labware and Life Sciences.................... $268,788 $347,437 $ 78,649 29.3%
Clinical and Industrial...................... 176,059 208,686 32,627 18.5%
Diagnostics and Microbiology................. 171,647 210,147 38,500 22.4%
Laboratory Equipment......................... 98,543 97,305 (1,238) (1.3)%
-------- -------- -------- ----
Total Net Sales.............................. $715,037 $863,575 $148,538 20.8%
======== ======== ======== ====
</TABLE>
Overall Company. Net sales for the year ended September 30, 2000 increased
by $148.5 million or 20.8% from 1999.
Labware and Life Sciences. Increased net sales in the Labware and Life
Sciences segment resulted primarily from: (a) net sales of products of acquired
companies (approximately $65.4 million), (b) increased net sales of existing
products (approximately $8.9 million), (c) increased net sales of new products
(approximately $4.1 million) and (d) price increases (approximately $3.0
million). Increased net sales were partially offset by unfavorable foreign
currency fluctuations (approximately $2.7 million).
Clinical and Industrial. Increased net sales in the Clinical and
Industrial segment resulted primarily from: (a) net sales of products of
acquired companies (approximately $30.0 million), (b) price increases
(approximately $4.6 million) and (c) increased net sales of existing products
(approximately $0.5 million). Increased net sales were partially offset by
unfavorable foreign currency fluctuations (approximately $2.5 million).
Diagnostics and Microbiology. Increased net sales in the Diagnostics and
Microbiology segment resulted primarily from: (a) net sales of products of
acquired companies (approximately $30.1 million), (b) increased net sales of new
products (approximately $3.9 million), (c) increased net sales of existing
products (approximately $3.4 million) and (d) price increases (approximately
$1.7 million). Increased net sales were partially offset by unfavorable foreign
currency fluctuations (approximately $0.6 million).
Laboratory Equipment. Decreased net sales in the Laboratory Equipment
segment resulted primarily from: (a) decreased sales of existing products
(approximately $4.4 million) and (b) unfavorable foreign currency fluctuations
(approximately $0.2 million). Decreased net sales were partially offset by: (a)
net sales of new products (approximately $2.1 million), (b) price increases
(approximately $1.1 million) and (c) net sales of products of acquired companies
(approximately $0.1 million).
GROSS PROFIT.
<TABLE>
<CAPTION>
PERCENT OF PERCENT OF DOLLAR PERCENT
GROSS PROFIT: (IN THOUSANDS) 1999 SALES 2000 SALES CHANGE CHANGE
---------------------------- -------- ---------- -------- ---------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Labware and Life Sciences......... $136,004 50.6% $179,460 51.7% $43,456 32.0%
Clinical and Industrial........... 75,407 42.8% 89,667 43.0% 14,260 18.9%
Diagnostics and Microbiology...... 89,458 52.1% 111,651 53.1% 22,193 24.8%
Laboratory Equipment.............. 41,089 41.7% 41,352 42.5% 263 0.6%
-------- ---- -------- ---- ------- ----
Total Gross Profit................ $341,958 47.8% $422,130 48.9% $80,172 23.4%
======== ==== ======== ==== ======= ====
</TABLE>
Overall Company. Gross profit for the year ended September 30, 2000
increased by $80.2 million or 23.4% from 1999.
Labware and Life Sciences. Increased gross profit in the Labware and Life
Sciences segment resulted primarily from: (a) the effects of acquired companies
(approximately $36.2 million), (b) increased volume (approximately $7.2
million), (c) a favorable product mix (approximately $4.6 million), (d) price
increases
25
<PAGE> 28
(approximately $3.0 million), (e) favorable foreign currency fluctuations
(approximately $1.0 million) and (f) inventory valuation adjustments
(approximately $1.1 million). Increased gross profit was partially offset by:
(a) increased manufacturing overhead (approximately $7.8 million) and (b) the
non-recurring 2000 Special Charges (approximately $1.8 million).
Clinical and Industrial. Increased gross profit in the Clinical and
Industrial segment resulted primarily from: (a) the effects of acquired
companies (approximately $11.3 million), (b) a favorable product mix
(approximately $2.1 million), (c) price increases (approximately $4.6 million),
(d) increased volume (approximately $0.9 million) and (f) inventory valuation
adjustments (approximately $0.4 million). Increased gross profit was partially
offset by: (a) increased manufacturing overhead (approximately $4.8 million) and
(b) unfavorable foreign currency fluctuations (approximately $0.3 million).
Diagnostics and Microbiology. Increased gross profit in the Diagnostics
and Microbiology segment resulted primarily from: (a) the effects of acquired
companies (approximately $19.9 million), (b) a favorable product mix
(approximately $5.3 million), (c) price increases (approximately $1.7 million)
and (d) increased volume (approximately $0.4 million). Increased gross profit
was partially offset by: (a) increased manufacturing overhead (approximately
$2.5 million), (b) the non-recurring 2000 Special Charges (approximately $2.4
million) and (c) unfavorable foreign currency fluctuations (approximately $0.3
million).
Laboratory Equipment. Increased gross profit in the Laboratory Equipment
segment resulted primarily from: (a) price increases (approximately $1.1
million), (b) a favorable product mix (approximately $0.5 million) and (c) the
effects of acquired companies (approximately $0.2 million). Increased gross
profit was partially offset by: (a) reduced volume (approximately $1.2 million),
(b) increased manufacturing overhead (approximately $0.1 million), (c) the
non-recurring 2000 Special Charges (approximately $0.1 million) and (d)
unfavorable foreign currency fluctuations (approximately $0.1 million).
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES.
<TABLE>
<CAPTION>
SELLING GENERAL AND ADMINISTRATIVE PERCENT OF PERCENT OF DOLLAR PERCENT
EXPENSES: (IN THOUSANDS) 1999 SALES 2000 SALES CHANGE CHANGE
---------------------------------- -------- ---------- -------- ---------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Labware and Life Sciences......... $ 68,600 25.5% $100,365 28.9% $31,765 46.3%
Clinical and Industrial........... 30,102 17.1% 37,077 17.8% 6,975 23.2%
Diagnostics and Microbiology...... 46,246 26.9% 60,797 28.9% 14,551 31.5%
Laboratory Equipment.............. 20,632 20.9% 21,148 21.7% 516 2.5%
Corporate Office.................. 7,252 N/A 9,754 N/A 2,502 34.5%
-------- --- -------- --- ------- ----
Total Selling, General and
Administrative Expenses......... $172,832 24.2% $229,141 26.5% $56,309 32.6%
======== === ======== === ======= ====
</TABLE>
Overall Company. Selling, general and administrative expenses for the year
ended September 30, 2000 increased by $56.3 million or 32.6% from 1999.
Labware and Life Sciences. Increased selling, general and administrative
expenses in the Labware and Life Sciences segment resulted primarily from: (a)
increased selling, general and administrative expenses as a result of acquired
businesses (approximately $19.9 million), (b) increased amortization of
intangibles primarily as a result of acquisitions (approximately $6.2 million),
(c) increased marketing expenses (approximately $4.3 million), (d) the
non-recurring 2000 Special Charges (approximately $1.3 million) and (e)
increased general and administrative expenses (approximately $1.2 million),
partially offset by favorable foreign currency fluctuations (approximately $1.2
million).
Clinical and Industrial. Increased selling, general and administrative
expenses in the Clinical and Industrial segment resulted primarily from: (a)
increased selling, general and administrative expenses as a result of acquired
businesses (approximately $6.2 million), (b) increased marketing expenses
(approximately $1.3 million), (c) increased amortization of intangibles
primarily as a result of acquisitions (approximately $1.0 million) and (d) the
non-recurring 2000 Special Charges (approximately $0.1 million), partially
offset
26
<PAGE> 29
by: (a) a reduction in general and administrative expenses (approximately $1.2
million) and (b) favorable foreign currency fluctuations (approximately $0.5
million).
Diagnostics and Microbiology. Increased selling, general and
administrative expenses in the Diagnostics and Microbiology segment resulted
primarily from: (a) increased selling, general and administrative expenses as a
result of acquired businesses (approximately $6.8 million), (b) increased
amortization of intangibles primarily as a result of acquisitions (approximately
$4.6 million), (c) the non-recurring 2000 Special Charges (approximately $2.1
million) and (d) increased marketing expenses (approximately $3.1 million),
partially offset by: (a) decreased general and administrative expenses
(approximately $1.1 million), (b) decreased research and development expense
(approximately $0.6 million) and (c) favorable foreign currency fluctuations
(approximately $0.3 million).
Laboratory Equipment. Increased selling, general and administrative
expenses in the Laboratory Equipment segment resulted primarily from: (a)
increased selling, general and administrative expenses as a result of acquired
businesses (approximately $0.5 million), (b) the non-recurring 2000 Special
Charges (approximately $0.5 million), (c) increased research and development
expenses (approximately $0.3 million) and (d) increased amortization of
intangibles primarily as a result of acquisitions (approximately $0.2 million),
partially offset by: (a) decreased marketing expenses (approximately $0.8
million) and (b) decreased general and administrative expenses (approximately
$0.2 million).
Corporate Office. Increased general and administrative expenses at the
corporate office resulted primarily from: (a) the non-recurring 2000 Special
Charges (approximately $1.7 million), (b) a decrease in expenses charged to SDS
as a result of a decrease in domestic sales at SDS in proportion to the domestic
sales of the Company (approximately $1.3 million) and (c) an increase in legal
and professional fees (approximately $0.3 million), partially offset by a
reduction in employee compensation and benefits (approximately $0.8 million)
OPERATING INCOME.
<TABLE>
<CAPTION>
PERCENT PERCENT OF DOLLAR PERCENT
OPERATING INCOME (IN THOUSANDS) 1999 OF SALES 2000 SALES CHANGE CHANGE
------------------------------- -------- -------- -------- ---------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Labware and Life Sciences.......... $ 67,404 25.1% $ 79,095 22.8% $11,691 17.3%
Clinical and Industrial............ 45,305 25.7% 52,590 25.2% 7,285 16.1%
Diagnostics and Microbiology....... 43,212 25.2% 50,854 24.2% 7,642 17.7%
Laboratory Equipment............... 20,457 20.8% 20,204 20.8% (253) (1.2)%
Corporate Office................... (7,252) N/A (9,754) N/A (2,502) 34.5%
-------- --- -------- --- ------- ----
Total Operating Income............. $169,126 23.7% $192,989 22.3% $23,863 14.1%
======== === ======== === ======= ====
</TABLE>
As a result of the foregoing, operating income in 2000 increased by 14.1%
or $23.9 million over operating income in 1999.
INTEREST EXPENSE.
Interest expense was $48.7 million in 2000, an increase of $8.6 million
from 1999. The increase resulted from higher average debt balances resulting
primarily from funding acquisitions and increased interest rates in 2000.
INCOME TAXES.
Taxes on income from continuing operations were $57.6 million, an increase
of $7.6 million from 1999. The increase resulted primarily from increased
taxable earnings.
INCOME FROM CONTINUING OPERATIONS BEFORE EXTRAORDINARY ITEM.
As a result of the foregoing we had net income from continuing operations
of $86.7 million in 2000, as compared to $77.4 million in 1999.
27
<PAGE> 30
DISCONTINUED OPERATIONS.
Income from discontinued operations was $41.6 million in 2000, a decrease
of $6.4 million from income of $48.0 million in 1999. The decrease in income
from discontinued operations resulted primarily from restructuring charges
incurred at SDS in 2000 of approximately $5.9 million, net of tax.
EXTRAORDINARY ITEM.
Income from an extraordinary item decreased by $17.2 million and related to
a non recurring gain on the sale of the Company's Nalge Process Technologies
Group, Inc. in 1999.
NET INCOME.
As a result of the foregoing, we had net income of $128.3 million in 2000,
as compared to net income of $142.5 million in 1999.
DEPRECIATION AND AMORTIZATION.
Depreciation and amortization expense is allocated among cost of sales,
selling, general and administrative expenses and other expense. Depreciation and
amortization increased $17.6 million in 2000 due to additional depreciation and
amortization from the step-up of assets and goodwill recorded from the various
acquisitions as well as routine operating capital expenditures.
NEW ACCOUNTING PRONOUNCEMENTS.
On October 1, 2000, the Company adopted Financial Accounting Standard Board
Opinions No. 133 as modified by FASB Opinion No. 138. These standards establish
accounting and reporting standards for derivative instruments, including certain
derivative instruments embedded in other contracts, and hedging activities. They
require the recognition of all derivative instruments as assets or liabilities
in the balance sheet at fair value. The accounting treatment of changes in fair
value is dependent upon whether or not a derivative instrument is designated as
a hedge and if so, the type of hedge. For derivatives designated as a cash flow
hedge, changes in fair value are recognized in other comprehensive income until
the hedged item is recognized in earnings. At October 1, 2000 the Company had no
freestanding derivatives in place other than interest rate swaps used to hedge
variable rate long-term debt and had no material embedded derivatives. The
interest rate swaps meet the criteria for cash flow hedge accounting. As a
result, the swaps are recorded on the balance sheet as an asset at fair value
with the corresponding gain or loss recorded in other comprehensive income
beginning October 1, 2000. The impact on other comprehensive income upon
adoption of the standard was an unrealized gain, net of tax, of approximately
$2.5 million.
On September 29, 2000, the Financial Accounting Standard Board ("FASB")
issued Statement of Financial Accounting Standards No. 140, Accounting of
Transfers and Servicing of Financial Assets and Extinguishments of Liabilities
("SFAS 140"). SFAS 140 modifies and replaces Statement of Financial Accounting
Standards No. 125. SFAS 140 provides the accounting and reporting guidance for
transfers and servicing of financial assets and extinguishments of liabilities
and will be the authoritative accounting literature for: (1) securitization
transactions involving financial assets; (2) sales of financial assets
(including loan participations); (3) factoring transactions; (4) wash sales; (5)
servicing assets and liabilities; (6) collateralized borrowing arrangements; (7)
securities lending transactions; (8) repurchase agreements; and (9)
extinguishment of liabilities, and is applicable prospectively. Adoption of the
statement in 2001 is not expected to have any material affect on the
consolidated financial position or results of operations.
In March 2000, the FASB issued Interpretation No. 44, "Accounting for
Certain Transactions Involving Stock Compensation" -- an interpretation of APB
Opinion No. 25 ("FIN 44"). This Interpretation clarifies the definition of
employee for purposes of applying Accounting Principles Board Opinion No. 25,
Accounting for Stock Issued to Employee ("APB #25"), the criteria for
determining whether a plan qualifies as a non-compensatory plan, the accounting
consequence of various modifications to the terms of a previously fixed stock
option or award, and the accounting for an exchange of stock compensation awards
in a business
28
<PAGE> 31
combination. This Interpretation is effective July 1, 2000, but certain
conclusions in this Interpretation cover specific events that occur after either
December 15, 1998, or January 12, 2000. We adopted FIN 44 during the year ended
September 30, 2000. This adoption did not have a material effect on our
consolidated financial position or results of operations.
YEAR ENDED SEPTEMBER 30, 1999
COMPARED TO THE YEAR ENDED SEPTEMBER 30, 1998
NET SALES.
<TABLE>
<CAPTION>
DOLLAR PERCENT
NET SALES: (IN THOUSANDS) 1998 1999 CHANGE CHANGE
------------------------- -------- -------- -------- -------
<S> <C> <C> <C> <C>
Labware and Life Sciences............................ $228,775 $268,788 $ 40,013 17.5%
Clinical and Industrial.............................. 135,438 176,059 40,621 30.0%
Diagnostics and Microbiology......................... 114,683 171,647 56,964 49.7%
Laboratory Equipment................................. 78,866 98,543 19,677 24.9%
-------- -------- -------- ----
Total Net Sales...................................... $557,762 $715,037 $157,275 28.2%
======== ======== ======== ====
</TABLE>
Overall Company. Net sales for the year ended September 30, 1999 increased
by $157.3 million or 28.2% from 1998.
Labware and Life Sciences. Increased net sales in the Labware and Life
Sciences segment resulted primarily from: (a) net sales of products of acquired
companies (approximately $22.1 million), (b) increased net sales of existing
products (approximately $10.5 million), (c) increased net sales of new products
(approximately $3.6 million), (d) price increases (approximately $2.2 million)
and (e) favorable foreign currency fluctuations (approximately $1.6 million).
Clinical and Industrial. Increased net sales in the Clinical and
Industrial segment resulted primarily from: (a) net sales of products of
acquired companies (approximately $32.4 million), (b) increased net sales of
existing products (approximately $4.0 million), (c) price increases
(approximately $3.9 million) and (d) increased net sales of new products
(approximately $0.2 million).
Diagnostics and Microbiology. Increased net sales in the Diagnostics and
Microbiology segment resulted primarily from: (a) net sales of products of
acquired companies (approximately $50.1 million), (b) increased net sales of
existing products (approximately $4.9 million), (c) price increases
(approximately $1.2 million) and (d) increased net sales of new products
(approximately $0.8 million).
Laboratory Equipment. Increased net sales in the Laboratory Equipment
segment resulted primarily from: (a) net sales of products of acquired companies
(approximately $21.6 million), (b) increased net sales of new products
(approximately $2.8 million) and (c) price increases (approximately $1.4
million). Increased net sales were partially offset by decreased sales of
existing products (approximately $6.0 million).
GROSS PROFIT.
<TABLE>
<CAPTION>
PERCENT OF PERCENT OF DOLLAR PERCENT
GROSS PROFIT: (IN THOUSANDS) 1998 SALES 1999 SALES CHANGE CHANGE
---------------------------- -------- ---------- -------- ---------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Labware and Life Sciences......... $115,724 50.6% $136,004 50.6% $20,280 17.5%
Clinical and Industrial........... 57,351 42.3% 75,407 42.8% 18,056 31.5%
Diagnostics and Microbiology...... 59,407 51.8% 89,458 52.1% 30,051 50.6%
Laboratory Equipment.............. 34,697 44.0% 41,089 41.7% 6,392 18.4%
-------- ---- -------- ---- ------- ----
Total Gross Profit................ $267,179 47.9% $341,958 47.8% $74,779 28.0%
======== ==== ======== ==== ======= ====
</TABLE>
Overall Company. Gross profit for the year ended September 30, 1999
increased by $74.8 million or 28.0% from 1998.
29
<PAGE> 32
Labware and Life Sciences. Increased gross profit in the Labware and Life
Sciences segment resulted primarily from: (a) the effects of acquired companies
(approximately $12.0 million), (b) increased volume (approximately $5.9
million), (c) price increases (approximately $2.2 million), (d) favorable
foreign currency fluctuations (approximately $1.1 million) and (e) the
non-recurring 1998 Special Charges (approximately $0.8 million). Increased gross
profit was partially offset by: (a) increased manufacturing overhead
(approximately $1.2 million) and (b) an unfavorable product mix (approximately
$0.5 million).
Clinical and Industrial. Increased gross profit in the Clinical and
Industrial segment resulted primarily from: (a) the effects of acquired
companies (approximately $12.1 million), (b) price increases (approximately $3.9
million), (c) an improved product mix (approximately $1.2 million), (d)
increased volume (approximately $1.1 million) and (e) inventory valuation
adjustments (approximately $0.2 million). Increased gross profit was partially
offset by: (a) unfavorable foreign currency fluctuations (approximately $0.4
million) and (b) increased manufacturing overhead (approximately ($0.2 million).
Diagnostics and Microbiology. Increased gross profit in the Diagnostics
and Microbiology segment resulted primarily from: (a) the effects of acquired
companies (approximately $28.7 million), (b) a favorable product mix
(approximately $2.4 million), (c) price increases (approximately $1.2 million),
(d) increased volume (approximately $1.2 million) and (e) the non-recurring 1998
Special Charges (approximately $0.7 million). Increased gross profit was
partially offset by: (a) increased manufacturing overhead (approximately $4.0
million) and (b) inventory valuation adjustments (approximately $0.3 million).
Laboratory Equipment. Increased gross profit in the Laboratory Equipment
segment resulted primarily from: (a) the effects of acquired companies
(approximately $7.3 million), (b) price increases (approximately $1.4 million),
(c) inventory valuation adjustments (approximately $1.0 million) and (d) a
favorable product mix (approximately $0.1 million). Increased gross profit was
partially offset by: (a) reduced volume (approximately $1.3 million) and (b)
increased manufacturing overhead (approximately $2.1 million).
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES.
<TABLE>
<CAPTION>
SELLING, GENERAL AND ADMINISTRATIVE PERCENT OF PERCENT OF DOLLAR PERCENT
EXPENSES: (IN THOUSANDS) 1998 SALES 1999 SALES CHANGE CHANGE
----------------------------------- -------- ---------- -------- ---------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Labware and Life Sciences......... $ 65,570 28.7% $ 68,600 25.5% $ 3,030 4.6%
Clinical and Industrial........... 23,082 17.0% 30,102 17.1% 7,020 30.4%
Diagnostics and Microbiology...... 34,294 29.9% 46,246 26.9% 11,952 34.9%
Laboratory Equipment.............. 16,405 20.8% 20,632 20.9% 4,227 25.8%
Corporate Office.................. 5,410 N/A 7,252 N/A 1,842 34.0%
-------- --- -------- --- ------- ----
Total Selling General and
Administrative Expenses......... $144,761 26.0% $172,832 24.2% $28,071 19.4%
======== === ======== === ======= ====
</TABLE>
Overall Company. Selling, general and administrative expenses for the year
ended September 30, 1999 increased by $28.1 million or 19.4% from 1998.
Labware and Life Sciences. Increased selling, general and administrative
expenses in the Labware and Life Sciences segment resulted primarily from: (a)
increased selling, general and administrative expenses as a result of acquired
businesses (approximately $4.9 million), (b) increased general and
administrative expenses (approximately $1.6 million), (c) increased amortization
of intangibles primarily as a result of acquisitions (approximately $0.9
million) and (d) unfavorable foreign currency fluctuations (approximately $0.5
million), partially offset by: (a) decreased marketing expenses (approximately
$2.3 million) and (b) the non-recurring 1998 Special Charges (approximately $2.4
million).
Clinical and Industrial. Increased selling, general and administrative
expenses in the Clinical and Industrial segment resulted primarily from: (a)
increased general and administrative expenses (approximately $2.8 million), (b)
increased selling, general and administrative expenses as a result of acquired
businesses (approximately $2.6 million), (c) increased amortization of
intangibles primarily as a result of acquisitions (approximately $1.4 million),
(d) increased marketing expenses (approximately $0.3 million),
30
<PAGE> 33
(e) unfavorable foreign currency fluctuations (approximately $0.2 million) and
(f) the non-recurring 1999 Special Charges (approximately $0.2 million),
partially offset by non-recurring 1998 Special Charges (approximately $0.4
million).
Diagnostics and Microbiology. Increased selling, general and
administrative expenses in the Diagnostics and Microbiology segment resulted
primarily from: (a) increased selling, general and administrative expenses as a
result of acquired businesses (approximately $11.4 million), (b) increased
amortization of intangibles primarily as a result of acquisitions (approximately
$3.0 million), (c) increased general and administrative expenses (approximately
$0.6 million), (d) increased marketing expenses (approximately $0.3 million) and
(e) increased research and development expense (approximately $0.1 million),
partially offset by non-recurring 1998 Special Charges (approximately $3.6
million).
Laboratory Equipment. Increased selling, general and administrative
expenses in the Laboratory Equipment segment resulted primarily from: (a)
increased selling, general and administrative expenses as a result of acquired
businesses (approximately $3.5 million), (b) increased amortization of
intangibles primarily as a result of acquisitions (approximately $0.4 million),
(c) increased general and administrative expenses (approximately $0.6 million),
(d) increased marketing expenses (approximately $0.3 million) and (e) increased
research and development expenses (approximately $0.1 million), partially offset
by: (a) the non-recurring 1998 Special Charges (approximately $0.4 million) and
(b) favorable foreign currency fluctuations (approximately $0.1 million).
Corporate Office. Increased general and administrative expenses at the
corporate office resulted primarily from: (a) an increase in legal expense and
professional fees (approximately $0.8 million), (b) increased salaries and
benefits (approximately $0.7 million) and (c) a decrease in the expenses charged
to SDS (approximately $0.3 million).
OPERATING INCOME.
<TABLE>
<CAPTION>
PERCENT OF PERCENT OF DOLLAR PERCENT
OPERATING INCOME: (IN THOUSANDS) 1998 SALES 1999 SALES CHANGE CHANGE
-------------------------------- -------- ---------- -------- ---------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Labware and Life Sciences......... $ 50,154 21.9% $ 67,404 25.1% $17,250 34.4%
Clinical and Industrial........... 34,269 25.3% 45,305 25.7% 11,036 32.2%
Diagnostics and Microbiology...... 25,113 21.9% 43,212 25.2% 18,099 72.1%
Laboratory Equipment.............. 18,292 23.2% 20,457 20.8% 2,165 11.8%
Corporate Office.................. (5,410) N/A (7,252) N/A (1,842) 34.0%
-------- --- -------- --- ------- ----
Total Operating Income............ $122,418 21.9% $169,126 23.7% $46,708 38.2%
======== === ======== === ======= ====
</TABLE>
As a result of the foregoing, operating income in 1999 increased by 38.2%
or $46.7 million over operating income in 1998.
INTEREST EXPENSE.
Interest expense was $40.1 million in 1999, an increase of $6.3 million
from 1998. The increase resulted from a higher average debt balance in 1999,
resulting primarily from funding acquisitions, partially offset by the reduction
of debt from our sale of NPT.
INCOME TAXES.
Taxes on income from continuing operations were $50.0 million, an increase
of $15.3 million from 1998. The increase resulted primarily from increased
taxable earnings offset partially by a lower effective tax rate.
INCOME FROM CONTINUING OPERATIONS.
As a result of the foregoing we had net income from continuing operations
of $77.4 million in 1999, as compared to $52.1 million in 1998.
31
<PAGE> 34
DISCONTINUED OPERATIONS.
Income from discontinued operations was $48.0 million in 1999, an increase
of $24.0 million from $23.9 million in 1998. The 1998 discontinued operations
resulted from income from the operations of SDS of $27.9 million net of tax, a
non-recurring charge of $7.8 million net of tax related to a legal settlement
partially offset by the operating results of NPT $3.8 million net of tax. The
1999 discontinued operations represent results of SDS of $47.8 million and the
results of NPT of $0.1 million through the sale date of March 31, 1999.
EXTRAORDINARY ITEM.
On March 31, 1999 Sybron completed the sale of NPT to Norton Performance
Plastics Corporation. Net proceeds from the sale, net of $1.9 million of selling
expenses and a reduction to the original purchase price of approximately $2.6
million, amounted to $83.2 million. The Company realized a gain on this sale of
$17.2 million (net of tax of $15.8 million). The proceeds of the sale net of tax
and expenses were used to repay approximately $67.9 million of debt under the
Company's credit facilities.
NET INCOME.
As a result of the foregoing, we had net income of $142.5 million in 1999,
as compared to net income of $76.0 million in 1998.
DEPRECIATION AND AMORTIZATION.
Depreciation and amortization expense is allocated among cost of sales,
selling, general and administrative expenses and other expense. Depreciation and
amortization increased $10.2 million in 1999 due to additional depreciation and
amortization from the step-up of assets and goodwill recorded from the various
acquisitions as well as routine operating capital expenditures.
INFLATION
We do not believe that inflation has had a material impact on net sales or
income during any of the periods presented above. There can be no assurance,
however, that our business will not be affected by inflation in the future.
LIQUIDITY AND CAPITAL RESOURCES
As a result of the acquisition of the Company's predecessor in 1987 and the
acquisitions we completed since 1987, we have increased the carrying value of
certain tangible and intangible assets consistent with generally accepted
accounting principles. Accordingly, our results of operations include a
significant level of non-cash expenses related to the depreciation of fixed
assets and the amortization of intangible assets, including goodwill. Goodwill
and intangible assets increased by approximately $187.7 million in 2000,
primarily as a result of continued acquisition activity.
Our capital requirements arise principally from indebtedness incurred in
connection with the permanent financing for the 1987 acquisition and our
subsequent refinancings, our obligation to pay rent under the Sale/ Leaseback
facility (as defined herein), our working capital needs, primarily related to
inventory and accounts receivable, our capital expenditures, primarily related
to purchases of machinery and molds, the purchase of various businesses and
product lines in execution of our acquisition strategy, payments to be made in
connection with our restructuring in 2000, and the periodic expansion of
physical facilities. It is currently our intent to pursue our acquisition
strategy. If acquisitions continue at our historical pace, of which there can be
no assurance, we may require financing beyond the capacity of our Credit
Facilities (as defined below). In addition, a certain acquisition previously
completed contains an "earnout provision" requiring a further payment of $6
million in the future if certain financial results are achieved by the acquired
company. Apogent expects this "earnout payment" to be made in fiscal 2001.
Approximately $116.5 million of cash was generated from operating activities in
2000, an increase of $1.4 million from 1999. Increased cash flow resulted
32
<PAGE> 35
from an increase in non-cash depreciation and amortization charged against net
income (approximately $17.6 million) partially offset by a decrease in cash flow
from operating activities resulting primarily from a decrease in net income
(approximately $14.2 million) and an increase in net assets (approximately $2.0
million). Approximately $193.2 million of cash was used in investing activities
in 2000, a decrease of $2.3 million, or 1.2%, from 1999. Decreased investing
activities resulted primarily from a decrease in acquisitions (approximately
$42.8 million), a non-recurring purchase of a security in 1999 (approximately
$50.5 million), an increase in dividends from Sybron Dental Management, Inc.
("SDM"), now a subsidiary of SDS, (approximately $22.0 million) partially offset
by non-recurring sale of NPT in 1999 (approximately $88.4 million), increased
capital expenditures (approximately $12.6 million), an increase in capital
contributions to SDM (approximately $5.2 million) and a decrease in the net
change in advances and loans to SDM (approximately $6.7 million). Approximately
$77.7 million of cash was provided from financing activities, primarily from
proceeds from the Company's Old Credit Facilities (as defined later herein) (net
of repayments) (approximately $57.8 million), proceeds from the exercise of
employee stock options (approximately $12.6 million) and other financing sources
(approximately $7.3 million). With respect to the 2000 Special Charges of
approximately $11.3 million, of which approximately $7.4 million represents cash
expenditures, as of September 30, 2000 we have made cash payments of
approximately $1.1 million. The Company expects to make future cash payments of
approximately $5.1 million in fiscal 2001 and approximately $1.2 million in
fiscal 2002 and beyond.
The statement contained in the immediately preceding paragraph concerning
our intent to continue to pursue our acquisition strategy is a forward-looking
statement. Our ability to continue our acquisition strategy is subject to a
number of uncertainties, including, but not limited to, our ability to raise
capital beyond the capacity of our Credit Facilities and the availability of
suitable acquisition candidates at reasonable prices. See "Cautionary Factors"
below.
Prior to the Spin-Off, the Company was party to a credit agreement (as
amended to date, the "Old Credit Agreement") with The Chase Manhattan Bank
("Chase") and certain other lenders providing for a tranche A term loan facility
of $300 million (the "Old Tranche A Term Loan Facility"), a tranche B term loan
facility of $300 million (the "Old Tranche B Term Loan Facility") and a
revolving credit facility of up to $600 million (the "Old Revolving Credit
Facility," and together with the Old Tranche A Term Loan Facility and the Old
Tranche B Term Loan Facility, the "Old Credit Facilities"). Both the Company and
SDM were obligors under the Old Credit Facilities and as such, certain
outstanding amounts under the Old Credit Facilities were historically recorded
on the books of SDM. Outstanding amounts under the Old Tranche A Term Loan
Facility, the Old Tranche B Term Loan Facility and the Old Revolving Credit
Facility at September 30, 2000 (including amounts recorded on the books of SDM)
were $270.8 million, $299.3 million and $379.0 million, respectively.
Outstanding amounts under the Old Tranche A Term Loan Facility, the Old Tranche
B Term Loan Facility and the Old Revolving Credit Facility at September 30, 2000
recorded on the books of the Company were $201.0 million, $179.9 million and
$256.4 million, respectively.
On December 1, 2000, the Company entered into a new credit agreement (the
"Credit Agreement") with Chase and certain other lenders providing for a term
loan facility of $300 million (the "Term Loan Facility") due in a single payment
on December 1, 2005, and a revolving credit facility of up to $500 million for a
period of up to five years (the "Revolving Credit Facility") and together with
the Term Loan Facility, the "Credit Facilities"). On December 11, 2000, the
Company borrowed approximately $563.0 million under the Credit Facilities and
together with funds aggregating $375.0 million ($307.1 million, the amount equal
to the outstanding amounts under the Old Credit Facilities attributable to SDS
on December 11, 2000 including accrued interest plus a cash dividend of $67.9
million from SDM to the Company), used such funds to repay all of the
outstanding amounts under the Old Credit Facilities, aggregating $938.0 million
(including accrued interest).
Payment of principal and interest with respect to the Old Credit
Facilities, the Credit Facilities and the Sale/Leaseback (as defined later
herein) have been and are anticipated to be our largest use of operating funds
in the future. The Old Tranche A Term Loan Facility and Old Revolving Credit
Facility provided for an annual interest rate, at our option, equal to (a) the
higher of (i) the rate from time to time publicly announced by Chase in New York
City as its prime rate, (ii) the federal funds rate plus 1/2 of 1%, and (iii)
the base CD
33
<PAGE> 36
rate plus 1%, (collectively referred to as "Old Tranche A ABR") or (b) the
adjusted interbank offered rate for eurodollar deposits ("Eurodollar Rate") plus
1/2% to 7/8% (the "Old Tranche A Eurodollar Rate Margin") depending upon the
ratio of our total debt to Consolidated Adjusted Operating Profit (as defined in
the Old Credit Agreement), or (c) with respect to certain advances under Old
Revolving Credit Facility, the rate set by the competitive bid process among the
parties to the Old Revolving Credit Facility ("CAF"). The Old Tranche B Term
Loan Facility provided for an annual interest rate, at our option, equal to (a)
the higher of (i) the rate from time to time publicly announced by Chase in New
York City as its prime rate plus 1% to 1 1/4%, (ii) the federal funds rate plus
of 1 1/2% to 1 3/4%, and (iii) the base CD rate plus 2% to 2 1/4%, depending
upon the ratio of our total debt to Consolidated Adjusted Operating Profit or
(b) the Eurodollar Rate plus 2% to 2 1/4% depending upon the ratio of our total
debt to Consolidated Adjusted Operating Profit. The average interest rate on the
Old Tranche A Term Loan Facility (inclusive of the swap agreements described
below) in 2000 was 6.25%. The average interest rate on the Old Tranche B Term
Loan Facility in 2000 was 8.3%. The average interest rate on the Old Revolving
Credit Facility in 2000 was 6.9%.
The Term Loan Facility provides for an annual interest rate, at the option
of the Company, equal to (a) the alternate base rate ("ABR") plus 0% to 1% (the
"Term ABR Margin") where ABR is the higher of (i) the rate from time to time
publicly announced by Chase in New York City as its prime rate, (ii) the federal
funds rate plus 1/2 of 1%, and (iii) the base CD rate plus 1% or (b) the
adjusted interbank offered rate for Eurodollar deposits ("Eurodollar Rates")
plus 3/4% to 2.0% (the "Term Loan Eurodollar Rate Margin"). The range on the
Term ABR Margin and the Eurodollar Rate Margin depend upon the Company's credit
rating from Standard and Poor's Rating Group ("S&P") and Moody's Investors
Service, Inc. ("Moody's"). Based on the Company's current credit rating, the
Term ABR margin and the Term Loan Eurodollar Margin would be 0.25% and 1.25%,
respectively. All amounts outstanding under the Term Loan facility are due in a
single installment on December 1, 2005.
The Revolving Credit Facility provides for an annual interest rate at the
option of the Company, equal to (a) ABR plus 0% to .375% (the "Revolving ABR
Margin") or (b) the Eurodollar Rates plus .375% to 1.375% (the "Revolving Loan
Eurodollar Rate Margin"). In addition, the Company has a third option to set the
rate by a competitive bid process among the parties to the Revolving Credit
Facility (the "CAF"). The Company also will pay a facility fee of .125% to .375%
for all commitments from the lenders, whether drawn or undrawn and a will pay a
utilization fee of 0.25% per annum if more than 50% of the Revolving Credit
Facility is drawn or the Term Loan Facility is still outstanding. The range on
the Revolving ABR Margin, the Revolving Loan Eurodollar Rate Margin and the
facility fee depend upon the Company's credit rating from S&P and Moody's. The
Revolving Credit Facility also provides for a multi currency sub facility
providing up to $100 million in sub commitments in non-dollar currencies. Terms
and conditions on the multi currency sub facility are to be agreed upon between
the Company and Chase and the lenders providing funding under such facility. The
Company may not exceed a total of $500 million in dollar and non-dollar
commitments under this Revolving Credit Facility. The Credit Facility also
provides for the issuance of standby letters of credit and commercial letters of
credit on behalf of the Company's subsidiaries as required in the ordinary
course of business as part of the working capital line. Based upon the Company's
current credit rating, the Revolving ABR Margin, the Revolving Loan Eurodollar
Rate Margin and the facility fee would be 0%, 0.8% and 0.2%, respectively. All
amounts outstanding under the Revolving Credit Facility are due on December 1,
2005.
As a result of the terms of our Old Credit Facilities and our Credit
Facilities, we are sensitive to a rise in interest rates. In order to reduce our
sensitivity to interest rate increases, from time to time we enter into interest
rate swap agreements. As of September 30, 2000, the Company has eight interest
rate swaps outstanding aggregating a notional amount of $381.0 million. Under
the terms of the swap agreements, the Company is required to pay a fixed rate
amount equal to the swap agreement rate listed below. In exchange for the
payment of the fixed rate amount, the Company receives a floating rate amount
equal to the three-month LIBOR rate in effect on the date of the swap agreements
and the subsequent reset dates. For each of the swap agreements the rate resets
on each quarterly anniversary of the swap agreement date until the swap
expiration date. The net interest rate paid by the Company is approximately
equal to the sum of the swap agreement rate plus the applicable Eurodollar Rate
Margin. In 2000, the Tranche A and Revolver Eurodollar Rate Margins
34
<PAGE> 37
were .75%. The Tranche B Eurodollar Margin was 2.0%. The swap agreement rates
and durations as of September 30, 2000 are as follows:
<TABLE>
<CAPTION>
EXPIRATION DATE NOTIONAL AMOUNT SWAP AGREEMENT DATE SWAP AGREEMENT RATE
--------------- --------------- ------------------- -------------------
<S> <C> <C> <C>
February 7, 2001................. $50 million August 7, 1997 5.910%
August 7, 2001................... $50 million August 7, 1997 5.900%
September 10, 2001............... $50 million December 8, 1995 5.623%
December 31, 2001................ $ 6 million March 24, 1999 5.500%
June 8, 2002..................... $50 million December 8, 1995 5.500%
July 31, 2002.................... $75 million May 7, 1997 6.385%
July 31, 2002.................... $50 million October 23, 1998 4.733%
October 1, 2002.................. $50 million October 1, 1999 6.260%
</TABLE>
On December 11, 2000, due to the extinguishment of debt, interest rate
swaps previously designated as cash flow hedges ceased to meet hedge criteria
under SFAS 133 as modified by SFAS 138. The approximate fair value on December
11, 2000 was $1.7 million. The Company sold these interest rate swaps on
December 12, 2000 for approximately $1.7 million and realized a gain of $1.1
million (net of tax). Because these interest rate swaps were designated as a
hedge against future variable rate interest payments and the extinguished debt,
the gain will continue to be carried in other comprehensive income and
recognized as an adjustment of yield interest expense of the Credit Facilities
over the remaining term of the interest rate contract.
Also as part of the permanent financing for the acquisition of Sybron's
predecessor in 1987, on December 22, 1988, we entered into the sale and
leaseback of what were our principal domestic facilities at that time (the
"Sale/Leaseback"). On December 11, 2000, the Sale/Leaseback was amended in
connection with the Distribution. Two of the five facilities covered by the
Sale/Leaseback were transferred to SDS in connection with the Spin-Off and the
annual obligation was reduced from $3.6 million to $2.2 million. On the fifth
anniversary of the leases and every five years thereafter (including renewal
terms), the rent will be increased by the percentage equal to 75% of the
percentage increase in the Consumer Price Index over the preceding five years.
The percentage increase to the rent in any five-year period is capped at 15%.
The next adjustment will occur on January 1, 2004.
We intend to fund our acquisitions, working capital requirements, capital
expenditure requirements, principal and interest payments, obligations under the
Sale/Leaseback, restructuring expenditures, other liabilities and periodic
expansion of facilities, to the extent available, with funds provided by
operations and short-term borrowings under the Revolving Credit Facility. To the
extent that funds are not available from those sources, particularly with
respect to our acquisition strategy, we intend to raise additional capital.
The Credit Agreement contains financial and operating covenants, including,
among other things: restrictions on investments; requirements that the Company
maintain certain financial ratios; restrictions on the ability of the Company
and its subsidiaries to create or permit liens, or to pay dividends or make
other restricted payments (as defined) in excess of $100,000 plus 50% of the
defined consolidated net income of the Company for each fiscal quarter ending
after September 30, 2000, less any dividends paid or other restricted payments
made after September 30, 2000; and limitations on incurrence of additional
indebtedness. The borrowings under the Credit Agreement are unsecured.
EUROPEAN ECONOMIC MONETARY UNIT
On January 1, 1999, eleven of the European Union countries (including four
countries in which we have operations) adopted the Euro as their single
currency. At that time, a fixed exchange rate was established between the Euro
and the individual countries' existing currencies (the "legacy currencies"). The
Euro trades on currency exchanges and is available for non-cash transactions.
Following the introduction of the Euro, the legacy currencies will remain legal
tender in the participating countries during a transition period from January 1,
1999 through January 1, 2002. Beginning on January 1, 2002, the European Central
Bank will issue
35
<PAGE> 38
Euro-denominated bills and coins for use in cash transactions. On or before July
1, 2002, the participating countries will withdraw all legacy bills and coins
and use the Euro as their legal currency.
Our operating units located in European countries affected by the Euro
conversion intend to keep their books in their respective legacy currencies
through a portion of the transition period. At this time, we do not expect
reasonably foreseeable consequences of the Euro conversion to have a material
adverse effect on our business operations or financial condition.
CAUTIONARY FACTORS
This report contains various forward-looking statements concerning our
prospects that are based on the current expectations and beliefs of management.
Forward-looking statements may also be made by us from time to time in other
reports and documents as well as oral presentations. When used in written
documents or oral statements, the words "anticipate," "believe," "continue,"
"estimate," "goal," "expect," "objective," "outlook" and similar expressions are
intended to identify forward-looking statements. The statements contained herein
and such future statements involve or may involve certain assumptions, risks and
uncertainties, many of which are beyond our control, that could cause our actual
results and performance to differ materially from what is expected. In addition
to the assumptions and other factors referenced specifically in connection with
such statements, the following factors could impact our business and financial
prospects:
- A significant portion of our revenue is generated outside the United
States, and we have significant operations outside the United States. We
are therefore subject to factors affecting our international operations,
including relevant foreign currency exchange rates, which can affect the
cost to produce our products or the ability to sell our products in
foreign markets, and the value in U.S. dollars of sales made in foreign
currencies. Other factors include our ability to obtain effective hedges
against fluctuations in currency exchange rates; foreign trade, monetary
and fiscal policies; laws, regulations and other activities of foreign
governments, agencies and similar organizations; risks associated with
having major manufacturing facilities located in countries, such as
Mexico and Hungary, which have historically been less stable than the
United States in several respects, including fiscal and political
stability; and risks associated with the economic downturn in other
countries.
- A significant portion of our growth over the past several years has been
achieved through our acquisition program, which has generated over 70
acquisitions since 1993. Our rate of continued growth is therefore
subject to factors affecting our ability to continue pursuing our current
acquisition strategy and to be successful with that strategy. These
factors include our ability to raise capital beyond the capacity of our
existing credit facilities or to use our stock for acquisitions, the cost
of the capital required to effect our acquisition strategy, the
availability of suitable acquisition candidates at reasonable prices,
competition for appropriate candidates, our ability to realize the
synergies expected to result from acquisitions, and the ability of our
existing personnel to efficiently handle increased transitional
responsibilities resulting from acquisitions.
- Our reliance on major independent distributors for a substantial portion
of our sales subjects our sales performance to volatility in demand from
distributors. We can experience volatility when distributors merge or
consolidate, when inventories are not managed to end-user demand, or when
distributors experience a softness in their sales. This volatility in
demand can also arise with large OEM customers to whom we sell direct.
Sales to our distributors and OEM customers are sometimes unpredictable
and wide variances sometimes occur quarter to quarter.
- Factors affecting certain high growth industries we serve, such as
consolidation in the drug discovery and diagnostics industries.
- Our ability to increase revenues, and to profitably distribute and sell
our products is subject to a number of risks, including any changes in
our business relationships with our principal distributors or OEM
customers, competitive factors such as the entrance of additional
competitors into our markets, pricing and technological competition,
risks associated with the development and marketing of new products in
order to remain competitive by keeping pace with advancing laboratory and
life science
36
<PAGE> 39
technologies, particularly in the genomics and other rapidly developing
technologies, and risks of unanticipated technological developments that
result in competitive disadvantages and create the potential for
impairment of our existing assets.
- Our business is subject to quarterly variations in operating results
caused by a number of factors, including business and industry
conditions, timing of acquisitions, distribution and OEM customer issues,
and other factors listed here. All these factors make it difficult to
predict operating results for any particular period.
- With respect to the Clinical and Industrial segment, factors affecting
our Erie Electroverre S.A. subsidiary's ability to manufacture the glass
used by the Clinical and Industrial segment's worldwide manufacturing
operations, including delays encountered in connection with the periodic
rebuild of the sheet glass furnace and furnace malfunctions at a time
when inventory levels are not sufficient to sustain this segment's flat
glass operations.
- Our ability to hire and retain competent employees is subject to a number
of risks, including unionization of our non-union employees and changes
in relationships with our unionized employees.
- Factors affecting our ability to obtain raw materials at reasonable
prices, especially white glass, which comes from a single source, our
Electroverre, SA facility in Switzerland.
- Our business has a significant amount of floating rate debt and can be
adversely affected by a rise in interest rates.
- There is a risk of strikes or other labor disputes at those locations
which are unionized which could affect our operations.
- Our ability to continue manufacturing and selling those of our products
that are subject to regulation by the United States Food and Drug
Administration or other domestic or foreign governments or agencies is
subject to a number of risks, including the promulgation of stricter laws
or regulations, reclassification of our products into categories subject
to more stringent requirements, or the withdrawal of the approval needed
to sell one or more of our products.
- The impact of changing public and private health care budgets including
reimbursement by private or governmental insurance programs, can affect
demand for or pricing of our products.
- Our business is subject to the risks of claims involving our products and
other legal and administrative proceedings, including the expense of
investigating, litigating and settling any claims.
- Our business is subject to risks affecting our operations in European
countries related to the conversion from local legacy currencies to the
Euro.
- Our business may be required to satisfy certain indemnification
obligations to SDS, or may not be able to collect on indemnification
rights from SDS. The domestic subsidiaries of Apogent and SDS,
respectively, have each agreed to indemnify the other (and related
parties) from and after the Distribution with respect to certain
indebtedness, liabilities and obligations. These indemnification
obligations could be significant. The availability of these indemnities
and our ability to collect on such indemnities from SDS depend upon the
future financial strength of both the Apogent and SDS.
- We may be subject to risks arising from other business and investment
considerations that may be disclosed from time to time in our Securities
and Exchange Commission filings or in other publicly available written
documents.
We undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
37
<PAGE> 40
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
RISK MANAGEMENT
We are exposed to market risk from changes in foreign currency exchange
rates and interest rates. To reduce our risk from these foreign currency rate
and interest rate fluctuations, we occasionally enter into various hedging
transactions. We do not anticipate material changes to our primary market risks
other than fluctuations in magnitude from increased or decreased foreign
currency denominated business activity or floating rate debt levels. We do not
use financial instruments for trading purposes and are not a party to any
leveraged derivatives.
FOREIGN EXCHANGE
We have, from time to time, used foreign currency options to hedge our
exposure from adverse changes in foreign currency rates. At September 30, 1999
and 2000 we had no outstanding foreign currency options. Our foreign currency
exposure exists primarily in the Danish Krone versus the U.S. dollar. Hedging is
accomplished by the use of foreign currency options, and the gain or loss on
these options is used to offset gains or losses in the foreign currencies to
which they pertain. The purpose of our foreign currency hedging activities is to
protect against risk that eventual cash flows from foreign activities will be
adversely affected by changes in exchange rates. Recognized gains or losses on
foreign currency option contracts entered into to hedge sales are recorded as
"net sales." We have not entered into any foreign currency options to hedge our
exposure in fiscal 2001.
In 2001, we expect our exposure from our primary foreign currency, the
Danish Krone to approximate the following:
<TABLE>
<CAPTION>
ESTIMATED
EXPOSURE DENOMINATED ESTIMATED
IN THE RESPECTIVE EXPOSURE IN
CURRENCY FOREIGN CURRENCY U.S. DOLLARS
-------- -------------------- ------------
(IN THOUSANDS)
<S> <C> <C>
Danish Krone (DKK)..................................... 92,500 DKK $11,000
</TABLE>
As a result of this exposure, Apogent intends to enter into foreign
currency protection agreements to mitigate the risk of the dollar strengthening
against the Danish Krone.
INTEREST RATES
We use interest rate swaps to reduce our exposure to interest rate
movements. Our net exposure to interest rate risk consists of floating rate
instruments whose interest rates are determined by the Eurodollar Rate. Interest
rate risk management is accomplished by the use of swaps to create fixed
interest rate debt by resetting Eurodollar Rate loans concurrently with the
rates applying to the swap agreements. At September 30, 2000 we had floating
rate debt of approximately $949.1 million (inclusive of floating rate debt
recorded on the books of SDS of $311.4 million) which a total of $381 million
was swapped to fixed rates. The net interest rate paid by the Company is
approximately equal to the sum of the swap agreement rate plus the applicable
Eurodollar Rate Margin. In 2000, the Old Tranche A and Old Revolver Eurodollar
Rate Margins were .75%. The Old Tranche B Eurodollar Margin, which became
applicable on July 29, 1999, was 2.0%. The
38
<PAGE> 41
Eurodollar Rate Margins on the Credit Facility entered into on December 11, 2000
is 1.25%. The swap agreement rates and durations as of September 30, 2000 are as
follows:
<TABLE>
<CAPTION>
EXPIRATION DATE NOTIONAL AMOUNT SWAP AGREEMENT DATE SWAP AGREEMENT RATE
--------------- --------------- ------------------- -------------------
<S> <C> <C> <C>
February 7, 2001................. $50 million August 7, 1997 5.910%
August 7, 2001................... $50 million August 7, 1997 5.900%
September 10, 2001............... $50 million December 8, 1995 5.623%
December 31, 2001................ $ 6 million March 24, 1999 5.500%
June 8, 2002..................... $50 million December 8, 1995 5.500%
July 31, 2002.................... $75 million May 7, 1997 6.385%
July 31, 2002.................... $50 million October 23, 1998 4.733%
October 1, 2002.................. $50 million October 1, 1999 6.260%
</TABLE>
On December 11, 2000, due to the extinguishment of debt, interest rate
swaps previously designated as cash flow hedges ceased to meet hedge criteria
under SFAS 133 as modified by SFAS 138. The approximate fair value on December
11, 2000 was $1.7 million. The Company sold these interest rate swaps on
December 12, 2000 for approximately $1.7 million and realized a gain of $1.1
million (net of tax). Because these interest rate swaps were designated as a
hedge against future variable rate interest payments and the extinguished debt,
the gain will continue to be carried in other comprehensive income and
recognized as an adjustment of yield interest expense of the Credit Facilities
over the remaining term of the interest rate contract.
In addition to the aforementioned swaps, on September 29, 1999, the Company
entered into a securities lending agreement in which we purchased a United
States Treasury Bond ("Treasury") with a par value of $50 million, an interest
rate of 6.15% and a maturity date of August 15, 2029. Concurrent with the
purchase of the Treasury, the Company lent the security to an unrelated third
party for a period of 23 years. In exchange for the loaned Treasury, the Company
has received collateral equal to the market value of the Treasury on the date of
the loan, and adjusted on a weekly basis. This securities lending transaction is
related to the Company's consistent hedging policy by fixing $50.0 million of
its floating rate debt. For a period of five years the Company is obligated to
pay a rebate on the loaned collateral at an annual fixed rate of 6.478% and is
entitled to receive a fee for the loan of the security at a floating rate equal
to LIBOR minus .75%. Thereafter, the Company is required to pay the unrelated
third party a collateral fee equal to the one-week general collateral rate of
interest (as determined weekly in good faith by the unrelated third party,
provided that such rate shall not exceed the federal funds rate in effect as of
the day of determination plus .25%) and the Company receives all distributions
on or in respect to the Treasury.
The model below quantifies the Company's sensitivity to interest rate
movements as determined by the Eurodollar Rate and the effect of the interest
rate swaps which reduce that risk. The model assumes a) a base Eurodollar Rate
of 6.8% (the "Eurodollar Base Rate") which approximates the September 30, 2000
three month Eurodollar Rate, b) the Company's floating rate debt is equal to its
September 30, 2000 floating rate debt balance of $637.7 million, c) the Company
pays interest on floating rate debt equal to the Eurodollar Rate + 125 basis
points, d) the Company has interest rate swaps (including the securities lending
agreement) with a notional amount of $431.0 million (equal to the notional
amount of the Company's interest rate swaps at September 30, 2000), and e) the
Eurodollar Rate varies by 10% of the Base Rate.
<TABLE>
<CAPTION>
INTEREST EXPENSE INCREASE FROM A 10% INTEREST EXPENSE DECREASE FROM A 10%
INTEREST RATE EXPOSURE INCREASE IN THE EURODOLLAR BASE RATE DECREASE IN THE EURODOLLAR BASE RATE
---------------------- ------------------------------------ ------------------------------------
<S> <C> <C>
Without interest rate swaps:....... $4.3 million $(4.3 million)
With interest rate swaps:.......... $1.4 million $(1.4 million)
</TABLE>
As discussed above, the Company sold the interest rate swaps on December
12, 2000. As a result of the refinancing of the Company's debt in connection
with the Distribution, and the sale of the interest rate swaps, the Company's
exposure at December 12, 2000 differed from its exposure on September 30, 2000.
39
<PAGE> 42
The model below quantifies the Company's sensitivity to interest rate
movements as determined by the Eurodollar Rate. The model assumes a) a base
Eurodollar Rate of 6.6% (the "Eurodollar Base Rate") which approximates the
December 11, 2000 three month Eurodollar Rate, b) the Company's floating rate
debt is equal to its December 11, 2000 floating rate debt balance of $569.0
million, c) the Company pays interest on floating rate debt equal to the
Eurodollar Rate + 125 basis points, d) the Company has interest rate swaps of
$50 million (including the securities lending agreement), and e) the Eurodollar
Rate varies by 10% of the Base Rate.
<TABLE>
<CAPTION>
INTEREST EXPENSE INCREASE FROM A 10% INTEREST EXPENSE DECREASE FROM A 10%
INTEREST RATE EXPOSURE INCREASE IN THE EURODOLLAR BASE RATE DECREASE IN THE EURODOLLAR BASE RATE
---------------------- ------------------------------------ ------------------------------------
<S> <C> <C>
Without interest rate swaps:....... $3.8 million $(3.8 million)
With interest rate swaps:.......... $3.4 million $(3.4 million)
</TABLE>
40
<PAGE> 43
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
SYBRON INTERNATIONAL CORPORATION
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Independent Auditors' Report................................ 42
Consolidated Balance Sheets as of September 30, 1999 and
2000...................................................... 43
Consolidated Statements of Income for the years ended
September 30, 1998, 1999 and 2000......................... 44
Consolidated Statements of Shareholders' Equity for the
years ended September 30, 1998, 1999 and 2000............. 45
Consolidated Statements of Cash Flows for the years ended
September 30, 1998, 1999 and 2000......................... 46
Notes to Consolidated Financial Statements.................. 47
</TABLE>
41
<PAGE> 44
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Shareholders
Sybron International Corporation:
We have audited the accompanying consolidated balance sheets of Sybron
International Corporation and subsidiaries as of September 30, 1999 and 2000,
and the related consolidated statements of income, shareholders' equity, and
cash flows for each of the years in the three-year period ended September 30,
2000. These consolidated financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial position of Sybron
International Corporation and subsidiaries as of September 30, 1999 and 2000,
and the results of their operations and their cash flows for each of the years
in the three-year period ended September 30, 2000, in conformity with accounting
principles generally accepted in the United States of America.
KPMG LLP
Milwaukee, Wisconsin
November 13, 2000 except as to footnote 19
which is as of December 11, 2000.
42
<PAGE> 45
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 1999 AND 2000
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
<TABLE>
<CAPTION>
SEPTEMBER 30,
-----------------------
1999 2000
---------- ----------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents................................. $ 12,401 $ 12,411
Accounts receivable (less allowance for doubtful
receivables of $3,098 and $4,041 in 1999 and 2000,
respectively) (note 2)................................. 147,296 173,585
Inventories (note 3)...................................... 123,628 141,779
Deferred income taxes (note 4)............................ 18,325 13,226
Net assets held for discontinued operations (note 15)..... 155,595 152,970
Prepaid expenses and other current assets................. 9,083 16,564
---------- ----------
Total current assets.............................. 466,328 510,535
---------- ----------
Available for sale security (note 7)...................... 50,900 54,444
Property, plant and equipment, net (notes 5 and 7)........ 187,759 208,094
Intangible assets (note 6)................................ 820,475 1,008,153
Deferred income taxes (note 4)............................ 7,667 7,870
Other assets.............................................. 6,846 3,268
---------- ----------
Total assets...................................... $1,539,975 $1,792,364
========== ==========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable.......................................... $ 49,296 $ 51,899
Advances and loans from SDS (note 13)..................... 56,777 77,762
Current portion of long-term debt (notes 7 and 8)......... 7,391 34,327
Income taxes payable (note 4)............................. 18,372 16,604
Accrued payroll and employee benefits (note 10)........... 35,594 30,509
Restructuring reserve (note 11)........................... 987 5,609
Deferred income taxes (note 4)............................ 717 807
Other current liabilities (notes 11 and 15)............... 29,045 23,622
---------- ----------
Total current liabilities......................... 198,179 241,139
---------- ----------
Long-term debt (notes 7 and 8)............................ 591,807 649,409
Securities lending agreement (note 7)..................... 50,461 54,444
Deferred income taxes (note 4)............................ 69,888 93,048
Other liabilities (note 10)............................... 4,296 4,808
Commitments and contingent liabilities (notes 8, 10 and
13)
Shareholders' equity (note 12):
Preferred stock, $0.01 par value; authorized 20,000,000
shares................................................ -- --
Common stock, $0.01 par value; authorized 250,000,000
shares, issued 104,023,917 and 105,191,692 shares in
1999 and 2000, respectively; outstanding 104,023,697
and 105,191,692 shares in 1999 and 2000,
respectively.......................................... 1,040 1,052
Equity rights, 50 rights at $1.09 per right in 1999 and
2000.................................................. -- --
Additional paid-in capital............................. 251,251 271,739
Retained earnings...................................... 403,380 531,701
Accumulated other comprehensive income (note 17)....... (30,327) (54,976)
Treasury common stock, 220 shares at cost in 1999 and
2000.................................................. -- --
---------- ----------
Total shareholders' equity........................ 625,344 749,516
---------- ----------
Total liabilities and shareholders' equity........ $1,539,975 $1,792,364
========== ==========
</TABLE>
See accompanying notes to consolidated financial statements.
43
<PAGE> 46
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
FOR THE YEARS ENDED SEPTEMBER 30, 1998, 1999 AND 2000
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
1998 1999 2000
-------- -------- --------
<S> <C> <C> <C>
Net sales................................................... $557,762 $715,037 $863,575
Cost of sales:
Cost of product sold...................................... 288,522 372,528 436,508
Restructuring charge (note 11)............................ 1,510 -- 4,413
Depreciation of purchase accounting adjustments........... 551 551 524
-------- -------- --------
Total cost of sales......................................... 290,583 373,079 441,445
-------- -------- --------
Gross profit................................................ 267,179 341,958 422,130
-------- -------- --------
Selling, general and administrative expenses................ 118,523 147,883 186,418
Restructuring charge (note 11).............................. 7,093 245 5,840
Depreciation and amortization of purchase accounting
adjustments............................................... 19,145 24,704 36,883
-------- -------- --------
Total selling, general and administrative expenses.......... 144,761 172,832 229,141
-------- -------- --------
Operating income............................................ 122,418 169,126 192,989
-------- -------- --------
Other income (expense):
Interest expense (notes 7 and 10)......................... (33,772) (40,073) (48,684)
Interest expense -- SDS (note 13)......................... (1,498) (1,151) (766)
Amortization of deferred financing fees (note 7).......... (151) (224) (533)
Other, net................................................ (161) (286) 1,319
-------- -------- --------
Income from continuing operations before income taxes and
extraordinary items....................................... 86,836 127,392 144,325
Income taxes (note 4)....................................... 34,714 49,981 57,601
-------- -------- --------
Income from continuing operations........................... 52,122 77,411 86,724
Discontinued operations (net of income tax expense of
$16,347, $30,930 and $28,339) (notes 14 and 15)........... 23,921 47,965 41,597
-------- -------- --------
Income before extraordinary item............................ 76,043 125,376 128,321
Extraordinary item --
Gain on sale of discontinued operations (net of income tax
expense of $15,828) (note 15).......................... -- 17,171 --
-------- -------- --------
Net income.................................................. $ 76,043 $142,547 $128,321
======== ======== ========
Basic earnings per common share from continuing
operations................................................ $ .51 $ .75 $ .83
Discontinued operation...................................... .23 .46 .40
Extraordinary item.......................................... -- .17 --
-------- -------- --------
Basic earnings per common share............................. $ .74 $ 1.38 $ 1.23
======== ======== ========
Diluted earnings per common share from continuing
operations................................................ $ .49 $ .73 $ .81
Discontinued operation...................................... .23 .45 .39
Extraordinary item.......................................... -- .16 --
-------- -------- --------
Diluted earnings per common share........................... $ .72 $ 1.34 $ 1.20
======== ======== ========
</TABLE>
See accompanying notes to consolidated financial statements.
44
<PAGE> 47
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
FOR THE YEARS ENDED SEPTEMBER 30, 1998, 1999 AND 2000
(IN THOUSANDS, EXCEPT SHARE DATA)
<TABLE>
<CAPTION>
ACCUMULATED TOTAL
ADDITIONAL OTHER TREASURY SHARE-
COMMON EQUITY PAID-IN RETAINED COMPREHENSIVE COMMON HOLDERS'
STOCK RIGHTS CAPITAL EARNINGS INCOME STOCK EQUITY
------ ------ ---------- -------- ------------- -------- --------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance at September 30, 1997...... $1,014 $-- $212,665 $189,952 $(24,981) $(1) $378,649
Comprehensive Income:
Net income....................... -- -- -- 76,043 -- -- 76,043
Translation adjustment........... 4,293 4,293
------ --- -------- -------- -------- --- --------
Total comprehensive income......... -- -- -- 76,043 4,293 -- 80,336
Shares issued in connection with
1,445,760 stock options.......... 15 -- 12,970 -- -- -- 12,985
Conversion of 200 equity rights to
872 common stock................. -- -- -- (1) -- 1 --
Tax benefits related to stock
options.......................... -- -- 7,291 -- -- -- 7,291
Dividends paid by "A" Company prior
to the merger.................... -- -- 314 (479) -- -- (165)
Dividends paid by Pinnacle Products
prior to merger.................. -- -- -- (4,682) -- -- (4,682)
Shares issued -- deferred
compensation Plan "A" Company.... -- -- 830 -- -- -- 830
------ --- -------- -------- -------- --- --------
Balance at September 30, 1998...... 1,029 -- 234,070 260,833 (20,688) -- 475,244
Comprehensive Income:
Net income....................... -- -- -- 142,547 -- -- 142,547
Translation adjustment........... -- -- -- -- (9,905) -- (9,905)
Unrealized gain on security
available for sale............. -- -- -- -- 266 -- 266
------ --- -------- -------- -------- --- --------
Total comprehensive income......... -- -- -- 142,547 (9,639) -- 132,908
Shares issued in connection with
1,121,421 stock options.......... 11 -- 10,680 -- -- -- 10,691
Tax benefits related to stock
options.......................... -- -- 6,501 -- -- -- 6,501
------ --- -------- -------- -------- --- --------
Balance at September 30, 1999...... 1,040 -- 251,251 403,380 (30,327) -- 625,344
Comprehensive Income:
Net income....................... -- -- -- 128,321 -- -- 128,321
Translation adjustment........... -- -- -- -- (26,773) -- (26,773)
Unrealized gain on security
available for sale............. -- -- -- -- 2,124 -- 2,124
------ --- -------- -------- -------- --- --------
Total comprehensive income......... -- -- -- 128,321 (24,649) -- 103,672
Shares issued in connection with
1,167,775 stock options.......... 12 -- 12,587 -- -- -- 12,599
Tax benefits related to stock
options.......................... -- -- 7,901 -- -- -- 7,901
------ --- -------- -------- -------- --- --------
Balance at September 30, 2000...... $1,052 $-- $271,739 $531,701 $(54,976) $-- $749,516
====== === ======== ======== ======== === ========
</TABLE>
See accompanying notes to consolidated financial statements.
45
<PAGE> 48
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED SEPTEMBER 30, 1998, 1999 AND 2000
(IN THOUSANDS)
<TABLE>
<CAPTION>
1998 1999 2000
--------- -------- --------
<S> <C> <C> <C>
Cash flows from operating activities:
Net income................................................ $ 76,043 $142,547 $128,321
Adjustments to reconcile net income to net cash provided
by operating activities:
Discontinued operations................................. (23,921) (47,965) (41,597)
Depreciation............................................ 18,970 24,105 27,957
Amortization............................................ 19,860 24,890 38,630
Loss (gain) on sales of property, plant and equipment... 50 (39) 79
Provision for losses on doubtful receivables............ 462 907 863
Inventory provisions.................................... (599) 706 (833)
Deferred income taxes................................... (5,072) 17,876 10,258
Extraordinary item...................................... -- (17,171) --
Changes in assets and liabilities, net of effects of
businesses acquired:
Increase in accounts receivable....................... (6,001) (19,817) (15,537)
Increase in inventories............................... (5,870) (12,646) (7,248)
(Increase) decrease in prepaid expenses and other
current assets...................................... (2,359) 4,627 (7,200)
Increase (decrease) in accounts payable............... 2,196 2,436 (294)
Increase (decrease) in income taxes payable........... 13,892 (1,269) (1,768)
Decrease in other current liabilities................. (11,410) (5,812) (6,211)
Increase (decrease) in accrued payroll and employee
benefits............................................ 2,549 7,212 (4,993)
Increase (decrease) in restructuring reserve.......... 14,037 (7,036) 1,744
Net change in other assets and liabilities............ 11,828 1,551 (5,627)
--------- -------- --------
Net cash provided by operating activities............. 104,655 115,102 116,544
Cash flows from investing activities:
Capital expenditures...................................... (32,797) (29,920) (42,493)
Security purchased........................................ -- (50,461) --
Proceeds from sales of property, plant and equipment...... 5,129 945 924
Proceeds from sale of NPT................................. -- 85,841 (2,600)
Dividends received from SDS............................... 47,225 36,483 58,512
Capital contributions paid to SDS......................... (49,268) (16,210) (21,399)
Net change in advances and loans to SDS................... (26,088) 27,689 20,985
Net payments for businesses acquired...................... (192,017) (249,923) (207,153)
--------- -------- --------
Net cash used in investing activities............... (247,816) (195,556) (193,224)
Cash flows from financing activities:
Proceeds from long term debt.............................. 100,000 180,000 --
Principal payments on long-term debt...................... (19,562) (66,770) (450)
Securities lending agreement.............................. -- 50,461 3,544
Proceeds from the exercise of stock options............... 12,985 10,691 12,599
Refinancing fees.......................................... (357) (4,163) --
Proceeds -- revolving credit facility..................... 291,960 351,060 332,640
Principal payments -- revolving credit facility........... (243,960) (448,980) (274,320)
Other..................................................... 521 6,093 3,646
--------- -------- --------
Net cash provided by financing activities........... 141,587 78,392 77,659
Effect of exchange rate changes on cash and cash
equivalents............................................... 429 (146) (969)
Net increase (decrease) in cash and cash equivalents........ (1,145) (2,208) 10
Cash and cash equivalents at beginning of year.............. 15,754 14,609 12,401
--------- -------- --------
Cash and cash equivalents at end of year.................... $ 14,609 $ 12,401 $ 12,411
========= ======== ========
Supplemental disclosures of cash flow information:
Cash paid during the year for:
Interest.................................................. $ 32,645 $ 41,718 $ 55,833
========= ======== ========
Income taxes.............................................. $ 20,462 $ 32,431 $ 42,412
========= ======== ========
Capital lease obligations incurred.......................... $ 183 $ 457 $ 25
========= ======== ========
</TABLE>
See accompanying notes to consolidated financial statements.
46
<PAGE> 49
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 1998, 1999 AND 2000
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA)
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The subsidiaries of Sybron International Corporation are leading
manufacturers of value-added products for the laboratory market in the United
States and abroad. The Company's laboratory subsidiaries manufacture products
for the Labware and Life Sciences, Clinical and Industrial, Diagnostic and
Microbiology and Laboratory Equipment business segments. See note 16.
On November 8, 2000, Sybron International Corporation announced that it had
declared a pro rata distribution to its shareholders of the common stock and
related preferred stock purchase rights of Sybron Dental Specialties, Inc.
(formerly known as SDS Holding Co.) (the "Distribution"). On December 11, 2000,
shareholders of record as of November 30, 2000 received one share of Sybron
Dental Specialties, Inc. common stock for every three shares of Sybron
International common stock they owned as of the record date. Sybron Dental
Specialties, Inc. owns all of the outstanding stock of Sybron Dental Management,
Inc., formerly named Sybron Dental Specialties, Inc. Prior to the Distribution,
Sybron Dental Management, Inc. was a direct wholly-owned subsidiary of the
Company and operated the Company's dental business. Immediately prior to the
Distribution, the Company contributed all of the stock of Sybron Dental
Management, Inc. to Sybron Dental Specialties, Inc. As used in these Notes to
the Consolidated Financial Statements, the term "SDS" means Sybron Dental
Management, Inc. (formerly known as Sybron Dental Specialties, Inc.) for the
periods prior to the Distribution, and Sybron Dental Specialties, Inc. (formerly
known as SDS Holding Co.) for periods after the Distribution.
(a) Principles of Consolidation and Fiscal Year End
The consolidated financial statements reflect the accounts of Sybron
International Corporation and its subsidiaries. The term "Company" or "Sybron"
as used herein refers to Sybron International Corporation and its subsidiaries
and their respective predecessors, unless the context otherwise requires. All
significant intercompany balances and transactions have been eliminated. The
Company's fiscal year ends on September 30. The fiscal years ended September 30,
1998, 1999 and 2000 are hereinafter referred to as "1998," "1999" and "2000,"
respectively. On March 31, 1999 and December 11, 2000, respectively, the Company
sold Nalge Process Technologies Group, Inc. ("NPT") (the "NPT Sale") and
completed the Distribution. The net assets and results of operations of SDS and
NPT have been presented as discontinued operations in all years presented
herein.
(b) Cash Equivalents
For purposes of reporting cash flows, cash and cash equivalents include
investments in debt obligations with original maturities of three months or
less.
(c) Inventories
Inventories are stated at the lower of cost or market. Elements of cost
included in inventories are: raw materials, direct labor, manufacturing overhead
(which includes indirect labor, fringe benefits, consumable supplies,
depreciation of production equipment and tooling) and retained costs
representing the excess of manufacturing or production costs over amounts
charged to cost of sales. Certain domestic inventories of approximately $53,884
and $50,854 at September 30, 1999 and 2000, respectively, are valued on the
last-in, first-out (LIFO) method. The remaining inventories are valued on the
first-in, first-out (FIFO) method.
47
<PAGE> 50
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(d) Securities
When securities are purchased they are classified as held-to-maturity,
available for sale or trading securities. Held to maturity securities are those
which the Company has the positive intent and ability to hold until maturity.
Trading securities are those purchased and held with the intent to sell in the
near term. Available for sale securities include debt securities which are held
for an indefinite period but are neither held to maturity nor trading
securities. At September 30, 1999 and 2000, the Company held a U.S. Treasury
Bond classified as an available for sale security. Available for sale securities
are reported at fair market value. Unrealized gains and losses for this security
are included in comprehensive income as a separate component of shareholders'
equity. See note 7.
(e) Property, Plant and Equipment
Property, plant and equipment are stated at cost less accumulated
depreciation. Depreciation is provided over the estimated useful lives of
depreciable assets (5 to 45 years for land improvements, buildings and building
improvements, and 3 to 12 years for machinery and equipment) using the
straight-line method. The Company assesses the recoverability of assets by
comparing the carrying amount of an asset to future net cash flows expected to
be generated by that asset. If such assets are considered impaired, the
impairment to be recognized is measured by the amount by which the carrying
amount of the assets exceed the fair market value of the assets.
(f) Intangible Assets
Intangible assets are recorded at cost and are amortized, using the
straight-line method, over their estimated useful lives. Excess costs over net
asset values acquired (goodwill) are amortized over 10 to 40 years; proprietary
technology, trademarks, customer lists and other intangibles are amortized over
12 to 20 years, 5 to 40 years, 7 to 40 years, and 1 to 40 years, respectively.
The Company assesses the recoverability of its goodwill by determining whether
the amortization of the goodwill balance over its remaining life can be
recovered through projected undiscounted future cash flows of the acquired
businesses. If projected future cash flows indicate that unamortized goodwill
will not be recovered, an adjustment would be made to reduce the net goodwill to
fair value. Cash flow projections are based on trends of historical performance
and management's estimate of future performance, giving consideration to
existing and anticipated competitive and economic conditions. Adjustments to
goodwill were made in 1998 as referred to in note 11. No adjustments were made
to goodwill in 1999 or 2000.
(g) Revenue Recognition
The Company recognizes revenue upon shipment of products when persuasive
evidence of a sales arrangement exists, the price to the buyer is fixed and
determinable and collectibility of the sales price is reasonably assured. A
large portion of the Company's sales are sold through distributors. Revenues
associated with sales to distributors are also recognized upon shipment of
products when all risks and rewards of ownership of the product are passed. The
Company is not obligated to allow for returns.
(h) Income Taxes
Income taxes are accounted for under the asset and liability method wherein
deferred tax assets and liabilities are recognized for future tax consequences
attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases and operating
loss and tax credit carryforwards. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or
settled. The effect on deferred tax assets and liabilities of a change in tax
rates is recognized in income or other comprehensive income in the period that
includes the enactment date.
48
<PAGE> 51
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(i) Research and Development Costs
Research and development costs are charged to selling, general and
administrative expenses in the year they are incurred. Research and development
costs for 1998, 1999 and 2000 were approximately $8,738, $12,562 and $18,302,
respectively.
(j) Foreign Currency Translation
The functional currency for the Company's foreign operations is the
applicable local currency. The translation from the applicable foreign
currencies to U.S. dollars is performed for balance sheet accounts using current
exchange rates in effect at the balance sheet date and for revenue and expense
accounts using a weighted average exchange rate during the period. The gains or
losses, net of applicable deferred income taxes, resulting from such
translations are included in shareholders' equity. Gains and losses resulting
from foreign currency transactions are included in net income. Foreign currency
transaction gains for 1998, 1999 and 2000 were approximately $247, $403 and
$1,306, respectively.
(k) Pensions
The Company and its subsidiaries have various pension plans covering
substantially all employees. U.S. pension obligations are funded by payments to
pension fund trustees. Other foreign pensions are funded as expenses are
incurred. The Company's policy with respect to its defined benefit plans is
generally to fund the minimum amount required under the Employee Retirement
Income Security Act of 1974, as amended, for plans subject thereto.
(l) Earnings Per Common Share
Basic earnings per common share is calculated by dividing net income by the
weighted average number of common shares outstanding in the period presented.
Diluted earnings per common share is calculated by dividing net income by the
weighted average number of common shares outstanding plus dilutive effects of
potential common shares outstanding during the period. A reconciliation of
shares used in calculating basic and diluted earnings per share follows:
<TABLE>
<CAPTION>
1998 1999 2000
------- ------- -------
<S> <C> <C> <C>
Basic................................................... 102,320 103,412 104,570
Effect of assumed conversion of employee stock
options............................................... 3,541 3,158 2,233
------- ------- -------
Diluted................................................. 105,861 106,570 106,803
======= ======= =======
</TABLE>
Options to purchase 4,162,920 shares of common stock at prices ranging from
$23.81 to $24.50 per share were outstanding during a portion of 1998 but were
not included in the computation of diluted earnings per share because the
options' exercise price was greater than the average market price of the common
shares. The options, which expire in fiscal 2008, were still outstanding at the
end of fiscal year 1998.
Options to purchase 570,724 shares of common stock at prices ranging from
$25.74 to $26.75 per share were outstanding during a portion of 1999 but were
not included in the computation of diluted earnings per share because the
options' exercise price was greater than the average market price of the common
shares. The options, which expire in fiscal 2009, were still outstanding at the
end of fiscal year 1999.
Options to purchase 904,844 shares of common stock at prices ranging from
$25.31 to $32.00 per share were outstanding during a portion of 2000 but were
not included in the computation of diluted earnings per share because the
options' exercise price was greater than the average market price of the common
shares. The options, which expire in fiscal 2010, were still outstanding at the
end of fiscal year 2000.
49
<PAGE> 52
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(m) Deferred Financing Fees
Deferred financing fees are capitalized and amortized as a separate
component of other income over the life of the related debt agreements.
(n) Advertising Costs
Advertising costs included in selling, general and administrative expenses
are expensed as incurred and were $4,480, $5,730 and $6,014 in 1998, 1999 and
2000, respectively.
(o) Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
(p) Derivative Financial Instruments
Derivative financial instruments are used by the Company in the management
of its interest rate and foreign currency exposures.
The Company uses interest rate swaps to manage its interest rate risk. The
net amounts to be paid or received under interest rate swap agreements
designated as hedges are accrued as interest rates change and are recognized
over the life of the swap agreements, as an adjustment to interest expense from
the underlying debt to which the swap is designated. The related amounts payable
to, or receivable from, the counterparties are included in other current assets
or other current liabilities. See note 9.
The Company, from time to time, enters into foreign exchange options
relating to the anticipated cash flow in local currencies of certain foreign
operations. These options allow the Company to exchange foreign currencies for
U.S. dollars. The purpose of the Company's foreign currency hedging activities
is to protect the Company from the risk that eventual cash flows from foreign
activities will be adversely affected by changes in exchange rates. The
recognition of gains or losses on foreign currency option contracts entered into
to hedge sales are recorded as "net sales." The Company had no foreign exchange
option contracts at September 30, 1999 or 2000.
On October 1, 2000, the Company adopted Financial Accounting Standard Board
Opinions No. 133 ("SFAS 133") as modified by FASB Opinion No. 138. These
standards establish accounting and reporting standards for derivative
instruments, including certain derivative instruments embedded in other
contracts, and hedging activities. They require the recognition of all
derivative instruments as assets or liabilities in the balance sheet at fair
value. The accounting treatment of changes in fair value is dependent upon
whether or not a derivative instrument is designated as a hedge and if so, the
type of hedge. For derivatives designated as a cash flow hedge, changes in fair
value are recognized in other comprehensive income until the hedged item is
recognized in earnings. At October 1, 2000 the Company had no freestanding
derivatives in place other than interest rate swaps used to hedge variable rate
long-term debt and had no material embedded derivatives. The interest rate swaps
meet the criteria for cash flow hedge accounting. As a result, the swaps are
recorded on the balance sheet as an asset at fair value with the corresponding
gain or loss recorded in other comprehensive income beginning October 1, 2000.
The impact on other comprehensive income upon adoption of the standard was an
unrealized gain, net of tax, of approximately $2,530.
On September 29, 2000, the Financial Accounting Standard Board issued
Statement of Financial Accounting Standards No. 140, Accounting of Transfers and
Servicing of Financial Assets and Extinguish-
50
<PAGE> 53
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
ments of Liabilities ("SFAS 140"). SFAS 140 modifies and replaces Statement of
Financial Accounting Standards No. 125. SFAS 140 provides the accounting and
reporting guidance for transfers and servicing of financial assets and
extinguishments of liabilities and will be the authoritative accounting
literature for: (1) securitization transactions involving financial assets; (2)
sales of financial assets (including loan participations); (3) factoring
transactions; (4) wash sales; (5) servicing assets and liabilities; (6)
collateralized borrowing arrangements; (7) securities lending transactions; (8)
repurchase agreements; and (9) extinguishment of liabilities, and is applicable
prospectively. Adoption of the statement in 2001 is not expected to have any
material affect on the consolidated financial position or results of operations.
In March 2000, the FASB issued Interpretation No. 44, "Accounting for
Certain Transactions Involving Stock Compensation" -- an interpretation of APB
Opinion No. 25 ("FIN 44"). This Interpretation clarifies the definition of
employee for purposes of applying Accounting Principles Board Opinion No. 25,
Accounting for Stock Issued to Employee ("APB #25"), the criteria for
determining whether a plan qualifies as a non-compensatory plan, the accounting
consequence of various modifications to the terms of a previously fixed stock
option or award, and the accounting for an exchange of stock compensation awards
in a business combination. This Interpretation is effective July 1, 2000, but
certain conclusions in this Interpretation cover specific events that occur
after either December 15, 1998, or January 12, 2000. We adopted FIN 44 during
the year ended September 30, 2000. This adoption did not have a material effect
on out consolidated financial position or results of operations
(q) Environmental Expenditures
Environmental expenditures that relate to current ongoing operations or to
conditions caused by past operations are expensed. The Company determines its
liability on a site by site basis and records a liability at the time when the
liability is probable and can be reasonably estimated. The estimated liability
is not reduced for possible recoveries from insurance carriers.
(2) BUSINESS AND CREDIT CONCENTRATIONS
Many of the Company's products are sold through major distributors, two of
which have exceeded 10% of the Company's consolidated net sales in prior years.
These distributors accounted for approximately 15.0% and 11.6%, respectively of
the Company's net sales in 1998, 14.9% and 10.7%, respectively of the Company's
net sales in 1999, and 13.9% and 9.7%, respectively of the Company's net sales
in 2000. Accounts receivable from these distributors comprised approximately
16.9% and 11.8%, respectively of the outstanding consolidated accounts
receivable balances at September 30, 1999 and approximately 15.8% and 8.6%,
respectively of the outstanding consolidated accounts receivable balances at
September 30, 2000. (see note 16)
(3) INVENTORIES
Inventories at September 30, 1999 and 2000 consist of the following:
<TABLE>
<CAPTION>
1999 2000
-------- --------
<S> <C> <C>
Raw materials and supplies.................................. $ 44,505 $ 59,178
Work in process............................................. 28,332 29,848
Finished goods.............................................. 59,413 60,887
Excess and obsolescence reserves............................ (3,880) (3,872)
LIFO reserve................................................ (4,742) (4,262)
-------- --------
$123,628 $141,779
======== ========
</TABLE>
During 2000, Quantities of inventory valued on a LIFO basis were consumed.
This resulted in the liquidation of LIFO inventories valued at lower prevailing
costs when such LIFO quantities were originally
51
<PAGE> 54
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
acquired in prior years. If these LIFO quantities had not been consumed, but
replenished with the quantities valued at current costs, net income in 2000
would have been decreased by approximately $125 and would have had no impact on
either basic or diluted earnings per share.
(4) INCOME TAXES
Total income tax expense (benefit) for the years ended September 30, 1998,
1999 and 2000 is allocated as follows:
<TABLE>
<CAPTION>
1998 1999 2000
------- ------- -------
<S> <C> <C> <C>
Income from continuing operations....................... $34,714 $49,981 $57,601
Extraordinary items..................................... -- 15,828 --
Discontinued operations................................. 16,347 30,930 28,339
Shareholders' equity for unrealized gain on security
available for sale.................................... -- (173) (1,420)
Shareholders' equity for compensation expense for tax
purposes in excess of amounts recognized for financial
reporting purposes.................................... (7,291) (6,501) (7,901)
------- ------- -------
$43,770 $90,065 $76,619
======= ======= =======
</TABLE>
Income tax expense (benefit) attributable to income from continuing
operations consists of:
<TABLE>
<CAPTION>
CURRENT DEFERRED TOTAL
------- -------- -------
<S> <C> <C> <C>
Year ended September 30, 1998:
U.S., state and local................................. $33,353 $(2,577) $30,776
Foreign............................................... 6,433 (2,495) 3,938
------- ------- -------
$39,786 $(5,072) $34,714
======= ======= =======
Year ended September 30, 1999:
U.S., state and local................................. $30,294 $14,700 $44,994
Foreign............................................... 1,811 3,176 4,987
------- ------- -------
$32,105 $17,876 $49,981
======= ======= =======
Year ended September 30, 2000:
U.S., state and local................................. $42,664 $ 8,401 $51,065
Foreign............................................... 4,679 1,857 6,536
------- ------- -------
$47,343 $10,258 $57,601
======= ======= =======
</TABLE>
The domestic and foreign components of income from continuing operations
before income taxes, discontinued operations and extraordinary items are as
follows:
<TABLE>
<CAPTION>
1998 1999 2000
------- -------- --------
<S> <C> <C> <C>
United States......................................... $74,081 $111,930 $123,422
Foreign............................................... 12,755 15,462 20,903
------- -------- --------
Income before income taxes, discontinued operations
and extraordinary items............................. $86,836 $127,392 $144,325
======= ======== ========
</TABLE>
Income tax expense attributable to income from continuing operations was
$34,714, $49,981 and $57,601 in 1998, 1999 and 2000, respectively, and differed
from the amounts computed by applying the U.S. Federal
52
<PAGE> 55
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
income tax rate of 35 percent to income from continuing operations before income
taxes, discontinued operations and extraordinary items in 1998, 1999 and 2000 as
a result of the following:
<TABLE>
<CAPTION>
1998 1999 2000
------- ------- -------
<S> <C> <C> <C>
Computed "expected" tax expense......................... $30,393 $44,587 $50,514
Increase (reduction) in income taxes resulting from:
Change in beginning of year valuation allowance for
deferred tax assets allocated to income tax expense... (1,541) (277) (21)
Amortization of goodwill................................ 1,807 2,332 3,931
State and local income taxes, net of Federal income tax
benefit............................................... 1,740 3,077 3,898
Foreign income taxed at rates higher than U.S. Federal
income................................................ (588) (561) (836)
Foreign tax credits utilized in excess of U.S. tax on
foreign earnings...................................... 325 512 205
Other, net.............................................. 2,578 311 (90)
------- ------- -------
$34,714 $49,981 $57,601
======= ======= =======
</TABLE>
The significant components of deferred income tax benefit attributable to
income from continuing operations for 1998, 1999 and 2000 are as follows:
<TABLE>
<CAPTION>
1998 1999 2000
------- ------- -------
<S> <C> <C> <C>
Deferred tax (benefit)/expense (exclusive of the effects
of other components listed below)..................... $(3,410) $18,388 $10,038
Decrease in the valuation allowance for deferred tax
assets................................................ (1,662) (512) 220
------- ------- -------
$(5,072) $17,876 $10,258
======= ======= =======
</TABLE>
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities at September
30, 1999 and 2000 are presented below.
<TABLE>
<CAPTION>
1999 2000
-------- --------
<S> <C> <C>
Deferred tax assets:
Inventories................................................. $ 2,115 $ 3,560
Compensation................................................ 2,766 2,679
Sale/Leaseback.............................................. 4,622 4,531
Employee benefits........................................... 1,726 1,979
Net operating loss carryforwards............................ 891 1,111
Warranty and other accruals................................. 14,763 8,347
-------- --------
Total gross deferred tax assets........................... 26,883 22,207
Less valuation allowance.................................. (891) (1,111)
-------- --------
Net deferred tax assets................................... 25,992 21,096
-------- --------
Deferred tax liabilities:
Depreciation................................................ (13,675) (16,928)
Purchase accounting......................................... (56,144) (74,474)
Unrealized appreciation on securities available for sale.... (173) (1,593)
Other....................................................... (613) (860)
-------- --------
Total gross deferred tax liabilities...................... (70,605) (93,855)
-------- --------
Net deferred tax liability................................ $(44,613) $(72,759)
======== ========
</TABLE>
53
<PAGE> 56
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The change in the net deferred tax liability contains $16,295 and $1,420 of
deferred tax liabilities related to acquisitions and the unrealized appreciation
on securities available-for-sale. The valuation allowance for deferred tax
assets as of October 1, 1998 was $1,403. The net change in the total valuation
allowance for the years ended September 30, 1998 and 1999 was a decrease of $512
and an increase of $220, respectively. The valuation allowance relates primarily
to net operating loss carryforwards in certain foreign jurisdictions and U.S.
states, in which there is a history of pre-tax accounting losses. Management is
unable to conclude that there will be pre-tax accounting income in those
jurisdictions in the near term. In assessing the realizability of deferred tax
assets, management considers whether it is more likely than not that some
portion or all of the deferred tax assets will not be realized. The ultimate
realization of deferred tax assets is dependent upon the generation of future
taxable income during the periods in which those temporary differences become
deductible. Management considers the scheduled reversal of deferred tax
liabilities, projected future taxable income and tax planning strategies in
making this assessment.
At September 30, 2000, the Company has an aggregate of $1,200 of foreign
net operating loss carry forwards from certain foreign jurisdictions, the
majority of which have no expiration. The Company has an aggregate of $13,000 of
various state net operating losses, the majority of which expire between 2005
and 2007.
Accumulated earnings of foreign subsidiaries at September 30, 1998, 1999
and 2000 of approximately $2,000, $1,000 and $11,000, respectively, have been
reinvested in the business and no provision for income taxes has been made for
the repatriation of these earnings.
(5) PROPERTY, PLANT AND EQUIPMENT
Major classifications of property, plant and equipment at September 30,
1999 and 2000 are as follows:
<TABLE>
<CAPTION>
1999 2000
--------- ---------
<S> <C> <C>
Land and land improvements.................................. $ 13,445 $ 12,813
Buildings and building improvements......................... 87,192 94,556
Machinery and equipment..................................... 223,688 259,112
Construction in progress.................................... 15,196 17,444
--------- ---------
339,521 383,925
Less: Accumulated depreciation.............................. (151,762) (175,831)
--------- ---------
$ 187,759 $ 208,094
========= =========
</TABLE>
(6) INTANGIBLE ASSETS
Intangible assets at September 30, 1999 and 2000 are as follows:
<TABLE>
<CAPTION>
1999 2000
--------- ----------
<S> <C> <C>
Excess costs over net asset values acquired (goodwill)...... $ 708,109 $ 881,593
Proprietary technology...................................... 38,029 48,302
Trademarks.................................................. 36,988 45,409
Customer lists.............................................. 113,159 107,419
Other....................................................... 33,893 71,444
--------- ----------
930,178 1,154,167
Less: Accumulated amortization.............................. (109,703) (146,014)
--------- ----------
$ 820,475 $1,008,153
========= ==========
</TABLE>
The increases in intangible assets from 1999 to 2000 were primarily due to
acquisitions accounted for as purchases net of removal of fully written off
intangible assets.
54
<PAGE> 57
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(7) LONG-TERM DEBT
Long-term debt at September 30, 1999 and 2000 consists of the following:
<TABLE>
<CAPTION>
1999 2000
-------- --------
<S> <C> <C>
Term Loan Facility.......................................... $381,370 $380,920
Revolving Credit Facility................................... 198,080 256,400
Securities lending agreement................................ 50,461 54,444
Sale/Leaseback Obligation................................... 12,273 12,024
Capital leases and other (See Note 8)....................... 7,475 34,392
-------- --------
649,659 738,180
Less: Current portion of long-term debt..................... (7,391) (34,327)
-------- --------
$642,268 $703,853
======== ========
</TABLE>
CREDIT AGREEMENTS: Until December 11, 2000, the Company and its principal
domestic subsidiaries (including certain subsidiaries of SDS) were parties to a
credit agreement (as amended, the "Previous Credit Agreement") with The Chase
Manhattan Bank ("Chase") and certain other lenders providing for a term A loan
facility of $300,000 (the "Tranche A Term Loan Facility"), a term B loan
facility of $300,000 (the "Tranche B Term Loan Facility") and a revolving credit
facility of up to $600,000 (the "Previous Revolving Credit Facility"). In
connection with the Distribution, on December 1, 2000, the Company entered into
a new credit agreement (the "Credit Agreement") with Chase and certain other
lenders providing for a term loan of $300,000 (the "Term Loan Facility") and a
revolving credit facility up to $500,000 (the "Revolving Credit Facility" and
together with the Term Loan Facility, the "Credit Facilities"). Borrowings under
the Credit Facilities are unsecured. On December 11, 2000, the Company borrowed
approximately $563,000 under the Credit Facilities and together with funds
aggregating $375,000 (approximately $307,100, the amount equal to the
outstanding amounts under the Previous Credit Agreement attributable to SDS on
December 11, 2000 including accrued interest plus a cash dividend of $67,900
from SDS to the Company), used such funds to repay all of the outstanding
amounts under the Previous Credit Agreement (including amounts attributable to
SDS and accrued interest) aggregating $938,000.
The Credit Agreement contains financial and operating covenants, including,
among other things: restrictions on investments; requirements that the Company
maintain certain financial ratios; restrictions on the ability of the Company
and its subsidiaries to create or permit liens, or to pay dividends or make
other restricted payments (as defined) in excess of $100,000 plus 50% of the
defined consolidated net income of the Company for each fiscal quarter ending
after September 30, 2000, less any dividends paid or other restricted payments
made after September 30, 2000; and limitations on incurrence of additional
indebtedness.
TERM LOAN FACILITY: Borrowings under the Term Loan Facility are required
to be repaid in one installment due on December 1, 2005. The Term Loan Facility
provides for an annual interest rate, at the option of the Company, equal to (a)
the alternate base rate ("ABR") plus 0% to 1% (the "Term ABR Margin") where ABR
is the higher of (i) the rate from time to time publicly announced by Chase in
New York City as its prime rate, (ii) the federal funds rate plus 1/2 of 1%, and
(iii) the base CD rate plus 1% or (b) the adjusted interbank offered rate for
Eurodollar deposits ("Eurodollar Rates") plus 3/4% to 2.0% (the "Term Loan
Eurodollar Rate Margin"). The Term ABR Margin and the Eurodollar Rate Margin
depend upon the Company's credit rating from Standard and Poor's Rating Group
("S&P") and Moody's Investors Service, Inc. ("Moody's"). Based on the Company's
current credit rating, the Term ABR Margin and the Term Loan Eurodollar Margin
would be 0.25% and 1.25%, respectively.
REVOLVING CREDIT FACILITY: Borrowings under the Revolving Credit Facility
mature on December 1, 2005. The Revolving Credit Facility provides for an annual
interest rate at the option of the Company, equal to
55
<PAGE> 58
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(a) ABR plus 0% to .375% (the "Revolving ABR Margin") or (b) the Eurodollar
Rates plus .375% to 1.375% (the "Revolving Loan Eurodollar Rate Margin"). In
addition, the Company has a third option to set the rate by a competitive bid
process among the parties to the Revolving Credit Facility (the "CAF"). The
Company also will pay a facility fee of .125% to .375% for all commitments from
the lenders, whether drawn or undrawn and a will pay a utilization fee of 0.25%
per annum if more than 50% of the Revolving Credit Facility is drawn or the Term
Loan Facility is still outstanding. The Revolving ABR Margin, the Revolving Loan
Eurodollar Rate Margin and the facility fee depend upon the Company's credit
rating from S&P and Moody's. Based upon the Company's current credit rating, the
Revolving ABR Margin, the Revolving Loan Eurodollar Rate Margin and the facility
fee would be 0%, 0.8% and 0.2%, respectively. The Revolving Credit Facility also
provides for a multi currency sub facility providing up to $100,000 in sub
commitments in non-dollar currencies. Terms and conditions on the multi currency
sub facility are to be agreed upon between the Company and Chase and the lenders
providing funding under such facility. The Company may not exceed a total of
$500,000 in dollar and non-dollar commitments under this Revolving Credit
Facility. The Credit Facility also provides for the issuance of standby letters
of credit and commercial letters of credit on behalf of the Company's
subsidiaries as required in the ordinary course of business as part of the
working capital line.
TRANCHE A TERM LOAN FACILITY: Borrowings under the Tranche A Term Loan
Facility were required to be repaid in 21 consecutive quarterly installments of
principal. On July 31, 1997 the Company began repaying the principal balance by
paying the $8,750 due in 1997, $35,000 due in 1998 and $17,500 of the $36,250
due in fiscal 1999. On March 31, 1999 as a result of the sale of NPT, the
Company received approximately $87,500 ($83,200 net of fees, expenses and an
adjustment to the purchase price). Net proceeds of the sale, after a reduction
for applicable income taxes, were required to be used to repay amounts owed by
the Company under the Tranche A Term Loan Facility. On March 31, 1999, the
Company paid approximately $67,900 due under the Tranche A Term Loan Facility.
In connection with the Distribution on December 11, 2000, the Company repaid the
remaining balance (including amounts attributable to SDS and accrued interest)
of approximately $260,600 of the Tranche A Term Loan Facility.
TRANCHE B TERM LOAN FACILITY: Borrowings under the Tranche B Term Loan
Facility were required to be repaid in consecutive quarterly installments
beginning January 31, 2000 as follows: $750 due in fiscal 2000, $1,000 due in
fiscal 2001, $1,000 due in fiscal 2002, $120,250 due in fiscal 2003 and $177,000
due in fiscal 2004, with the final payment due on July 31, 2004. In connection
with the Distribution, on December 11, 2000, the Company repaid the remaining
balance (including amounts attributable to SDS and accrued interest) of $301,300
of the Tranche B Term Loan Facility.
Borrowings under the Tranche A and Tranche B Term Loan Facilities (and the
Revolving Credit Facility) were secured by the capital stock of the Company's
domestic subsidiaries, and by 65% of the stock held by the domestic subsidiaries
in their direct foreign subsidiaries. The Tranche A Term Loan Facility provided
for an annual interest rate, at the option of the Company, equal to (a) the
higher of (i) the rate from time to time publicly announced by Chase in New York
City as its prime rate, (ii) the federal funds rate plus 1/2 of 1%, and (iii)
the base CD rate plus 1% (collectively referred to as "ABR") or (b) the adjusted
interbank offered rate for Eurodollar deposits ("Eurodollar Rates") plus 1/2%
to 7/8% (the "Tranche A Eurodollar Rate Margin") depending upon the ratio of
the Company's total debt to Consolidated Adjusted Operating Profit (as defined).
The Tranche B Term Loan Facility provided for an annual interest rate, at
our option, equal to (a) the higher of (i) the rate from time to time publicly
announced by Chase in New York City as its prime rate plus 1% to 1 1/4%, (ii)
the federal funds rate plus of 1 1/2% to 1 3/4%, and (iii) the base CD rate plus
2% to 2 1/4%, depending upon the ratio of our total debt to Consolidated
Adjusted Operating Profit or (b) the Eurodollar Rate plus 2% to 2 1/4% depending
upon the ratio of our total debt to Consolidated Adjusted Operating Profit.
As of September 30, 2000, the Company has seven interest rate swaps
outstanding aggregating a notional amount of $381,000. Under the terms of the
swap agreements, the Company is required to pay a fixed rate
56
<PAGE> 59
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
amount equal to the swap agreement rate listed below. In exchange for the
payment of the fixed rate amount, the Company receives a floating rate amount
equal to the three-month LIBOR rate in effect on the date of the swap agreements
and the subsequent reset dates. For each of the swap agreements the rate resets
on each quarterly anniversary of the swap agreement date until the swap
expiration date. The net interest rate paid by the Company is approximately
equal to the sum of the swap agreement rate plus the applicable Eurodollar Rate
Margin. In 2000, the Tranche A and Revolver Eurodollar Rate Margins were .75%.
The Tranche B Eurodollar Margin was 2.0%. The swap agreement rates and duration
as of September 30, 2000 are as follows:
<TABLE>
<CAPTION>
EXPIRATION DATE NOTIONAL AMOUNT SWAP AGREEMENT DATE SWAP AGREEMENT RATE
--------------- --------------- ------------------- -------------------
<S> <C> <C> <C>
February 7, 2001................. $50,000 August 7, 1997 5.910%
August 7, 2001................... $50,000 August 7, 1997 5.900%
September 10, 2001............... $50,000 December 8, 1995 5.623%
December 31, 2001................ $ 6,000 March 24, 1999 5.500%
June 8, 2002..................... $50,000 December 8, 1995 5.500%
July 31, 2002.................... $75,000 May 7, 1997 6.385%
July 31, 2002.................... $50,000 October 23, 1998 4.733%
October 1, 2002.................. $50,000 October 1, 1999 6.260%
</TABLE>
The Company's risk with regard to the swaps is limited to the
counterparty's (Bank of America, Illinois, with a notional amount of $131,000,
The Sumitomo Bank Limited, The Bank of Nova Scotia, The Bank of New York, Bank
of Tokyo Mitsubishi and First Union with notional amounts of $50,000 each)
ability to meet the payment terms of the contract. All interest expense for all
debt is calculated using the interest method.
On December 11, 2000, due to the extinguishment of debt, interest rate
swaps previously designated as cash flow hedges ceased to meet hedge criteria
under SFAS 133 as modified by SFAS 138. The approximate fair value on December
11, 2000 was $1,700. The Company sold these interest rate swaps on December 12,
2000 for approximately $1,700, and realized a gain of $1,100 (net of tax).
Because these interest rate swaps were designated as a hedge against future
variable rate interest payments and the extinguished debt, the gain will
continue to be carried in other comprehensive income and recognized as an
adjustment of yield interest expense of the Credit Facilities over the remaining
term of the interest rate contract.
PREVIOUS REVOLVING CREDIT FACILITY: The Company paid a commitment fee of
.20% with the ability to increase or reduce the amount from .225% to .15%
depending upon the ratio of the Company's total debt to Consolidated Adjusted
Operating Profit. The Revolving Credit Facility also provided for the issuance
of standby letters of credit and commercial letters of credit on behalf of the
Company's subsidiaries as required in the ordinary course of business as part of
the working capital line. Borrowings under the Revolving Credit Facility were
similar in terms of interest as those under the Tranche A Term Loan Facility
described above, except that the Company had a third option to set the rate by a
competitive bid process among the parties to the Revolving Credit Facility (the
"CAF"). In connection with the Distribution, on December 11, 2000, the Company
repaid the remaining balance (including amounts attributable to SDS and accrued
interest) of approximately $376,100 of the Previous Revolving Credit Facility.
The Company paid fees on the average unused portion of credit commitments
under the Previous Revolving Credit Facility of approximately $327, $201 and
$479 in 1998, 1999 and 2000, respectively. The Company paid fees of
approximately $55, $38 and $59 for standby letters of credit under the Previous
Revolving Credit Facility in 1998, 1999 and 2000, respectively. Standby letters
of credit were approximately $2,985 and $18,562 at September 30, 1999 and 2000,
respectively.
SECURITIES LENDING AGREEMENT: On September 29, 1999, the Company purchased
a United States Treasury Bond ("Treasury") with a par value of $50,000, an
interest rate of 6.15% and a maturity date of August 15, 2029. Concurrent with
the purchase of the Treasury, the Company lent the security to an unrelated
57
<PAGE> 60
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
third party for a period of 23 years. In exchange for the loaned Treasury, the
Company has received collateral equal to the market value of the Treasury on the
date of the loan, and adjusted on a weekly basis. This securities lending
transaction is related to the Company's existing lending policy by fixing
$50,000 of its floating rate debt. For a period of five years, the Company is
obligated to pay a rebate on the loaned collateral at an annual fixed rate of
6.478% and is entitled to receive a fee for the loan of the security at a
floating rate equal to LIBOR minus .75%. The weighted-average pay and receive
rates in 2000 were 6.478% and 5.26%, respectively, at a weighted average
notional amount of $52,500. Thereafter, the Company is required to pay the
unrelated third party a collateral fee equal to the one-week general collateral
rate of interest (as determined weekly in good faith by the unrelated third
party, provided that such rate shall not exceed the federal funds rate in effect
as of the day of determination plus .25%) and the Company receives all
distributions made on or in respect to the Treasury. This transaction is
accounted for as a secured borrowing under Statement of Financial Accounting
Standards No. 125.
SALE/LEASEBACK: On December 22, 1988, the Company completed the sale and
leaseback (the "Sale/ Leaseback") of its then principal domestic manufacturing
and office facilities with an unaffiliated third party. The proceeds of $22,500
(net of approximately $1,100 in fees) were used to retire debt. The transaction
has been accounted for as a financing for financial statement purposes and as a
sale for income tax purposes. The financing obligation is being amortized over
the initial 25-year lease term.
The Company pays all costs of maintenance and repair, insurance, taxes, and
all other expenses associated with the properties. In addition, each of the
leases is unconditionally guaranteed by the Company.
The initial term of each lease is 25 years with five five-year renewal
options. The initial aggregate annual payments relating to the Company under the
leases were $1,727 payable monthly in advance. On the fifth anniversary of the
leases and every five years thereafter (including renewal terms), the rent is
increased by the percentage equal to 75% of the percentage increase in the
Consumer Price Index over the preceding five years. The percentage increase to
the rent in any five-year period will be capped at 15%. Beginning January 1,
1999 annual payments increased to $2,176. The next adjustment will not occur
until January 1, 2004.
The Company has the option to purchase the facilities according to the
terms of any bona fide offer received by the lessor from a third party (the
"Third Party Offer") at any time during the term of the leases. The purchase
price upon exercise of the option will be an amount equal to the purchase price
contained in the Third Party Offer. The Company also has the option to purchase
the facilities, subject to complying with the notice provision in the leases, on
any date between June 1, 2008 and May 31, 2009. The purchase price upon the
exercise of the option is the greater of the fair market value of the leased
premises or the sum of the landlord's acquisition cost for the leased premises
and any prepayment premiums that would be payable under the landlord's financing
for the premises.
In the event of a breach of certain covenants which include, subject to
certain exceptions, restrictions on the Company's and its subsidiaries'
incurrence of certain additional indebtedness, payment of dividends or the
making of other distributions or the repurchase of the Company's capital stock,
or the creation of liens on their respective properties, the Company must cause
each subsidiary to make a rejectable offer to the lessor to purchase its
facility. If the lessor accepts the rejectable offer, each subsidiary will pay
to the lessor a formula price based upon the lessor's equity in the property and
the lessor's pre-payment premium to its lender. The Company may also be
obligated to repurchase the property upon the occurrence of certain other
events.
58
<PAGE> 61
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
MATURITIES OF LONG-TERM DEBT: As of September 30, 2000, maturities of
long-term debt, including capital leases, are as follows:
<TABLE>
<CAPTION>
FISCAL
------
<S> <C>
2001...................................................... $ 34,327
2002...................................................... 566
2003...................................................... 473
2004...................................................... 504
2005...................................................... 556
Thereafter................................................ 701,754
--------
$738,180
========
</TABLE>
Maturity of long term debt related to the Term Loan Facility and the
Revolving Credit Facility are based upon their maturity dates of December 11,
2005.
(8) LEASE COMMITMENTS
As of September 30, 2000, minimum rentals, excluding rent payments under
the Sale/Leaseback described in note 7, under capital and noncancellable
operating leases consisting primarily of machinery and equipment, and building
leases are:
<TABLE>
<CAPTION>
FISCAL CAPITAL OPERATING
------ ------- ---------
<S> <C> <C>
2001........................................................ $336 $ 8,019
2002........................................................ 178 7,176
2003........................................................ 48 5,922
2004........................................................ 3 4,331
2005........................................................ -- 3,703
Thereafter.................................................. -- 17,610
---- -------
$565 $46,761
=======
Less amounts representing interest.......................... 67
----
Present value of net minimum lease payments................. 498
Less current portion........................................ 264
----
Long-term obligations under capital leases.................. $234
====
</TABLE>
Amortization of assets held under capital leases is included with
depreciation expense.
Rental expense under operating leases was $4,028, $6,704 and $9,434 in
1998, 1999 and 2000, respectively.
(9) FAIR MARKET VALUE OF FINANCIAL INSTRUMENTS
The carrying amounts of financial instruments approximate fair value due to
the short maturity of those instruments except as follows:
Long-Term Debt
TERM LOAN FACILITY AND REVOLVING CREDIT FACILITY: The fair value was
determined by estimating the interest rate margins (the premium over the
Eurodollar Rate) on each of the Tranche A Term Loan Facility, Tranche B Term
Loan Facility and the Previous Revolving Credit Facility for companies with
credit risk
59
<PAGE> 62
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
similar to that of the Company. In 2000 the Company's spread over the Eurodollar
Rate was 75 basis points for the Tranche A Term Loan Facility and the Previous
Revolving Credit Facility and a spread of the Eurodollar Rate plus 200 basis
points on the Tranche B Term Loan Facility. Since the Company has refinanced
these facilities on December 11, 2000 at a rate of LIBOR + 125 basis points,
LIBOR + 125 basis points was used for the calculations of fair market value.
SALE/LEASEBACK: The fair value was determined by estimating the interest
rate at which the Company could refinance the Sale/Leaseback given the same
maturity period.
INTEREST RATE SWAP AGREEMENTS: The fair values of interest rate swap
agreements are obtained from dealer quotes. These values represent the estimated
amount the Company would receive/(pay) if the agreements were terminated as
quoted by the bank with which the Company executed the swap agreements.
<TABLE>
<CAPTION>
SEPTEMBER 30, SEPTEMBER 30,
1999 2000
--------------------- ---------------------
REPORTED ESTIMATED REPORTED ESTIMATED
AMOUNT FAIR VALUE AMOUNT FAIR VALUE
-------- ---------- -------- ----------
<S> <C> <C> <C> <C>
Long-term debt (including current
portion)................................. $649,959 $654,126 $738,180 $742,132
Interest rate swap agreements.............. -- 2,768 -- 4,221
</TABLE>
DERIVATIVES: The Company uses derivative financial instruments to manage
its foreign currency exposures and interest rate risk. The Company does not hold
or issue financial instruments for trading purposes. The notional amounts of
these contracts do not represent amounts exchanged by the parties and, thus, are
not a measure of the Company's risk. The net amounts exchanged are calculated on
the basis of the notional amounts and other terms of the contracts, such as
interest rates or exchange rates, and only represent a small portion of the
notional amounts. The credit and market risk under these agreements is minimized
through diversification among counter parties with high credit ratings.
Depending on the item being hedged, gains and losses on derivative financial
instruments are either recognized in the results of operations as they accrue or
are deferred until the hedged transaction occurs. Derivatives used as hedges are
effective at reducing the risk associated with the exposure being hedged and are
designated as a hedge at the inception of the derivative contract. Accordingly,
changes in the market value of the derivative are highly correlated with changes
in the market value of the underlying hedged item at the inception of the hedge
and over the life of the hedge contract.
FOREIGN EXCHANGE CONTRACTS: The Company enters into foreign exchange
hedging contracts to hedge certain sales commitments and loans made to foreign
subsidiaries denominated in foreign currencies. The term of these contracts is
less than one year. The purpose of the Company's foreign currency hedging
activities is to protect the Company from the risk that the eventual cash flows
resulting from foreign activities will be adversely affected by changes in
exchange rates. The recognition of gains and losses on contracts entered into to
hedge sales commitments are included in net income as an adjustment to net
sales. At September 30, 1999 and 2000, the Company had no foreign exchange
option contracts.
INTEREST RATE SWAPS: The Company enters into interest rate swaps to
stabilize funding costs by minimizing the effect of potential interest rate
increases on floating-rate debt in a rising interest rate environment. Under
these agreements, the Company contracts with a counter party to exchange the
difference between a fixed rate and a floating rate applied to the notional
amount of the swap. Swap contracts are principally between one and five years in
duration. The differential to be paid or received on interest rate swap
agreements is accrued as interest rates change and is recognized in net income
as an adjustment to interest expense. Gains and losses resulting from terminated
interest rate swap agreements are deferred and recognized in net income over the
shorter term of the remaining contractual life of the swap agreement or the
remaining term of the debt underlying the swap agreement. If swap agreements are
terminated due to the underlying debt being extinguished, any resulting gain or
loss is recognized in net income as an adjustment to interest expense at the
time of the termination. The Company has not terminated any interest rate swap
agreements.
60
<PAGE> 63
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The weighted-average pay and receive rates for the swaps outstanding at
September 30, 2000, were 5.79% and 6.24%, respectively, at a weighted average
notional amount of $382,000. The weighted-average pay and receive rates for the
swaps outstanding at September 30, 1999 were 5.78% and 5.22%, respectively at a
weighted average notional amount of $382,000.
(10) EMPLOYEE BENEFIT PLANS
Effective September 30, 1999, the Company adopted Statement of Financial
Accounting Standards No. 132, "Employers' Disclosures about Pensions and Other
Postretirement Benefits." This standard only modifies the financial statement
presentation of the Company's pension and post retirement benefit obligations
and does not impact measurement of such obligations.
PENSION AND OTHER POSTRETIREMENT BENEFITS: The Company has defined benefit
pension plans covering approximately 48 percent of its U.S. employees. The
benefits are generally based on various formulas, the principal factors of which
are years of service and compensation. The Company's funding policy is to
generally make the minimum annual contributions required by applicable
regulations. Plan assets are invested primarily in U.S. stocks, bonds and
International stocks. In addition to the defined benefit plans, the Company
provides certain health care benefits for eligible retired employees which are
funded as costs are incurred. Certain employees who reached the age of 55 prior
to January 1, 1996 will become eligible for postretirement health care only if
they reach retirement age while working for the Company. The Company accrues, as
current costs, the future lifetime retirement benefits for both qualifying
active and retired employees and their dependents. The postretirement health
care plans for subsidiaries of the Company and certain divested operations are
generally contributory, with retiree contributions adjusted annually. In 1986,
the Company instituted a policy with respect to postretirement medical premiums
where the Company's contributions were frozen at the levels equal to the
Company's contribution on December 31, 1988, except where collective bargaining
agreements prohibited such a freeze.
The following assumptions were used in determining the funded status of the
Company's defined benefit plans:
<TABLE>
<CAPTION>
1999 2000
---- ----
<S> <C> <C>
Discount rate............................................... 7.75% 8.0%
Rate of increase in compensation levels..................... 4.0% 4.0%
Expected long-term rate of return on assets................. 10.0% 10.0%
</TABLE>
The following assumptions were used in determining the accumulated
postretirement benefit obligation of the Company's postretirement plans.
<TABLE>
<CAPTION>
1999 2000
---- ----
<S> <C> <C>
Discount rate............................................... 7.75% 8.0%
Average increase in medical costs........................... 5.5% 5.5%
</TABLE>
61
<PAGE> 64
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
<TABLE>
<CAPTION>
PENSION BENEFITS OTHER BENEFITS
------------------ -----------------
1999 2000 1999 2000
-------- ------- ------- -------
<S> <C> <C> <C> <C>
Change in benefit obligations:
Obligations at beginning of year.................... $ 50,761 $44,275 $ 8,961 $ 5,556
Service cost........................................ 2,818 2,032 28 12
Interest cost....................................... 3,435 3,691 557 399
Actuarial (gain) loss............................... (10,497) 3,129 (2,555) (68)
Benefit payments.................................... (2,242) (2,118) (1,435) (1,442)
-------- ------- ------- -------
Obligations at end of year.......................... $ 44,275 $51,009 $ 5,556 $ 4,457
Change in fair value of plan assets:
Fair value of plan assets at beginning of year...... $ 42,343 $44,898 $ -- $ --
Actual return on plan assets........................ 4,614 6,463 -- --
Employer contributions.............................. 184 1,240 -- --
Benefit payments.................................... (2,242) (2,118) -- --
-------- ------- ------- -------
Fair value of plan assets at end of year............ $ 44,899 $50,483 $ -- $ --
Funded Status:
Funded status at end of year........................ $ 624 $ (526) $(5,556) $(4,457)
Unrecognized transition (asset) obligation.......... 113 6 -- --
Unrecognized prior service cost..................... 92 144 -- --
Unrecognized (gain) loss............................ (7,979) (6,869) 314 245
Remaining excess of fair value of plan assets over
projected benefit obligation recognized as a
result of the 1987 acquisition of Sybron
Corporation...................................... 2,341 1,869 -- --
-------- ------- ------- -------
Net amount recognized at measurement date............. (4,809) (5,376) (5,242) (4,212)
Employer contribution paid after measurement date..... -- 167 -- --
-------- ------- ------- -------
Net amount recognized at end of year.................. $ (4,809) $(5,209) $(5,242) $(4,212)
======== ======= ======= =======
</TABLE>
The following table provides the amounts recognized in the Company's
consolidated balance sheets:
<TABLE>
<CAPTION>
PENSION BENEFITS OTHER BENEFITS
----------------- -----------------
1999 2000 1999 2000
------- ------- ------- -------
<S> <C> <C> <C> <C>
Prepaid benefit cost................................... $ 124 $ 188 $(5,242) $(4,212)
Accrued benefit liability.............................. (7,274) (7,433) -- --
Remaining excess of fair value of plan assets over
projected benefit obligation recognized as a result
of the 1987 acquisition of Sybron Corporation........ 2,341 1,869 -- --
------- ------- ------- -------
Net amount recognized at measurement date.............. (4,809) (5,376) (5,242) (4,212)
Employer contribution paid after measurement date...... -- 167 -- --
------- ------- ------- -------
Net amount recognized at September 30.................. $(4,809) $(5,209) $(5,242) $(4,212)
======= ======= ======= =======
</TABLE>
62
<PAGE> 65
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The following table provides disclosure of the net periodic benefit cost:
<TABLE>
<CAPTION>
PENSION BENEFITS OTHER BENEFITS
--------------------------- ------------------
1998 1999 2000 1998 1999 2000
------- ------- ------- ---- ---- ----
<S> <C> <C> <C> <C> <C> <C>
Service cost............................... $ 2,544 $ 2,818 $ 2,032 $ 23 $ 28 $ 12
Interest cost.............................. 3,074 3,435 3,691 662 557 399
Expected return on plan assets............. (4,118) (4,123) (4,509) -- -- --
Amortization of transition (asset)
obligation............................... 107 108 107 -- -- --
Amortization of prior service cost......... (52) (52) (52) -- -- --
Amortization of net (gain) loss............ 13 126 65 42 66 --
------- ------- ------- ---- ---- ----
Net periodic benefit cost.................. $ 1,568 $ 2,312 $ 1,334 $727 $651 $411
======= ======= ======= ==== ==== ====
</TABLE>
The projected benefit obligation, accumulated benefit obligation, and fair
value of plan assets for the pension plans with accumulated benefit obligations
in excess of fair value of plan assets were $4,139, $1,853, and $0,
respectively, as of September 30, 1999 and $2,880, $1,732 and $0, respectively
as of September 30, 2000.
An increase of one percentage point in the per capita cost of health care
costs associated with the plans for which the Company contributions are not
frozen would increase the accumulated postretirement benefit obligation and
service and interest cost components as of September 30, 2000 by approximately
$61 and $3, respectively.
Because the majority of the postretirement plans are remaining liabilities
from certain divested operations and more than 85% of the 1998, 1999 and 2000
net periodic postretirement benefit costs relate to interest costs, the Company
has classified such interest costs as interest expense. This results in a
non-cash increase in interest expense of approximately $662, $557 and $399 in
1998, 1999 and 2000, respectively.
Savings Plans: Employees in the United States are eligible to participate
in contributory savings plans maintained by the Company under Section 401(k) of
the Internal Revenue Code of 1986, as amended (the "Code"). Company matching
contributions under the plans, net of forfeitures, were approximately $2,321,
$2,324 and $2,770 for 1998, 1999 and 2000, respectively.
(11) RESTRUCTURING CHARGES
In June 1998, the Company recorded a restructuring charge of approximately
$8,500 (approximately $5,400 after tax or $.05 per share on a diluted basis) for
the rationalization of certain acquired companies, combination of certain
duplicate production facilities, movement of certain customer service and
marketing functions, and the exiting of several product lines. The restructuring
charge was classified as components of cost of sales (approximately $1,800
relating to the write-off of inventory discussed below), selling, general and
administrative expenses (approximately $6,700).
63
<PAGE> 66
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Restructuring activity since June 30, 1998 and its components are as
follows:
<TABLE>
<CAPTION>
LEASE INVENTORY FIXED
SEVERANCE PAYMENTS WRITE-OFF ASSETS GOODWILL
(A) (B) (C) (C) (D) TOTAL
--------- -------- --------- ------ -------- ------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C> <C>
1998 Restructuring Charge..... $3,400 $200 $1,800 $1,000 $2,100 $8,500
1998 Cash Payments............ 900 100 -- -- -- 1,000
1998 Non-Cash Charges......... -- -- 1,800 1,000 2,100 4,900
------ ---- ------ ------ ------ ------
September 30, 1998 balance.... $2,500 $100 $ -- $ -- $ -- $2,600
1999 Cash Payments............ 1,900 100 -- -- -- 2,000
Adjustments(a)................ 300 -- -- -- -- 300
------ ---- ------ ------ ------ ------
September 30, 1999 balance.... $ 900 $ -- $ -- $ -- $ -- $ 900
2000 Cash Payments............ 700 -- -- -- -- 700
------ ---- ------ ------ ------ ------
September 30, 2000 balance.... $ 200 $ -- $ -- $ -- $ -- $ 200
====== ==== ====== ====== ====== ======
</TABLE>
---------------
(a) Amount represents severance and termination costs for approximately 65
terminated employees (primarily sales and marketing personnel). As of
September 30, 2000, all employees have been terminated as a result of the
restructuring plan. Payments will continue to certain employees previously
terminated under this restructuring plan. An adjustment of approximately
$300 was made in the third quarter of fiscal 1999 to adjust the accrual
primarily representing under accruals for anticipated costs associated with
outplacement services, accrued fringe benefits, and severance associated
with employees who were previously notified of termination. No additional
employees will be terminated under this restructuring plan.
(b) Amount represents lease payments on exited facilities.
(c) Amount represents write-offs of inventory and fixed assets associated with
discontinued product lines.
(d) Amount represents goodwill associated with exited product lines.
The Company expects to make future cash payments of approximately $200 in
fiscal 2001.
In September 2000, the Company recorded a restructuring charge of
approximately $11,300 (approximately $7,500 after tax or $.07 per share on a
diluted basis) for the consolidation of certain businesses, product
rationalizations, changes in management structure and taxes associated with
restructuring the U.K. operations. The restructuring charge was classified as
components of cost of sales (approximately $4,400 relating to the write-off of
inventory, write-offs of fixed assets, certain lease terminations and severance
associated with employees in production activities), selling, general and
administrative expense at $5,800 and income tax expense of $1,000, related to
the companies restructuring of its U.K. operations. Restructuring activity since
its inception in September 2000 and its components is as follows:
<TABLE>
<CAPTION>
FIXED LEASE SHUT-DOWN
SEVERANCE INVENTORY ASSETS COMMITMENTS COSTS TAX
(A) (B) (B) (C) (C) (D) OTHER TOTAL
--------- --------- ------ ----------- --------- ------ ----- -------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
2000 Restructuring charge............... $5,500 $2,100 $1,000 $500 $300 $1,000 $900 $11,300
2000 Cash payments...................... 1,100 -- -- -- -- -- -- 1,100
2000 Non-cash charges................... -- 2,100 1,000 -- -- -- 800 3,900
------ ------ ------ ---- ---- ------ ---- -------
September 30, 2000 balance.............. $4,400 $ -- $ -- $500 $300 $1,000 $100 $ 6,300
====== ====== ====== ==== ==== ====== ==== =======
</TABLE>
64
<PAGE> 67
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
---------------
(a) Amount represents severance and termination costs for 151 terminated
employees (primarily sales, marketing and corporate personnel). As of
September 30, 2000, 48 employees have been terminated as a result of the
restructuring plan.
(b) Amount represents write-offs of inventory and fixed assets associated with
discontinued product lines.
(c) Amount represents lease payments and shut down costs on exited facilities.
(d) Amount represents income tax expense associated with the restructuring of
our U.K. facilities.
The Company expects to make cash payments of approximately $1,700, $800,
$2,200 and $400 in each of the four quarters of fiscal 2001, respectively and
$1,200 in fiscal 2002 and beyond.
(12) CAPITAL STOCK
STOCK OPTION PLANS: The Company has five stock option plans. As of
September 30, 2000, there were options with respect to 5,616 shares of Common
Stock outstanding under the 1988 Stock Option Plan (the "1988 Plan"), and there
were no shares available for the granting of options under such plan; there were
options with respect to 26,800 shares of Common Stock outstanding under the 1990
Stock Option Plan (the "1990 Plan") and there were no shares remaining available
for the granting of options under such plan; there were options with respect to
7,869,242 shares of Common Stock outstanding under the Amended and Restated 1993
Long-Term Incentive Plan (the "1993 Plan") and there were 980,896 shares
remaining available for the granting of options under such plan; there were
options with respect to 324,000 shares of Common Stock outstanding under the
Amended and Restated 1994 Outside Directors' Stock Option Plan (the "1994
Outside Directors' Plan"), and there were no shares available for the granting
of options under such plan; there were options with respect to 168,000 shares of
Common Stock outstanding under the 1999 Outside Directors' Stock Option Plan
(the "1999 Outside Directors' Plan"), and there were 312,000 shares remaining
available for the granting of options under such plan. Changes in stock options
outstanding are as follows:
<TABLE>
<CAPTION>
NUMBER OF WEIGHTED AVERAGE
SHARES PRICE PER SHARE EXERCISE PRICE
---------- --------------- ----------------
<S> <C> <C> <C>
Options outstanding at September 30,
1997.................................. 6,943,280 $ 5.99 -- $15.35 $ 9.36
Granted............................... 4,188,064 $23.81 -- $24.50 $24.42
Exercised............................. (1,455,760) $ 5.99 -- $15.35 $ 8.63
Canceled and available for reissue.... (277,556) $ 8.34 -- $23.81 $10.92
----------
Options outstanding at September 30,
1998.................................. 9,398,028 $ 5.99 -- $24.50 $16.14
Granted............................... 896,748 $25.31 -- $26.75 $26.18
Exercised............................. (1,121,421) $ 5.99 -- $24.34 $ 9.53
Canceled and available for reissue.... (145,584) $11.55 -- $26.75 $20.86
----------
Options outstanding at September 30,
1999.................................. 9,027,771 $ 6.06 -- $26.75 $17.88
Granted............................... 764,040 $22.00 -- $32.00 $24.05
Exercised............................. (1,167,775) $ 6.06 -- $26.75 $10.79
Canceled and available for reissue.... (230,378) $11.54 -- $26.75 $24.13
----------
Options outstanding at September 30,
2000.................................. 8,393,658 $ 6.36 -- $32.00 $19.27
Options exercisable at September 30,
2000.................................. 5,212,321 $ 6.36 -- $26.75 $16.09
Options available for grant at September
30, 2000.............................. 1,292,896
==========
</TABLE>
65
<PAGE> 68
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The range of exercise prices for options outstanding at September 30, 2000
was $6.06 to $26.75. The range of exercise prices for options is wide due to the
increasing price of the Company's stock (upon which the exercise price is based)
over the period of the grants.
The following table summarizes information about options outstanding and
outstanding and exercisable on September 30, 1999:
<TABLE>
<CAPTION>
OPTIONS
OUTSTANDING OPTIONS
----------------------------------------------- OUTSTANDING AND EXERCISABLE
WEIGHTED AVERAGE WEIGHTED AVERAGE ----------------------------
RANGE OF NUMBER OF REMAINING EXERCISE NUMBER OF WEIGHTED AVERAGE
EXERCISE PRICES SHARES CONTRACTUAL LIFE PRICE SHARES EXERCISE PRICE
--------------- --------- ---------------- ---------------- --------- ----------------
<S> <C> <C> <C> <C> <C>
$ 5.00 -- $10.00..... 2,327,718 4.0 $ 8.43 2,327,718 $ 8.43
$10.01 -- $15.00..... 392,270 5.4 11.94 392,270 11.94
$15.01 -- $20.00..... 257,124 6.3 15.36 187,328 15.36
$20.01 -- $25.00..... 4,511,702 7.8 24.22 2,051,778 24.36
$25.01 -- $30.00..... 799,844 8.3 26.20 253,227 26.34
$30.01 -- $35.00..... 105,000 9.6 31.02 -- --
--------- ---------
8,393,658 6.7 19.27 5,212,321 16.09
========= =========
</TABLE>
1988, 1990 and 1993 Plans
No options may be granted under the plans after ten years from the date the
plans are approved by the shareholders of the Company. Options granted pursuant
to the plans shall be either incentive options which are intended to meet the
requirements of section 422 of the Code or nonstatutory options. The exercise
price of the options will be determined by the Compensation/Stock Option
Committee. The exercise price of any incentive option shall not be less than the
fair market value per share of the Common Stock on the date of the grant of such
option. An optionee under the plans must pay the full option price of an option
either (a) in cash or its equivalent, (b) with the Compensation/Stock Option
Committee's consent, by delivering previously acquired shares of Common Stock
having a fair market value at the time of the exercise equal to the total option
price, (c) with the Compensation/Stock Option Committee's consent, by a cashless
exercise as permitted under The Federal Reserve Board's Regulation T or (d) in
any combination of the foregoing.
In general, options granted under the 1990 Plan after May 14, 1992, and
under the 1993 Plan, vest in equal annual installments on each of the first four
anniversaries following the date of grant. The Company made significant
management changes in connection with the Spin-Off, including a change in the
Chief Executive Officer, Chief Financial Officer and General Counsel. The Board
of Directors and the Compensation Committee amended certain stock options
previously granted to each of the executive officers so replaced to provide for
the vesting of any unvested portion of the options granted to each of them in
April of 1998, provided the individual remains an employee of the Company until
June 1, 2001. If the individual is terminated prior to that date, the options
would fully vest at that time. These options were also amended to provide for a
five year period (rather than a three month period) to exercise the options
after termination of employment. The amendments to these options had no earnings
impact because the options had no intrinsic value (i.e. there was no positive
spread between the market price and exercise price of the option shares) at the
time of the amendment.
Outside Directors' Plans
The 1994 Outside Directors' Plan provided for the automatic granting of
nonstatutory stock options to those of the Company's directors who qualify as
"outside directors" at the time of grant. Following each annual meeting of
shareholders prior to September 30, 1998, the plan's expiration date, each
outside director was automatically granted an option to purchase 12,000 shares
of Common Stock at an exercise price equal to
66
<PAGE> 69
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
the fair market value of the Common Stock on the date of grant. Each option
granted under the 1994 Outside Directors' Plan became exercisable six months
after the date of grant, regardless of whether the grantee was still a director
of the Company on such date. All rights to exercise an option granted under the
1994 Outside Directors' Plan terminate upon the earlier of ten years from the
date of grant or two years from the date the grantee ceases to be a director of
the Company. The exercise price must be paid in full at the time of exercise,
and such payment may be made in cash, by delivering shares of Common Stock which
the optionee or the optionee's spouse or both have beneficially owned for at
least six months prior to the time of exercise, or through a combination of cash
and such delivered Common Stock.
The 1999 Outside Directors' Plan provides for the automatic granting of
nonstatutory stock options to those of the Company's directors who qualify as
"outside directors" at the time of grant. Following each annual meeting of
shareholders beginning in 1999, when the plan was approved by the shareholders,
each outside director is automatically granted an option to purchase 12,000
shares of Common Stock at an exercise price equal to the fair market value of
the Common Stock on the date of grant. Each option granted under the 1999
Outside Directors' Plan is exercisable immediately upon grant. All rights to
exercise an option granted under the 1999 Outside Directors' Plan terminate upon
the earlier of ten years from the date of grant or two years from the date the
grantee ceases to be a director of the Company. The exercise price must be paid
in full at the time of exercise, and such payment may be made in cash, by
delivering shares of Common Stock which the optionee or the optionee's spouse or
both have beneficially owned for at least six months prior to the time of
exercise, or through a combination of cash and such delivered Common Stock.
The Company has adopted the provisions of Statement of Accounting Standards
No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123"), and continues
to apply Accounting Principles Board Opinion No. 25 and related interpretations
in accounting for its stock plans. If the Company had elected to recognize
compensation cost for all of the plans based upon the fair value at the grant
dates for awards under those plans, consistent with the method prescribed by
SFAS 123, net income and earnings per share would have been changed to the pro
forma amounts indicated below:
<TABLE>
<CAPTION>
1998 1999 2000
------- -------- --------
<S> <C> <C> <C>
Pro forma net income.................................. $68,966 $130,902 $116,437
Basic pro forma earnings per share.................... .67 1.27 1.11
Diluted pro forma earnings per share.................. .65 1.23 1.09
</TABLE>
The fair value of the Company's stock options used to compute pro forma net
income and earnings per share disclosures is the estimated present value at
grant date using the Black-Scholes option pricing model with the following
weighted average assumptions:
<TABLE>
<CAPTION>
1998 1999 2000
--------- --------- ---------
<S> <C> <C> <C>
Volatility........................................... 34.1% 28.8% 35.0%
Risk-free interest rate.............................. 5.66% 4.99% 6.50%
Expected holding period.............................. 8.7 years 7.7 years 7.8 years
Dividend yield....................................... 0 0 0
</TABLE>
The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options that have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions, including the expected stock price
volatility. Because the Company's options have characteristics significantly
different from traded options, and because changes in the subjective input
assumptions can materially affect the fair value estimate, in the opinion of
management, the existing models do not necessarily provide a reliable single
value of its options and may not be representative of the future effects on
reported net income or the future stock price of the Company. The weighted
average estimated fair value of employee stock options granted in 1998, 1999 and
2000 was $13.13, $13.53 and
67
<PAGE> 70
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
$14.54 per share, respectively. For purposes of pro forma disclosure, the
estimated fair value of the options is amortized to expense over the options'
vesting period.
EQUITY RIGHTS: As of September 30, 2000, the Company holds 220 shares of
treasury stock for delivery to equity right holders who have not yet surrendered
their certificates. Equity right holders are entitled to receive 4.375 shares of
Common Stock upon surrender of such certificates.
(13) TRANSACTIONS WITH SYBRON DENTAL SPECIALTIES
CASH MANAGEMENT AND ADVANCES: The Company has managed the cash not
considered necessary for current operating requirements of its subsidiaries,
including the operations of SDS. Cash collected from and cash payments to the
operations of SDS are collected or funded from a centralized treasury operation
and are either credited or charged to SDS. Advances to and collections from SDS
are indirectly charged or credited with interest as such advances to or
collections from SDS were applied to borrowings or repayments under the Old
Credit Facilities. On an annual basis, outstanding balances are cleared via an
intercompany dividend to or capital contribution from Sybron International.
DIVIDENDS PAID TO SYBRON INTERNATIONAL: From time to time, SDS has paid
dividends to the Company. Dividends in 1998, 1999 and 2000 were $47,225, $36,483
and $58,512, respectively.
CAPITAL CONTRIBUTIONS TO SDS. From time to time, the Company has made
capital contributions to SDS. Capital contributions in 1998, 1999 and 2000 were
$49,268, $16,210 and $21,399, respectively.
SYBRON INTERNATIONAL CREDIT FACILITIES: Sybron, consistent with the terms
of its Old Credit Facilities, has historically recorded a portion of its
outstanding debt (and associated interest expense) under its Old Credit
Facilities to certain of its subsidiaries, including the operations of SDS.
SDS's historical debt outstanding under the Old Credit Facilities at September
30, 1999 and 2000 were $273,192 and $311,772, respectively. SDS's historical
interest expense was $20,195, $17,074 and $25,899 in 1998, 1999 and 2000,
respectively.
SYBRON INTERNATIONAL CHARGES: Sybron performs certain functions for its
subsidiaries (legal, tax, treasury, consolidation accounting, financial
reporting and insurance) and therefore charges its corporate office, general and
administration expenses to its subsidiaries. Such costs charged to SDS amounted
to $3,620, $4,228 and $2,979 in 1998, 1999 and 2000, respectively. Services
performed at the corporate office generally benefit the domestic operations, and
therefore Sybron International corporate office, general and administrative
expenses are generally charged based on SDS's domestic revenues as a percentage
of total Sybron International domestic revenues. Because corporate office
general and administrative expenses at Sybron International generally benefit
domestic operations, Sybron International considers this method to be a
reasonable basis for allocation. Management estimates that costs incurred by SDS
if it had operated as an unaffiliated entity would have exceeded the amounts
actually charged by approximately $2,500 in each of the three years reported.
68
<PAGE> 71
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
INTERCOMPANY LOANS WITH SYBRON DENTAL SPECIALTIES: Loans due from (to) SDS
at September 30, 1998, 1999 and 2000 were as follows:
<TABLE>
<CAPTION>
AMOUNT RATE MATURITY
-------- ----- ---------
<S> <C> <C> <C>
1998:
Sybron Holdings A/S.................................. $(21,098) 8.00% On Demand
Sybron Deutchland GmbH............................... (342) 6.50% 12/31/98
Sybron Deutchland GmbH............................... (1,497) 6.50% 8/3/99
Sybron Deutchland GmbH............................... (493) 3.75% On Demand
1999:
Sybron Holdings A/S.................................. $(11,472) 5.50% On Demand
Electrothermal....................................... (1,647) 8.00% 8/9/00
Sybron Deutchland GmbH............................... (1,367) 6.50% 8/3/00
Sybron U.K........................................... (554) 8.00% 7/30/00
Sybron Deutchland GmbH............................... (454) 3.75% On Demand
Sybron Deutchland GmbH............................... (110) 6.50% 12/31/99
Nalge U.K............................................ 1,071 0.00% None
2000:
Sybron Holdings A/S.................................. $ (1,773) 5.50% On Demand
</TABLE>
(14) COMMITMENTS AND CONTINGENT LIABILITIES
Applied Biotech, Inc. ("ABI"), a subsidiary in our Diagnostics and
Microbiology business segment, manufactures and supplies immunoassay pregnancy
tests to Warner Lambert Co. (now part of Pfizer Inc.). Warner Lambert sells the
tests to retailers who sell them over-the-counter to consumers. ABI supplies the
product to Warner Lambert pursuant to a supply agreement which Warner Lambert
claims requires ABI to defend and indemnify Warner Lambert with respect to any
liability arising out of claims that the product infringes any patents held by
third parties. On January 8, 1999, Conopco, Inc. d/b/a Unipath Diagnostics
Company filed a lawsuit against Warner Lambert in the U.S. District Court for
the District of New Jersey. Conopco claims in the suit that the Warner Lambert
pregnancy test supplied by ABI infringes certain patents owned by Conopco. ABI
has agreed to defend the lawsuit on behalf of Warner Lambert. In November 2000,
the U.S. District Court granted a motion for summary judgment in favor of Warner
Lambert and ABI, ruling that ABI's product does not infringe on the Conopco
patents. The Company therefore believes the resolution of this lawsuit will not
have a material adverse effect on the results of operations or financial
condition of the Company. Additionally, another third party has contacted Warner
Lambert regarding patents it holds which may apply to the Warner Lambert
pregnancy test. Thus, Warner Lambert or ABI may in the future be subject to
additional lawsuits by third parties for patent infringement with respect to
these products. ABI believes it has meritorious defenses to these patents and
will vigorously defend any such lawsuits against it, if brought.
The Company or its subsidiaries are at any one time parties to a number of
lawsuits or subject to claims arising out of their respective operations, or the
operation of businesses divested in the 1980's for which certain subsidiaries
may continue to have legal or contractual liability, including product
liability, patent and trademark or other intellectual property infringement,
contractual liability, workplace safety and environmental claims and cases, some
of which involve claims for substantial damages. The Company and its
subsidiaries are vigorously defending lawsuits and other claims against them.
Based upon the insurance available under an insurance program and the potential
for liability with respect to claims which are uninsured, the Company believes
that any liabilities which might reasonably result from any of the pending cases
and claims would not have a material adverse effect on the results of operations
or financial condition of the Company. There can be no assurance as to this,
however, or that litigation having such a material adverse effect will not arise
in the
69
<PAGE> 72
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
future. The Company does not reduce legal or contractual liabilities for
possible recoveries from insurance companies.
On September 30, 1999, the Company assigned its rights to receive in 2022 a
Treasury with a par value of $50,000 to an unrelated third party. The third
party has also agreed to assume any obligations for which the security has been
pledged.
(15) ACQUISITIONS AND DISCONTINUED OPERATIONS
The Company has completed 40 acquisitions, sold one business and spun off
one business since the beginning of 1998. The acquired companies are all engaged
in businesses which are similar to the Company's existing businesses. The
divested company was engaged in the business of process technologies. The spun
off company was engaged in the dental business.
1998
During 1998, the Company completed 17 acquisitions for cash. The aggregate
cash purchase price of the acquisitions was approximately $192,382, including
fees and expenses. The Company is not subject to future purchase price
adjustments based upon earnout provisions under any of the purchase and sale
agreements. All acquisitions were accounted for as purchases. The results of the
acquisitions were included as of the date they were acquired. The following
table outlines sales and operating income for the most recent available twelve-
month period prior to acquisition, and total assets at the most recent available
date prior to acquisition, for each of the acquired companies accounted for as
purchases. The total goodwill for the acquired companies was $143,886.
<TABLE>
<CAPTION>
OPERATING TOTAL TYPE OF
BUSINESS SEGMENT DATE SALES INCOME ASSETS ACQUISITION
COMPANY ACQUIRED ------------- ------- --------- ------- -----------
<S> <C> <C> <C> <C> <C>
LABWARE AND LIFE SCIENCES:
Lida Manufacturing Corporation....... October 1997 $ 5,694 $ 379 $ 1,585 Stock
CLINICAL AND INDUSTRIAL:
Chase Instruments Corp. ............. October 1997 21,592 1,957 11,946 Asset
Cel-Line Associates, Inc. ........... January 1998 1,878 39 155 Asset
SciCan Scientific.................... April 1998 5,483 311 2,982 Asset
Marks Polarized Corporation.......... May 1998 935 84 263 Asset
Scherf Prazision GmbH................ August 1998 2,621 184 1,327 Asset
DIAGNOSTICS AND MICROBIOLOGY:
Clinical Standards Labs, Inc. ....... November 1997 2,759 106 911 Stock
Diagnostic Reagents, Inc. ........... January 1998 7,609 3,057 5,795 Stock
Criterion Sciences................... April 1998 5,572 2,731 686 Asset
Custom Laboratories, Inc. ........... April 1998 1,444 72 1,616 Asset
DiMed Corporation.................... April 1998 1,830 154 1,248 Asset
Summit Biotechnology, Inc. .......... May 1998 1,237 414 455 Asset
Applied Biotech, Inc. ............... August 1998 25,141 13,663 12,920 Stock
Seradyn, Inc. ....................... August 1998 12,038 (535) 8,518 Asset
MicroBio Products, Inc. ............. August 1998 3,675 22 1,032 Stock
LABORATORY EQUIPMENT:
Electrothermal Engineering Ltd....... July 1998 5,565 (21) 2,627 Stock
Lab-Line Instruments, Inc. .......... July 1998 20,323 633 8,995 Stock
</TABLE>
See note 16 for a description of business segments.
70
<PAGE> 73
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
1999
Acquisitions
During 1999, the Company completed 16 acquisitions for cash. The aggregate
cash price of the acquisitions (none of which individually or aggregated was
significant) was $251,332. The Company is not subject to future purchase price
adjustments based upon earnout provisions under any of the purchase and sale
agreements. All acquisitions were accounted for as purchases. The results of the
acquisitions were included as of the date they were acquired. The following
table outlines sales and operating income for the most recent date prior to the
acquisition, and total assets at the most recent available date prior to
acquisition, for each of the acquired companies. The type of acquisition refers
to whether the Company purchased assets or the stock of the acquired companies.
The total goodwill for the acquired companies was $182,926.
<TABLE>
<CAPTION>
OPERATING TOTAL TYPE OF
BUSINESS SEGMENT DATE SALES INCOME ASSETS ACQUISITION
COMPANY ACQUIRED -------------- ------- --------- ------- -----------
<S> <C> <C> <C> <C> <C>
LABWARE AND LIFE SCIENCES:
InVitro Scientific Products, Inc. ..... October 1998 $ 5,095 $ 708 $ 1,897 Assets
Pacofin Intersep Filtration Products
Business of Pacofin, Ltd............. November 1998 902 343 952 Assets
Scientific Resources, Inc. ............ January 1999 4,480 165 1,043 Assets
Molecular BioProducts, Inc. ........... January 1999 15,617 4,217 6,727 Stock
Matrix Technologies Corporation........ September 1999 16,775 1,313 8,419 Stock
CLINICAL AND INDUSTRIAL:
Corning Samco Corporation.............. October 1998 22,996 2,316 15,690 Stock
HistoScreen(TM) and Histogel(TM)
product lines of Perk Scientific..... January 1999 932 254 227 Assets
Stahmer, Weston & Co., Inc. ........... February 1999 2,961 (74) 873 Stock
System Sales Associates, Inc. ......... August 1999 4,382 565 1,810 Assets
Novelty Glass & Mirror Co., Inc. ...... February 1999 280 (9) 4,949 Assets
DIAGNOSTICS AND MICROBIOLOGY:
Rascher & Betzold, Inc. ............... January 1999 104 (9) 200 Assets
Microgenics Corporation................ June 1999 37,165 8,034 25,573 Stock
MicroTest, Inc. ....................... July 1999 1,631 1,033 320 Assets
Bioreagent and ELISA immunochemistry
product lines of Genzyme
Diagnostics.......................... July 1999 3,391 2,465 434 Assets
LABORATORY EQUIPMENT:
Laboratory Devices, Inc. .............. January 1999 940 202 273 Assets
Stem Corporation Ltd. ................. August 1999 1,655 714 1,090 Stock
</TABLE>
See note 16 for a description of business segments.
2000
Acquisitions
During 2000, the Company completed 10 acquisitions, nine for all cash and
one for cash and notes in the amount of $30,600. The aggregate cash price of the
acquisitions (none of which individually or aggregated was significant) was
$206,900. The Company may be subject to future purchase price adjustments based
upon earnout provisions under one of the purchase and sale agreements. Such
earnout provision has a maximum payout of $6,000. The earnout provision is
subject to the achievement of certain financial goals and is not contingent upon
employment. The entire earnout is expected to be paid in fiscal 2001 and will be
accounted
71
<PAGE> 74
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
for as additional goodwill. All acquisitions were accounted for as purchases.
The results of the acquisitions were included as of the date they were acquired.
The following table outlines sales and operating income for the most recent date
prior to the acquisition, and total assets at the most recent available date
prior to acquisition, for each of the acquired companies. The type of
acquisition refers to whether the Company purchased assets or the stock of the
acquired companies. The total goodwill for the acquired companies was
approximately $205,100. which will be amortized over 20 to 40 years.
<TABLE>
<CAPTION>
OPERATING TOTAL TYPE OF
BUSINESS SEGMENT DATE SALES INCOME ASSETS ACQUISITION
COMPANY ACQUIRED -------------- ------- --------- ------ -----------
<S> <C> <C> <C> <C> <C>
LABWARE AND LIFE SCIENCES:
Robbins Scientific Corporation....... October 1999 $19,601 $ 4,088 $9,876 Stock
Versi Dry(R) product line of National
Packaging Services Corporation..... February 2000 2,494 1,300 Asset
Sun International.................... February 2000 5,818 (270) 2,269 Asset
Genevac Limited...................... May 2000 10,624 1,082 4,165 Stock
Genevac Inc. ........................ May 2000 1,626 -- N/A Stock
CLINICAL AND INDUSTRIAL:
Microm Laborgorate GmbH.............. October 1999 20,676 1,112 7,907 Asset
Lab Vision Corporation............... August 2000 7,487 1,146 4,426 Stock
DIAGNOSTICS AND MICROBIOLOGY:
Consolidated Technologies, Inc. ..... March 2000 7,782 2,888 6,100 Asset
Murex bacteriology latex
agglutination product line of
Abbott Laboratories................ August 2000 20,461 10,026 N/A Asset
The thyroid and coagulation product
line of Axis Shield................ September 2000 4,507 2,174 N/A Asset
</TABLE>
See note 16 for a description of business segments.
The following pro forma financial information presents the combined results
of the operations of the Company and the purchased businesses referred to above
as if the 1999 acquisitions had occurred as of the beginning of 1998, after
giving effect to certain adjustments, including amortization of goodwill,
additional depreciation expense, increased interest expense on debt related to
the acquisition and related tax effects. The pro forma information does not
necessarily reflect the results of operations that would have occurred had the
Company and the purchased companies listed above constituted a single entity
during such periods.
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
-------------------------
1999 2000
----------- -----------
<S> <C> <C>
Net sales................................................... $816,114 $903,781
Net income.................................................. $140,151 $128,936
Basic earnings per common share............................. $ 1.36 $ 1.23
Diluted earnings per common share........................... $ 1.32 $ 1.21
</TABLE>
Subsequent to September 30, 2000, the Company completed one acquisition for
cash which will be accounted for as a purchases. The following unaudited table
outlines the sales, operating income and total assets for the most recent
available twelve-month period prior to each cash acquisition.
72
<PAGE> 75
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(UNAUDITED)
<TABLE>
<CAPTION>
OPERATING TOTAL TYPE OF
BUSINESS SEGMENT DATE SALES INCOME ASSETS ACQUISITION
COMPANY ACQUIRED ------------- ------ --------- ------ -----------
<S> <C> <C> <C> <C> <C>
CLINICAL AND INDUSTRIAL:
Vacuum Process Technology, Inc. ....... November 2000 $3,977 $(19) $1,097 Asset
</TABLE>
Discontinued Operations:
Charge Related to Former Operations
In 1998, the Company incurred after tax charges of $7,750 related to legal
proceedings commenced by Combustion Engineering, Inc. against the Company with
respect to the former Taylor Instruments facility in Rochester, New York (the
"Site"), an operation accounted for as a discontinued operation when the
decision was made to exit the industrial capital goods business in 1983. See
note 12.
Divestiture
On March 31, 1999, Sybron completed the sale of NPT to Norton Performance
Plastics Corporation, a subsidiary of Saint-Gobain -- France. Net proceeds from
the sale, net of approximately $1,900 of selling expenses and a reduction to the
purchase price of approximately $2,600 paid subsequent to September 30, 1999,
amounted to approximately $83,200. The proceeds of the sale net of tax and
expenses were used to repay approximately $67,900 previously owed under the
Company's credit facilities.
Net sales from NPT were approximately $47,800 in 1998. Certain expenses
were allocated to discontinued operations in 1998 and 1999 (up to the date of
sale), including interest expense, which was allocated based upon the historical
purchase prices and cash flows of the companies comprising NPT. Income from the
discontinued operations of NPT in 1998 and 1999 were $3,848 and $121,
respectively.
Distribution
On November 8, 2000, Sybron International Corporation announced that it had
declared a pro rata distribution (or spin-off) to its shareholders of the common
stock and related preferred stock purchase rights of Sybron Dental Specialties,
Inc. (the "Distribution"). Shareholders of record as of November 30, 2000
received one share of Sybron Dental Specialties, Inc. ("SDS") common stock for
every three shares of Sybron International common stock they own. These
consolidated financial statements have reclassified SDS and its affiliates to
discontinued operations. On December 11, 2000 the Distribution was completed. No
proceeds will be received by the Company in connection with the Distribution.
Income included in discontinued operations for 1998, 1999 and 2000 was $27,823.
$47,844 and $41,597, respectively. SDS will issue its own financial statements
as of September 30, 2000.
As a result, these consolidated financial statements have reclassified SDS
and its affiliates to discontinued operations. SDS included the business
segments, Professional Dental, Orthodontics and Infection Control
73
<PAGE> 76
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Products. The components of net assets held for sale of discontinued operations
included in the consolidated balance sheets at September 30, 1999 and 2000 are
as follows:
<TABLE>
<CAPTION>
SEPTEMBER 30, SEPTEMBER 30,
1999 2000
------------- -------------
<S> <C> <C>
Cash....................................................... $ 6,090 $ 5,783
Net account receivables.................................... 84,210 85,767
Net inventories............................................ 79,574 74,383
Other current assets....................................... 6,336 6,497
Advances and loans to Sybron International................. 56,777 77,762
Property plant and equipment -- net........................ 57,488 55,326
Intangible assets.......................................... 207,606 220,705
Other assets............................................... 6,263 6,967
Current portion of long term debt.......................... (1,571) (21,761)
Accounts payable........................................... (13,122) (11,351)
Income taxes payable....................................... (3,918) (5,680)
Accrued liabilities........................................ (29,402) (27,859)
Deferred income taxes -- net............................... (6,203) (6,252)
Long term debt............................................. (283,447) (298,482)
Other liabilities.......................................... (11,086) (8,835)
--------- ---------
$ 155,595 $ 152,970
========= =========
</TABLE>
(16) SEGMENT INFORMATION
The Company's operating subsidiaries are engaged in the manufacture and
sale of laboratory products in the United States and other countries. The
Company's products are categorized in the business segments of Labware and Life
Sciences; Clinical and Industrial; Diagnostics and Microbiology; and Laboratory
Equipment. A description of the business segments follows:
Products in the Labware and Life Sciences business segment include
approximately 4,900 items, including reusable plastic products (bottles,
carboys, graduated ware, beakers and flasks) and disposable plastic products
(microfiltration and cryogenic storage products). Other labware products include
products for critical packaging applications (bottles for packaging diagnostic
and other reagents, media, pharmaceuticals and specialty chemicals), safety
products (hazard labeled containers and biohazard disposal products),
environmental containers, and autosampler vials and seals used in chromatography
analysis. Life sciences products include applications of cell culture,
filtration, molecular biology, cryopreservation, immunology, electrophoresis,
liquid handling and high throughput screening for pharmaceutical drug discovery.
Products in the Clinical and Industrial business segment include microscope
slides, cover glass, glass tubes and vials, stains and reagents and histology
and immunochemistry instrumentation for clinical testing, thin glass for watch
crystals, cosmetic mirrors, precision and coated glass used in various optic
applications, and precision thin film optical coating equipment.
Products in the Diagnostics and Microbiology business segment are used for
drug testing, therapeutic drug monitoring, infectious disease detection,
pregnancy testing, glucose tolerance testing, blood bank saline testing,
clinical diagnostic liquid standards and research application temperature
measurement. Products include diagnostic test kits, culture media, diagnostic
reagents, and other products used in detecting causes of various infections or
diseases.
Products in the Laboratory Equipment business segment include heating,
stirring and temperature control apparatus such as hot plates, stirrers,
shakers, heating tapes, muffle furnaces, incubators, dri-baths, bench top
sterilizers and cryogenic storage apparatus, which are fundamental to basic
procedures performed in
74
<PAGE> 77
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
the laboratory; systems for producing ultra pure water; bottle top dispensers,
positive displacement micropipettors, and small mixers used in biomolecular
research; constant temperature equipment including refrigerators/freezers,
ovens, water baths, environmental chambers; and furnaces and fluorometers,
spectrophotometers, and strip chart recorders.
Inter-business segment sales are not material. Information on these
business segments is summarized as follows:
<TABLE>
<CAPTION>
LABWARE CLINICAL DIAGNOSTICS
AND LIFE AND AND LABORATORY ELIMI- TOTAL
SCIENCES INDUSTRIAL MICROBIOLOGY EQUIPMENT NATIONS SLP OTHER(A) TOTAL
-------- ---------- ------------ ---------- ------- --------- -------- ---------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
1998
Revenues:
External customer............ 228,775 135,438 114,683 78,866 -- 557,762 -- 557,762
Intersegment................. 717 5,608 352 972 (6,761) 888 (888) --
Total revenues......... 229,492 141,046 115,035 79,838 (6,761) 558,650 (888) 557,762
Gross profit................... 115,724 57,351 59,407 34,697 -- 267,179 -- 267,179
Selling, general and admin..... 65,570 23,082 34,294 16,405 -- 139,351 5,410 144,761
Operating income............... 50,154 34,269 25,113 18,292 -- 127,828 (5,410) 122,418
Depreciation and
amortization................. 16,551 8,271 8,477 4,082 -- 37,381 1,449 38,830
Interest income................ 433 66 66 11 -- 576 47 623
Interest expense............... 138 201 10 16 -- 365 33,407 33,772
Segment assets................. 362,637 220,886 320,190 118,306 -- 1,022,019 205,833 1,227,852
Expenditures for property,
plant and equipment.......... 19,493 7,456 3,430 2,686 -- 33,065 180 33,245
1999
Revenues:
External customer............ 268,788 176,059 171,647 98,543 -- 715,037 -- 715,037
Intersegment................. 976 5,833 392 804 (7,367) 638 (638) --
Total revenues......... 269,764 181,892 172,039 99,347 (7,367) 715,675 (638) 715,037
Gross profit................... 136,004 75,407 89,458 41,089 -- 341,958 -- 341,958
Selling, general and admin..... 68,600 30,102 46,246 20,632 -- 165,580 7,252 172,832
Operating income............... 67,404 45,305 43,212 20,457 -- 176,378 (7,252) 169,126
Depreciation and
amortization................. 18,768 11,696 12,401 4,393 -- 47,258 1,737 48,995
Interest income................ 183 66 79 12 -- 340 421 761
Interest expense............... 233 204 203 45 -- 685 39,388 40,073
Segment assets................. 465,648 290,598 417,313 131,942 -- 1,305,501 234,474 1,539,975
Expenditures for property,
plant and equipment.......... 15,598 7,377 4,743 2,254 -- 29,972 405 30,377
2000
Revenues:
External customer............ 347,437 208,686 210,147 97,305 -- 863,575 -- 863,575
Intersegment................. 1,087 6,962 463 305 (8,817) -- -- --
Total revenues......... 348,524 215,648 210,610 97,610 (8,817) 863,575 -- 863,575
Gross profit................... 179,460 89,667 111,651 41,352 -- 422,130 -- 422,130
Selling, general and admin..... 100,365 37,077 60,797 21,148 -- 219,387 9,754 229,141
Operating income............... 79,095 52,590 50,854 20,204 -- 202,743 (9,754) 192,989
Depreciation and
amortization................. 27,962 13,049 18,921 4,649 -- 64,581 2,006 66,587
Interest income................ 217 120 353 14 -- 704 133 837
Interest expense............... 933 110 25 1 -- 1,069 47,615 48,684
Segment assets................. 428,044 274,968 521,987 88,439 -- 1,313,438 478,926 1,792,364
Expenditures for property,
plant and equipment.......... 21,670 8,511 10,527 1,726 -- 42,434 84 42,518
</TABLE>
---------------
(a) Includes the elimination of intercompany activity and corporate office
assets consisting primarily of cash, assets held for sale, securities
available for sale (1999 and 2000), deferred taxes, and property, plant and
equipment.
75
<PAGE> 78
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The Company's international operations are conducted principally in Europe.
Inter-geographic sales are made at prices approximating market.
<TABLE>
<CAPTION>
1998 1999 2000
-------- -------- --------
<S> <C> <C> <C>
Net Sales:
United States:
Customers................................................. $422,055 $543,846 $643,188
Inter-geographic.......................................... 37,237 43,777 55,616
-------- -------- --------
459,292 587,623 698,804
-------- -------- --------
Europe:
Customers................................................. 83,488 103,097 133,437
Inter-geographic.......................................... 21,069 23,653 28,059
-------- -------- --------
104,557 126,750 161,496
-------- -------- --------
All other areas:
Customers................................................. 52,219 68,094 86,950
Inter-geographic.......................................... 8,021 7,798 8,934
-------- -------- --------
60,240 75,892 95,884
Inter-geographic sales...................................... (66,327) (75,228) (92,609)
-------- -------- --------
Total net sales........................................... $557,762 $715,037 $863,575
======== ======== ========
Net Property:
United States............................................. $127,181 $147,802 $168,472
Europe.................................................... 40,424 39,174 38,766
All other areas........................................... 733 783 856
-------- -------- --------
Total net property........................................ $168,338 $187,759 $208,094
======== ======== ========
</TABLE>
Major customer information:
During 1998, 1999 and 2000, one customer, Fisher Scientific, accounted for
10% or more of the Company's net revenues. During 1998 and 1999, another
customer, VWR, accounted for 10% or more of the Company's net revenues. The
table below lists by segment the 1998, 1999 and 2000 sales to Fisher Scientific
and the 1998 and 1999 sales to VWR.
<TABLE>
<CAPTION>
FISCHER SCIENTIFIC VWR
----------------------------- -----------------
1998 1999 2000 1998 1999
------- -------- -------- ------- -------
<S> <C> <C> <C> <C> <C>
Labware and Life Sciences.......... $47,957 $ 55,514 $ 60,818 $48,504 $53,391
Clinical and Industrial............ 15,040 24,490 35,953 5,245 7,736
Laboratory Equipment............... 16,025 20,119 22,189 11,037 17,044
Diagnostics and Microbiology....... 4,602 6,230 5,571 190 450
------- -------- -------- ------- -------
$83,624 $106,353 $119,904 $64,976 $78,621
======= ======== ======== ======= =======
</TABLE>
76
<PAGE> 79
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(17) COMPREHENSIVE INCOME
The components of other comprehensive income (loss) are as follows:
<TABLE>
<CAPTION>
PRETAX TAX AFTER TAX
-------- ------- ---------
<S> <C> <C> <C>
Year ended September 30, 1998
Translation Adjustment.............................. $ 4,293 $ -- $ 4,293
======== ======= ========
Year ended September 30, 1999
Translation Adjustment.............................. $ (9,905) $ -- $ (9,905)
Unrealized gain on security......................... 439 (173) 266
-------- ------- --------
Total other comprehensive income.................... $ (9,466) $ (173) $ (9,639)
======== ======= ========
Year ended September 30, 2000
Translation Adjustment.............................. $(26,773) $ -- $(26,773)
Unrealized gain on security......................... 3,544 (1,420) 2,124
-------- ------- --------
Total other comprehensive income.................... $(23,229) $(1,420) $(24,649)
======== ======= ========
</TABLE>
(18) QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
<TABLE>
<CAPTION>
FIRST SECOND THIRD FOURTH
1999 QUARTER QUARTER QUARTER QUARTER TOTAL YEAR
---- -------- -------- -------- -------- ----------
<S> <C> <C> <C> <C> <C>
Net sales............................... $156,412 $175,406 $183,559 $199,660 $715,037
======== ======== ======== ======== ========
Gross profit............................ $ 73,620 $ 83,094 $ 88,142 $ 97,102 $341,958
======== ======== ======== ======== ========
Income from continuing operations....... $ 14,951 $ 20,596 $ 20,860 $ 21,004 $ 77,411
Discontinued operation.................. 8,909 11,496 12,484 15,076 $ 47,965
Income before extraordinary item
Extraordinary item...................... -- 18,796 (838) (787) 17,171
-------- -------- -------- -------- --------
Net income.............................. $ 23,860 $ 50,888 $ 32,506 $ 35,293 $142,547
======== ======== ======== ======== ========
Basic Per Common Share Earnings:
Income from continuing operations....... $ .14 $ .20 $ .20 $ .20 $ .75
Discontinued operations................. .09 .11 .12 .15 .46
Extraordinary item...................... -- .18 (.01) (.01) .17
-------- -------- -------- -------- --------
Net income.............................. $ .23 $ .49 $ .31 $ .34 $ 1.38
======== ======== ======== ======== ========
Diluted Per Common Share Earnings:
Income from continuing operations
Before extraordinary item............. $ .14 $ .19 $ .19 $ .20 $ .73
Discontinued operations................. .09 .11 .12 .14 .45
Extraordinary item...................... -- .18 (.01) (.01) .16
-------- -------- -------- -------- --------
Net income.............................. $ .23 $ .48 $ .30 $ .33 $ 1.34
======== ======== ======== ======== ========
</TABLE>
77
<PAGE> 80
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
<TABLE>
<CAPTION>
FIRST SECOND THIRD FOURTH
2000 QUARTER QUARTER QUARTER QUARTER TOTAL YEAR
---- -------- -------- -------- -------- ----------
<S> <C> <C> <C> <C> <C>
Net sales............................... $204,883 $218,074 $212,029 $228,589 $863,575
======== ======== ======== ======== ========
Gross profit............................ $100,091 $107,165 $105,409 $109,465 $422,130
======== ======== ======== ======== ========
Income from continuing operations....... $ 20,461 $ 25,340 $ 23,943 $ 16,980 $ 86,724
Discontinued operation.................. $ 9,963 $ 13,635 $ 11,275 $ 6,724 $ 41,597
-------- -------- -------- -------- --------
Net income.............................. $ 30,424 $ 38,975 $ 35,218 $ 23,704 $128,321
======== ======== ======== ======== ========
Basic Per Common Share Earnings:
Income from continuing operations....... $ .20 $ .24 $ .23 $ .16 $ .83
Discontinued operations................. .09 .13 .11 .07 .40
-------- -------- -------- -------- --------
Net income.............................. $ .29 $ .37 $ .34 $ .23 $ 1.23
======== ======== ======== ======== ========
Diluted Per Common Share Earnings:
Income from continuing operations
Before extraordinary item............. $ .20 $ .24 $ .22 $ .16 $ .81
Discontinued operations................. .09 .13 .11 .06 .39
-------- -------- -------- -------- --------
Net income.............................. $ .29 $ .37 $ .33 $ .22 $ 1.20
======== ======== ======== ======== ========
</TABLE>
(19) SUBSEQUENT EVENTS
On December 11, 2000 (the "Distribution Date"), the Company completed the
Spin-Off. Just prior to the Spin-Off, the Company received a cash dividend of
approximately $67,900 from SDS as well as a non-cash dividend equal to the net
intercompany payable from the Company to SDS and its affiliates on the
Distribution Date. On the Distribution Date, the Company borrowed approximately
$563,000 under the Credit Facilities and, together with funds aggregating
$375,000 (approximately $307,100, the amount equal to the outstanding amounts
under the Previous Credit Agreement attributable to SDS on the Distribution Date
including accrued interest, plus the cash dividend of $67,900 from SDS to the
Company), used such funds to repay all of the outstanding amounts under the
Previous Credit Agreement (including amounts attributable to SDS and accrued
interest) aggregating approximately $938,000. See footnote 7 regarding terms and
amount of the Credit Facilities.
On December 11, 2000, due to the extinguishment of debt, interest rate
swaps previously designated as cash flow hedges ceased to meet hedge criteria
under SFAS 133 as modified by SFAS 138. The approximate fair value on December
11, 2000 was $1,700. The Company sold these interest rate swaps on December 12,
2000 for approximately $1,700, and realized a gain of $1,100 (net of tax).
Because these interest rate swaps were designated as a hedge against future
variable rate interest payments and the extinguished debt, the gain will
continue to be carried in other comprehensive income and recognized as an
adjustment of yield interest expense of the Credit Facilities over the remaining
term of the interest rate contract. Options under Sybron's employee stock option
programs with respect to 1,320,515 shares of Company common stock were exchanged
for options to purchase SDS common stock by SDS employees in connection with the
Spin-Off.
On November 8, 2000, the Board of Directors adopted, effective upon
completion of the Distribution, a Rights Agreement, dated as of December 11,
2000, pursuant to which Rights are distributed as a dividend at the rate of one
Right for each share of common stock, par value $.01 per share, of the Company
held by shareholders of record as of the close of business on December 12, 2000,
the day after the Distribution, or issued thereafter. Each Right initially will
entitle shareholders to buy one one-hundredth of a share of a series of
preferred stock for one hundred forty dollars. The Rights generally will be
exercisable if a person or group acquires beneficial ownership of 15 percent or
more of the Company's common stock or commences a tender or exchange offer upon
consummation of which such person or group would beneficially own 15 percent or
78
<PAGE> 81
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
more of the Company's common stock. Thereafter, or if thereafter the Company is
involved in a merger or certain other business combinations not approved by the
Board of Directors, each right will entitle its holder, other than the acquiring
person or group, to purchase common stock of either the Company or the acquirer
having a value of twice the exercise price of the Right. The Rights are attached
to the common stock unless and until they become exercisable and will expire on
December 12, 2010, unless earlier redeemed for $.01 each, or exchanged by the
Company as provided in the Rights Agreement.
79
<PAGE> 82
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information called for by Item 10 of Form 10-K with respect to
directors and executive officers is incorporated herein by reference to such
information included in the Company's Proxy Statement for the Annual Meeting of
Shareholders to be held January 30, 2001 (the "2001 Annual Meeting Proxy
Statement"), under the captions "Election of Directors" and "Section 16(a)
Beneficial Ownership Reporting Compliance," and to the information under the
caption "Executive Officers of the Registrant" in Part I hereof.
ITEM 11. EXECUTIVE COMPENSATION
The information called for by Item 11 of Form 10-K is incorporated herein
by reference to such information included in the 2001 Annual Meeting Proxy
Statement under the captions "Executive Compensation" and "Election of
Directors -- Directors' Compensation."
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information called for by Item 12 of Form 10-K is incorporated herein
by reference to such information included in the 2001 Annual Meeting Proxy
Statement under the caption "Security Ownership of Certain Beneficial Owners and
Management."
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information called for by Item 13 of Form 10-K is incorporated herein
by reference to such information included in the 2001 Annual Meeting Proxy
Statement under the caption "Election of Directors."
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) Documents Filed. The following documents are filed as part of this
Annual Report or incorporated by reference as indicated:
1. The consolidated financial statements of Sybron International
Corporation and its subsidiaries filed under Item 8:
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Independent Auditors' Report................................ 42
Consolidated Balance Sheets as of September 30, 1999 and
2000...................................................... 43
Consolidated Statements of Income for the years ended
September 30, 1998, 1999 and 2000......................... 44
Consolidated Statements of Shareholders' Equity for the
Years ended September 30, 1998, 1999 and 2000............. 45
Consolidated Statements of Cash Flows for the years ended
September 30, 1998, 1999 and 2000......................... 46
Notes to Consolidated Financial Statements.................. 47
</TABLE>
80
<PAGE> 83
2. Financial Statement Schedules.
The following report and financial statement schedule should be read in
conjunction with the consolidated financial statements set forth in Item 8:
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Independent Auditors' Report................................ S-1
Schedule II -- Valuation and Qualifying Accounts............ S-2
</TABLE>
Schedules other than those listed above are omitted because they are not
applicable or because the required information is given in the consolidated
financial statements and notes thereto.
3. Exhibits and Exhibit Index.
See the Exhibit Index included as the last part of this report, which is
incorporated herein by reference. Each management contract and compensatory plan
or arrangement required to be filed as an exhibit to this report is identified
in the Exhibit Index by an asterisk following its exhibit number.
(b) Reports on Form 8-K.
A Form 8-K, dated September 22, 2000, was filed on September 22, 2000 to
report, under item 5, the pro forma data giving effect to the Distribution and
the refinancing of the Company's Old Credit Facilities.
A Form 8-K/A, dated October 10, 2000, was filed on October 10, 2000 to
report, under item 5, revised pro forma data giving effect to the Distribution
and the refinancing of the Company's Old Credit Facilities.
A Form 8-K, dated November 8, 2000, was filed on November 9, 2000 to
report, under item 5, the Company's declaration of the Distribution, pro forma
financial information giving effect to the Distribution, the expected financing
for the Distribution and certain financial data. A copy of the Company's press
release dated November 8, 2000 was filed as an exhibit.
81
<PAGE> 84
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
December 19, 2000 SYBRON INTERNATIONAL CORPORATION
By: /s/ FRANK H. JELLINEK, JR.
---------------------------------------------
Frank H. Jellinek, Jr., President and
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Principal Executive Officer:
<TABLE>
<S> <C>
/s/ FRANK H. JELLINEK, JR. President and Chief Executive Officer
---------------------------------------------
Frank H. Jellinek, Jr.
December 19, 2000
Principal Financial Officer and
Principal Accounting Officer:
/s/ JEFFREY C. LEATHE Executive Vice President -- Finance,
--------------------------------------------- Chief Financial Officer and Treasurer
Jeffrey C. Leathe
December 19, 2000
All of the members of the Board of Directors:
Don H. Davis, Jr. /s/ MICHAEL K. BRESSON
Christopher L. Doerr ---------------------------------------------
Robert B. Haas Michael K. Bresson
Thomas O. Hicks Attorney and Agent for each member of
Frank H. Jellinek, Jr. the Board of Directors of
William U. Parfet Sybron International Corporation
Joe L. Roby doing business as Apogent Technologies
Richard W. Vieser under Powers of Attorney
Kenneth F. Yontz dated December 12, 2000
December 19, 2000
</TABLE>
82
<PAGE> 85
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Shareholders
Sybron International Corporation:
On November 13, 2000, except as to footnote 19 which is as of December 11,
2000, we reported on the consolidated balance sheets of Sybron International
Corporation and subsidiaries as of September 30, 1999 and 2000, and the related
consolidated statements of income, shareholders' equity, and cash flows for each
of the years in the three-year period ended September 30, 2000, which are
included in the 2000 Annual Report on Form 10-K. In connection with our audits
of the aforementioned consolidated financial statements, we also audited the
related financial statement schedule as listed in Item 14. This financial
statement schedule is the responsibility of the Company's management. Our
responsibility is to express an opinion on the financial statement schedule
based on our audits.
In our opinion, such financial statement schedule, when considered in
relation to the basic consolidated financial statements taken as a whole,
presents fairly, in all material respects, the information set forth therein.
KPMG LLP
Milwaukee, Wisconsin
November 13, 2000 except as to footnote 19
which is as of December 11, 2000
S-1
<PAGE> 86
SCHEDULE II
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
VALUATION AND QUALIFYING ACCOUNTS
FOR THE YEARS ENDED SEPTEMBER 30, 1998, 1999 AND 2000
(IN THOUSANDS)
<TABLE>
<CAPTION>
ADDITIONS
-----------------------
BALANCE AT CHARGED TO CHARGED TO
BEGINNING COSTS AND OTHER BALANCE AT
DESCRIPTIONS OF YEAR EXPENSES ACCOUNTS DEDUCTIONS END OF YEAR
------------ ---------- ---------- ---------- ---------- -----------
<S> <C> <C> <C> <C> <C>
Year ended September 30, 1998
Deducted from asset accounts:
Allowance for doubtful
receivables....................... $1,766 $ 462 $ 533(d) $ 682(a) $2,079
====== ======= ====== ====== ======
Inventory reserves.................. $2,997 $ (763) $1,479(d) $ 254(b) $3,459
====== ======= ====== ====== ======
Legal reserves........................ $1,147 $ (649) $ -- $ 230(c) $ 268
====== ======= ====== ====== ======
Restructuring reserve................. $ 164 $ 9,424 $ -- $6,585(c) $3,003
====== ======= ====== ====== ======
Year ended September 30, 1999
Deducted from asset accounts:
Allowance for doubtful
receivables....................... $2,079 $ 907 $1,080(d) $ 968(a) $3,098
====== ======= ====== ====== ======
Inventory reserves.................. $3,459 $ 889 $ 967(d) $1,435(b) $3,880
====== ======= ====== ====== ======
Legal reserves........................ $ 268 $ 1,034 $ $ 866(c) $ 436
====== ======= ====== ====== ======
Restructuring reserve................. $3,003 $ 245 $ -- $2,261(c) $ 987
====== ======= ====== ====== ======
Year ended September 30, 2000
Deducted from asset accounts:
Allowance for doubtful
receivables....................... $3,098 $ 863 $ 109(d) $ 29(a) $4,041
====== ======= ====== ====== ======
Inventory reserves.................. $3,880 $ (305) $1,010(d) $ 713(b) $3,872
====== ======= ====== ====== ======
Legal reserves.......................... $ 436 $ 199 $ -- $ 110(c) $ 525
====== ======= ====== ====== ======
Restructuring reserve................... $ 987 $11,300 $ -- $5,687(c) $6,609
====== ======= ====== ====== ======
</TABLE>
---------------
Note: Above additions and deductions include the effects of foreign currency
rate changes.
(a) Uncollectible accounts written off, net of recoveries.
(b) Inventory written off.
(c) Net disbursements.
(d) Reserves of acquired businesses.
S-2
<PAGE> 87
SYBRON INTERNATIONAL CORPORATION
(THE "REGISTRANT")
(COMMISSION FILE NO. 1-11091)
EXHIBIT INDEX
TO
2000 ANNUAL REPORT ON FORM 10-K
<TABLE>
<CAPTION>
EXHIBIT FILED
NUMBER DESCRIPTION INCORPORATED HEREIN BY REFERENCE TO HEREWITH
------- ----------- ----------------------------------- --------
<C> <S> <C> <C>
2.1 Contribution Agreement, Plan and X
Agreement of Reorganization and
Distribution, dated as of November
28, 2000, between the Registrant and
Sybron Dental Specialties, Inc.
("SDS") and Sybron Dental Management,
Inc. (excluding the forms of the
ancillary agreements attached thereto
as exhibits, definitive copies of
which are filed as Exhibits 2.2
through 2.8 below)
2.2 General Assignment, Assumption and X
Agreement Regarding Litigation,
Claims and Other Liabilities, dated
as of December 11, 2000, between the
Registrant and SDS
2.3 Trade Name Assignment and X
Transitional Trade Name Use and
License Agreement, dated as of
December 11, 2000, between the
Registrant and SDS
2.4 Insurance Matters Agreement, dated as X
of December 11, 2000, between the
Registrant and SDS
2.5 Employee Benefits Agreement, dated as X
of December 11, 2000, between the
Registrant and SDS
2.6 Tax Sharing and Indemnification X
Agreement, dated as of December 11,
2000, between the Registrant and SDS
2.7 Interim Administrative Services X
Agreement, dated as of December 11,
2000, between the Registrant and SDS
2.8 Confidentiality and Nondisclosure X
Agreement, dated as of December 11,
2000, between the Registrant and SDS
3.1 (a) Restated Articles of Exhibit 4.1 to the Registrant's
Incorporation of the Registrant Registration Statement on Form S-8
(File No. 333-47015)
(b) Articles of Amendment containing X
Certificate of Designation,
Preferences and Rights of Series
A Preferred Stock
</TABLE>
EI-1
<PAGE> 88
<TABLE>
<CAPTION>
EXHIBIT FILED
NUMBER DESCRIPTION INCORPORATED HEREIN BY REFERENCE TO HEREWITH
------- ----------- ----------------------------------- --------
<C> <S> <C> <C>
3.2 Bylaws of the Registrant, as amended Exhibit 3 to the Registrant's Form
as of December 22, 1999 10-Q for the quarterly period ended
December 31, 1999
4.1 Restated Articles of Incorporation Exhibits 3.1 and 3.2 hereto
and Restated Bylaws of the Registrant
4.2 Rights Agreement, dated as of Decem- Exhibit 1 to the Registrant's
ber 11, 2000, between the Registrant Registration Statement on Form 8-A
and Fleet National Bank, as Rights and Exhibit 4 to the Registrant's
Agent, including the Form of Current Report on Form 8-K, both
Certificate of Designation, dated December 11, 2000 and filed
Preferences and Rights of Series A December 12, 2000
Preferred Stock (Exhibit A), Form of
Rights Certificate (Exhibit B) and
Form of Summary of Rights (Exhibit C)
4.3 Credit Agreement, dated as of X
December 1, 2000 (the "Credit
Agreement"), among the Registrant,
the several Lenders from time to time
parties thereto, Bank One, NA, as
Domestication Agent, Bank of America,
N.A., as Syndication Agent, and The
Chase Manhattan Bank, as
Administrative Agent
4.4 Subsidiaries Guarantee, dated as of X
December 1, 2000, executed pursuant
to the Credit Agreement
10.1* Form of former Employment Agreement Exhibit 10(a) to Sybron Corporation's
with the former executive officers of Form 10-K for the fiscal year ended
the Registrant September 30, 1993 (the "1993 10-K")
10.2* Schedule of former executive officers Exhibit 10.2 to the Registrant's Form
who were parties to the former 10-K for the fiscal year ended
Employment Agreement filed as Exhibit September 30, 1998 (the "1998 10-K")
10.1, with a summary of significant
terms
10.3* Form of current Employment Agreement X
with Kenneth F. Yontz, R. Jeffrey
Harris, and Dennis Brown
10.4* Summary of significant terms for each X
Employment Agreement filed as Exhibit
10.3.
10.5* Form of Employment Agreement with the X
current executive officers of the
Registrant
10.6* Schedule of executive officers who X
are parties to the Employment
Agreement filed as Exhibit 10.5, with
a summary of significant terms
10.7* Form of Indemnification Agreement Exhibit 10.36 to the Registrant's
with each of the executive officers Form 10-K for the fiscal year ended
and directors identified on the September 30, 1997 (the "1997 10-K")
schedule thereto
10.8* 1988 Stock Option Plan Exhibit 10(q) to Sybron Corporation's
Registration Statement on Form S-1
(No. 33-20829)
</TABLE>
EI-2
<PAGE> 89
<TABLE>
<CAPTION>
EXHIBIT FILED
NUMBER DESCRIPTION INCORPORATED HEREIN BY REFERENCE TO HEREWITH
------- ----------- ----------------------------------- --------
<C> <S> <C> <C>
10.9* Amendment to the 1998 Stock Option Exhibit 10(q-4) to the Registrant's
Plan Form 10-K for the fiscal year ended
September 30, 1992 (the "1992 10-K")
10.10* Form of Nonstatutory Stock Option Exhibit 10(r) to Sybron Corporation's
Agreement under the 1988 Stock option Registration Statement on Form S-1
Plan (No. 33-20829)
10.11* 1990 Stock Option Plan Exhibit 10(q-2) to Sybron
Corporation's Registration Statement
on Form S-1 (No. 33-20829)
10.12* Amendment to 1990 Stock Option Plan Exhibit 10(q-6) to the 1992 10-K
10.13* Form of Nonstatutory Stock Option Exhibit 10(s-1) to Sybron
Agreement under the 1990 Stock Option Corporation's Registration Statement
Plan on Form S-1 (No. 33-20829)
10.14* Amended and Restated 1994 Outside Di- Exhibit 10.41 to the Registrant's
rectors' Stock Option Plan Form 10-K for the fiscal year ended
September 30, 1996
10.15* Form of Nonstatutory Stock Option Exhibit 10.42 to the Registrant's
Agreement under the Amended and Form 10-K for the fiscal year ended
Restated 1994 Outside Directors' September 30, 1999 (the "1999 10-K")
Stock Option Plan
10.16* 1999 Outside Directors' Stock Option Exhibit A to the Registrant's Proxy
Plan Statement dated December 22, 1998 for
its Annual Meeting of Shareholders on
January 27, 1999
10.17* Form of Nonstatutory Stock Option Exhibit 10.43 to the 1999 10-K
Agreement under the 1999 Outside
Directors' Stock Option Plan
10.18* Amended and Restated 1993 Long-Term Exhibit A to the Registrant's Proxy
Incentive Plan Statement dated December 23, 1997 for
its Annual Meeting of Shareholders on
January 30, 1998
10.19 Form of Nonstatutory Stock Option Exhibit 10(u) to the 1993 10-K
Agreement under the 1993 Long-Term
Incentive Plan
10.20* Amended and Restated Senior Executive Exhibit A to the Registrant's Proxy
Incentive Compensation Plan Statement dated December 22, 1999 for
its Annual Meeting of Shareholders on
February 2, 2000
10.21* Sybron International Corporation Exhibit 10.40 to the 1998 10-K
Deferred Compensation Plan
10.22 Lease Agreement dated December 21, Exhibit 10(cc) to Sybron
1988 between CPA:7 and CPA:8, as Corporation's Registration Statement
landlord, and Barnstead Thermolyne on Form S-1 (No. 33-24640)
Company, as tenant (the "Barnstead
Thermolyne Lease")
10.23 First Amendment to the Barnstead X
Thermolyne Lease
</TABLE>
EI-3
<PAGE> 90
<TABLE>
<CAPTION>
EXHIBIT FILED
NUMBER DESCRIPTION INCORPORATED HEREIN BY REFERENCE TO HEREWITH
------- ----------- ----------------------------------- --------
<C> <S> <C> <C>
10.24 Lease Agreement dated December 21, Exhibit 10(ee) to Sybron
1988 between CPA:7 and CPA:8, as Corporation's Registration Statement
landlord, and Erie Scientific on Form S-1 (No. 33-24640)
Company, as tenant (the "Erie Lease")
10.25 First Amendment to the Erie Lease X
10.26 Lease Agreement dated December 21, Exhibit 10(ff) to Sybron
1988 between CPA:7 and CPA:8, as Corporation's Registration Statement
landlord, and Nalge Nunc on Form S-1 (No. 33-24640)
International Corporation, as tenant
(the "NNI Lease")
10.27 Second Amendment to the NNI lease X
10.28 Amended and Restated Guaranty and X
Suretyship Agreement, dated December
11, 2000, between the Registrant and
CPA:7 and CPA:8
10.29 Tenant Agreement dated December 21, Exhibit 10(tt) to Sybron
1988 between New England Mutual Life Corporation's Registration Statement
Insurance Company, as lender, and on Form S-1 (No. 33-24640) Form S-1
CPA:7 and CPA:8, as landlord, and (No. 33-24640)
Barnstead Thermolyne Corporation, as
tenant
10.30 Tenant Agreement dated December 21, Exhibit 10(uu) to Sybron
1988 between New England Mutual Life Corporation's Registration Statement
Insurance Company, as lender, and on Form S-1 (No. 33-24640) Form S-1
CPA:7 and CPA:8, as landlord, and (No. 33-24640)
Erie Scientific Company, as tenant
10.31 Tenant Agreement dated December 21, Exhibit 10(vv) to Sybron
1988 between New England Mutual Life Corporation's Registration Statement
Insurance Company, as lender, and on Form S-1 (No. 33-24640) Form S-1
CPA:7 and CPA:8, as landlord, and (No. 33-24640)
Nalge Nunc International Corporation
(formerly Nalge Company), as tenant
10.32 Sale and Leaseback Agreement dated Exhibit 10(ww) to Sybron
December 21, 1988 between Sybron Corporation's Registration Statement
Corporation and New England Mutual on Form S-1 (No. 33-24640)
Life Insurance Company, as lender
10.33 Environmental Risk Agreement dated Exhibit 10(yy) to Sybron
December 21, 1988 from Sybron Corporation's Registration Statement
Corporation and Barnstead Thermolyne on Form S-1 (No. 33-24640
Corporation, as indemnitors, to New
England Mutual Life Insurance
Company, as lender, and CPA:7 and
CPA:8, as Borrowers
10.34 Environmental Risk Agreement dated Exhibit 10(aaa) to Sybron
December 21, 1988 from Sybron Corporation's Registration Statement
Corporation and Erie Scientific on Form S-1 (No. 33-24640)
Company, as indemnitors, to New
England Mutual Life Insurance
Company, as lender, and CPA:7 and
CPA:8, as Borrowers
</TABLE>
EI-4
<PAGE> 91
<TABLE>
<CAPTION>
EXHIBIT FILED
NUMBER DESCRIPTION INCORPORATED HEREIN BY REFERENCE TO HEREWITH
------- ----------- ----------------------------------- --------
<C> <S> <C> <C>
10.35 Environmental Risk Agreement dated Exhibit 10(bbb) to Sybron
December 21, 1988 from Sybron Corporation's Registration Statement
Corporation and Nalge Nunc on Form S-1 (No. 33-24640)
International Corporation (formerly
Nalge Company), as indemnitors, to
New England Mutual Life Insurance
Company, as lender, and CPA:7 and
CPA:8, as borrowers
10.36* Life insurance policy for Kenneth F. Exhibit 10(eee) to Sybron
Yontz, executive officer of the Corporation's Registration Statement
Registrant on Form S-1 (No. 33-45948)
10.37* Life insurance policy for Frank H. Exhibit 10(eee-1) to Sybron
Jellinek, Jr., executive officer of Corporation's Registration Statement
the Registrant on Form S-1 (No. 33-45948)
10.38* Life insurance policy for R. Jeffrey Exhibit 10(rr) to the 1993 10-K
Harris, former executive officer of
the Registrant
10.39* Life insurance policy for Dennis Exhibit 10.42 to the Registrant's
Brown, former executive officer of Form 10-K for the fiscal year ended
the Registrant September 30, 1995
10.40* Consulting Agreement, dated as of Exhibit 10.43 to the 1997 10-K
June 8, 1995, by and between William
U. Parfet and Richard-Allan
Scientific Company
10.41* Sybron Laboratory Products X
Corporation Senior Salaried Executive
Financial Performance Incentive
Compensation Plan
21 Subsidiaries of the Registrant X
23 Consent of KPMG LLP X
24 Powers of Attorney of Directors of X
the Registrant
27.1 Financial Data Schedule X
27.2 Restated Financial Data Schedule X
(fiscal year ended September 30,
1999)
27.3 Restated Financial Data Schedule X
(fiscal year ended September 30,
1998)
</TABLE>
---------------
* Denotes management contract or executive compensation plan or arrangement
required to be filed as an exhibit pursuant to Item 14(c) of Form 10-K.
EI-5
